SCYNEXIS (SCYX) 8-K 30 Oct 15 Other Events Financial data

Document and Entity Information

Document and Entity Information	3 Months Ended
	Mar. 31, 2015
Document And Entity Information [Abstract]
Entity Registrant Name	SCYNEXIS INC
Entity Central Index Key	1,178,253
Document Type	8-K
Document Period End Date	Mar. 31, 2015
Amendment Flag	false

Balance Sheets

Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 27,620	$ 32,243	$ 1,402
Prepaid expenses and other current assets	899	703	243
Assets of discontinued operations, net	6,049	6,701	6,798
Total current assets	34,568	39,647	8,443
Deferred financing costs		0	2,144
Other assets	32	25	25
Deferred offering costs	257	0	1,775
Total assets	34,857	39,672	12,387
Liabilities, convertible preferred stock, and stockholders' equity (deficit)
Accounts payable	903	426	1,521
Accrued expenses	3,060	2,245	732
Deferred revenue, current portion	257	257	262
Current portion of long-term debt		0	15,000
Liabilities related to assets of discontinued operations	2,371	2,420	2,443
Total current liabilities	6,591	5,348	19,958
Deferred revenue, net of current portion	828	893	1,144
Derivative liability		0	12,237
Deferred rent		0	0
Total liabilities	$ 7,419	$ 6,241	$ 33,339
Commitments and contingencies
Stockholders' equity (deficit):
Common stock	$ 8	$ 8	$ 0
Additional paid-in capital	151,325	150,934	5,168
Accumulated deficit	(123,895)	(117,511)	(113,277)
Total stockholders’ equity (deficit)	27,438	33,431	(108,109)
Total liabilities, convertible preferred stock, and stockholders’ equity (deficit)	$ 34,857	39,672	12,387
Series A Convertible Preferred Stock [Member]
Liabilities, convertible preferred stock, and stockholders' equity (deficit)
Convertible preferred stock		0	250
Series B Convertible Preferred Stock [Member]
Liabilities, convertible preferred stock, and stockholders' equity (deficit)
Convertible preferred stock		0	4,215
Series C Convertible Preferred Stock [Member]
Liabilities, convertible preferred stock, and stockholders' equity (deficit)
Convertible preferred stock		0	28,121
Series C-2 Convertible Preferred Stock [Member]
Liabilities, convertible preferred stock, and stockholders' equity (deficit)
Convertible preferred stock		0	13,500
Series D-1 Convertible Preferred Stock [Member]
Liabilities, convertible preferred stock, and stockholders' equity (deficit)
Convertible preferred stock		0	16,952
Series D-2 Convertible Preferred Stock [Member]
Liabilities, convertible preferred stock, and stockholders' equity (deficit)
Convertible preferred stock		$ 0	$ 24,119

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2015	Dec. 31, 2014	May. 07, 2014	Jan. 31, 2014	Dec. 31, 2013	Dec. 11, 2013	Dec. 31, 2012	Mar. 31, 2008	Dec. 31, 2002	Dec. 31, 2001	Dec. 31, 2000	Dec. 30, 2000
Preferred stock, shares authorized			29,135,824
Issued and Outstanding			17,803,273
Preferred stock, shares outstanding			17,803,273
Common stock, par value	$ 0.001	$ 0.001			$ 0.001
Common stock, shares authorized	125,000,000	125,000,000			70,000,000
Common stock, shares issued	8,527,210	8,512,103			334,068
Common stock, shares outstanding	8,527,210	8,512,103			334,068		335,782
Series A Convertible Preferred Stock [Member]
Preferred stock, par value		$ 0.001			$ 0.001
Preferred stock, shares authorized		0	31,410		31,410
Issued and Outstanding		0	31,407		31,407						31,407
Preferred stock, shares outstanding		0	31,407		31,407		31,407
Series B Convertible Preferred Stock [Member]
Preferred stock, par value		$ 0.001			$ 0.001
Preferred stock, shares authorized		0	711,987		711,987
Issued and Outstanding		0	467,814		467,814						110,988	600,999
Preferred stock, shares outstanding		0	467,814		467,814		467,814
Series C Convertible Preferred Stock [Member]
Preferred stock, par value		$ 0.001			$ 0.001					$ 0.01
Preferred stock, shares authorized		0	2,967,678		2,967,678
Issued and Outstanding		0	2,770,633		2,770,633				2,867,154
Preferred stock, shares outstanding		0	2,770,633		2,770,633		2,770,633
Series C-2 Convertible Preferred Stock [Member]
Preferred stock, par value		$ 0.001			$ 0.001
Preferred stock, shares authorized		0	2,347,826		2,347,826
Issued and Outstanding		0	2,347,826		2,347,826			2,347,826
Preferred stock, shares outstanding		0	2,347,826		2,347,826		2,347,826
Series D-1 Convertible Preferred Stock [Member]
Preferred stock, par value		$ 0.001			$ 0.001
Preferred stock, shares authorized		0	10,000,000		10,000,000
Issued and Outstanding		0	6,054,255		6,054,255
Preferred stock, shares outstanding		0	6,054,255		6,054,255		0
Series D-2 Convertible Preferred Stock [Member]
Preferred stock, par value		$ 0.001			$ 0.001
Preferred stock, shares authorized		0	10,000,000		10,000,000
Issued and Outstanding		0	6,131,338	388,641	5,742,697	1,785,712
Preferred stock, shares outstanding		0	6,131,338		5,742,697		0

Statements of Operations

Statements of Operations - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Total revenue	$ 65	$ 65	$ 1,256	$ 95
Operating expenses:
Research and development	3,787	1,320	8,287	4,363
Selling, general and administrative	2,210	1,206	7,616	4,381
Total operating expenses	5,997	2,526	15,903	8,744
Loss from operations	(5,932)	(2,461)	(14,647)	(8,649)
Other (income) expense:
Amortization of deferred financing costs and debt discount	0	536	755	3,485
Loss on extinguishment of debt			1,389	0
Interest expense on beneficial conversion feature			0	10,802
Interest expense — related party			0	892
Interest expense	(1)	44	48	192
Derivative fair value adjustment	0	(2,783)	(10,080)	7,886
Other expense	0	10	10	0
Total other (income) expense:	(1)	(2,193)	(7,878)	23,257
Income (Loss) from continuing operations before taxes	(5,931)	(268)	(6,769)	(31,906)
Income tax benefit	0	313	1,166	575
Income (Loss) from continuing operations	(5,931)	45	(5,603)	(31,331)
Income (Loss) from discontinued operations, net of tax expense of $1,166 and $575 for the years ended December 31, 2014 and 2013, respectively	(453)	367	1,369	870
Net loss	(6,384)	412	(4,234)	(30,461)
Deemed dividend for beneficial conversion feature on Series D-2 preferred stock	0	(909)	(909)	(4,232)
Deemed dividend for antidilution adjustments to convertible preferred stock	0	(214)	(214)	(6,402)
Accretion of convertible preferred stock	0	(510)	(510)	(5,714)
Net loss attributable to common stockholders - basic	(6,384)	(1,221)	(5,867)	(46,809)
Derivative fair value adjustment	0	(2,783)	(10,080)	0
Net loss attributable to common stockholders - diluted	$ (6,384)	$ (4,004)	$ (15,947)	$ (46,809)
Net loss per share attributable to common stockholders - basic
Income (loss) per share, continuing operations, per basic share	$ (0.70)	$ (4.75)	$ (1.28)	$ (142.06)
Income (loss) per share, discontinued operations, per basic share	(0.05)	1.10	0.24	2.59
Basic (USD per share)	(0.75)	(3.65)	(1.04)	(139.47)
Income (loss) per share, continuing operations, per diluted share	(0.70)	(7.17)	(2.92)	(142.06)
Income (loss) per share, discontinued operations, per diluted share	(0.05)	0.60	0.23	2.59
Diluted (USD per share)	$ (0.75)	$ (6.57)	$ (2.69)	$ (139.47)
Weighted average common shares outstanding:
Basic (shares)	8,516,467	334,086	5,663,311	335,612
Diluted (shares)	8,516,467	609,074	5,937,087	335,612

Statements of Operations (Paren

Statements of Operations (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Tax effect of discontinued operations	$ 0	$ 313	$ 1,166	$ 575

Statement of Changes in Convert

Statement of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Series C Preferred Stock [Member]	Series C-1 Convertible Preferred Stock [Member]	Series C-2 Convertible Preferred Stock [Member]	Series D-1 Convertible Preferred Stock [Member]	Series D-2 Convertible Preferred Stock [Member]
Temporary equity at Dec. 31, 2012					$ 250	$ 4,215	$ 28,121	$ 0	$ 13,500	$ 0	$ 0
Increase (Decrease) in Temporary Equity [Roll Forward]
Sale of preferred stock											2,405
Conversion of convertible notes into preferred stock										8,476	5,540
Reclassification of warrants issued with preferred stock to derivative liability											(2,500)
Beneficial conversion feature for antidilution adjustment						594	4,748		1,060
Beneficial conversion feature on sale of preferred stock											4,232
Beneficial conversion feature on conversion of convertible notes										6,998	3,804
Adjustment of preferred stock to liquidation value	$ 5,714					(594)	(4,748)		(1,060)	1,478	10,638
Temporary equity at Dec. 31, 2013					250	4,215	28,121	0	13,500	16,952	24,119
Stockholders' equity at Dec. 31, 2012	(65,415)	$ 0	$ 17,401	$ (82,816)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(30,461)			(30,461)
Exercise of stock options	5		5
Stock-based compensation expense	180		180
Deemed contribution of a loan guarantee	3,930		3,930
Beneficial conversion feature for antidilution adjustment	(6,402)		(6,402)
Beneficial conversion feature on sale of preferred stock	(4,232)		(4,232)
Adjustment of preferred stock to liquidation value	(5,714)		(5,714)
Warrant derivative liability reclassified to additional paid-in capital	0
Stockholders' equity at Dec. 31, 2013	(108,109)	0	5,168	(113,277)
Increase (Decrease) in Temporary Equity [Roll Forward]
Sale of preferred stock											544
Reclassification of warrants issued with preferred stock to derivative liability											(544)
Beneficial conversion feature for antidilution adjustment						18	153		43
Beneficial conversion feature on sale of preferred stock											909
Conversion of preferred stock into shares of common stock					(250)	(4,215)	(28,121)		(13,500)	(16,952)	(25,752)
Adjustment of preferred stock to liquidation value	510					(18)	(153)		(43)		724
Temporary equity at Dec. 31, 2014					$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(4,234)			(4,234)
Exercise of stock options	9		9
Stock-based compensation expense	1,201		1,201
Beneficial conversion feature for antidilution adjustment	(214)		(214)
Beneficial conversion feature on sale of preferred stock	(909)		(909)
Adjustment of preferred stock to liquidation value	(510)		(510)
Issuance of common stock from the IPO, net of underwriting discounts and commissions and offering expenses	54,583	6	54,577
Conversion of preferred stock into shares of common stock	88,790	2	88,788
Warrant derivative liability reclassified to additional paid-in capital	2,701		2,701
Exercise of common stock warrants	55		55
Issuance of common stock - ESPP	68		68
Stockholders' equity at Dec. 31, 2014	33,431	$ 8	$ 150,934	$ (117,511)
Increase (Decrease) in Temporary Equity [Roll Forward]
Adjustment of preferred stock to liquidation value	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(6,384)
Stockholders' equity at Mar. 31, 2015	$ 27,438

Statement of Changes in Conver7

Statement of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Statement of Stockholders' Equity [Abstract]
Payments of stock issuance costs	$ 0	$ 95

Statements of Cash Flows

Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net income ( loss)	$ (6,384)	$ 412	$ (4,234)	$ (30,461)
Adjustments to reconcile net loss to net cash used in operating activities:
Beneficial conversion feature on convertible notes — related party			0	10,802
Gain on insurance recovery			(165)	0
Gain on sale of asset, net of transaction expenses			0	(988)
Loss on extinguishment of debt			1,389	0
Allowance for bad debts			0	(10)
Depreciation	323	308	1,238	1,329
Stock-based compensation expense	296	110	1,201	180
Amortization of deferred financing costs and debt discount	0	536	755	3,485
Change in fair value of derivative liability	0	(2,783)	(10,080)	7,886
Changes in deferred rent	(57)	(15)	(187)	(53)
Changes in operating assets and liabilities:
Accounts receivable and unbilled services	448	(275)	(439)	1,366
Prepaid expenses, other assets, and deferred costs	(160)	186	(490)	(102)
Accounts payable and accrued expenses	1,052	635	1,575	(82)
Interest payable — related party			0	892
Deferred revenue	(65)	1,047	(35)	1,449
Net cash used in operating activities	(4,547)	161	(9,472)	(4,307)
Cash flows from investing activities:
Proceeds from insurance recovery			216	0
Proceeds from sale of asset, net of transaction expenses			0	988
Purchases of property and equipment	(171)	(74)	(704)	(431)
Net cash (used in) provided by investing activities	(171)	(74)	(488)	$ 557
Cash flows from financing activities:
Proceeds from initial public offering			62,000
Proceeds from issuance of convertible notes			0	$ 899
Proceeds from sale of preferred stock	0	544	544	2,500
Preferred stock issuance costs			0	$ (95)
Repayment of debt			(15,000)
Payments of deferred offering costs and underwriting discounts and commissions	0	(1,388)	(6,875)	$ (542)
Proceeds from employee stock purchase plan issuance	95	0	68	0
Proceeds from exercise of stock warrants			55	0
Proceeds from exercise of stock options	0	5	9	5
Net cash provided by financing activities	95	(839)	40,801	2,767
Net increase (decrease) in cash and cash equivalents	(4,623)	(752)	30,841	(983)
Cash and cash equivalents, beginning of period	32,243	1,402	1,402	2,385
Cash and cash equivalents, end of period	27,620	650	32,243	1,402
Supplemental cash flow information:
Cash paid for interest	0	45	49	197
Noncash financing and investing activities:
Conversion of convertible notes into preferred stock			0	14,016
Beneficial conversion feature on sale of Series D-2 preferred stock	0	909	909	4,232
Beneficial conversion feature for antidilution adjustment	0	214	214	6,402
Adjustment of preferred stock to redemption value	0	(510)	(510)	(5,714)
Issuance of warrants allocated to debt discount			906	1,168
Deemed contribution of a loan guarantee			0	3,930
Issuance of warrants with preferred stock	0	544	0	2,500
Equipment purchase in accounts payable and accrued expenses	25	204	34	15
Impairment of fixed asset			51	0
Deferred offering costs included in accounts payable	$ 257	$ 1,715	0	1,233
Deferred offering costs reclassified to additional paid-in capital			4,126	0
Warrant derivative liability reclassified to additional paid-in capital			2,701	0
Conversion of convertible preferred stock to common stock			$ 88,790	$ 0

Description of Business and Bas

Description of Business and Basis of Preparation	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Preparation	Description of Business and Basis of Preparation Organization SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) is a Delaware corporation formed on November 4, 1999 . SCYNEXIS is a pharmaceutical company, headquartered in Jersey City, New Jersey, committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Historically, the Company also offered its services in drug discovery and development, primarily in the form of integrated research teams consisting of medicinal, computational, analytical, and process scientists working on a collaborative basis with its customers on research projects. These services were provided by the Company's contract research and development services business (the "Services Business") asset group. On July 21, 2015, the Company completed the sale of the Services Business asset group pursuant to an Asset Purchase Agreement (the "Agreement"), with an effective date of July 17, 2015, with Accuratus Lab Services, Inc. ("Accuratus"), a private-equity backed process chemistry, formulation, manufacturing and analytical development services provider. The material terms of the Services Business sale transaction are described in Note 13. Discontinued Operations As described above, the Company completed the sales of the Services Business on July 21, 2015. The accompanying unaudited interim financial statements reflect the retrospective adjustments for the periods presented to include the Services Business in Discontinued Operations. Unaudited Interim Financial Information The accompanying unaudited financial statements and notes have been prepared in accordance with accounting principles generally accepted in the United States, or US GAAP, as contained in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (the “Codification” or “ASC”) for interim financial information. In the opinion of management, the interim financial information includes all adjustments of a normal recurring nature necessary for a fair presentation of the results of operations, financial position, and cash flows. The results of operations for the three months ended March 31, 2015 , are not necessarily indicative of the results for the full year or the results for any future periods. These financial statements should be read in conjunction with the financial statements and notes set forth in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC") on March 30, 2015 and Exhibit 99.1 to the Form 8-K dated October 30, 2015. Use of Estimates The preparation of financial statements in conformity with US GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include: the accounts receivable allowance; the valuation of the related-party deemed contribution; the fair value of the Company’s common stock used to measure stock-based compensation for options granted to employees and nonemployees and to determine the fair value of common stock warrants; the Services Business asset group’s fair value less costs to sell, which was used to assess the Services Business asset group for impairment; the fair value of convertible preferred stock; the fair value of the Company’s derivative liability; the estimate of services and effort expended by third-party research and development service providers used to recognize research and development expense; and the estimated useful lives of property and equipment. Reverse Stock-splits On March 17, 2014, the Company amended its amended and restated certificate of incorporation to implement a 1-for-4 reverse stock split of its common stock. The reverse stock split did not cause an adjustment to the par value or the authorized shares of the common stock. As a result of the reverse stock split, the Company adjusted the share amounts under its employee incentive plans, outstanding options and common stock warrant agreements with third parties. On April 25, 2014, the Company amended its amended and restated certificate of incorporation to implement an additional 1-for-5.1 reverse stock split of its common stock. The reverse stock split did not cause an adjustment to the par value or the authorized shares of the common stock. As a result of the reverse stock split, the Company further adjusted the share amounts under its employee incentive plans, outstanding options and common stock warrant agreements with third parties. All disclosures of common shares and per common share data in the accompanying interim financial statements and related notes reflect these two reverse stock splits for all periods presented. Initial Public Offering On May 7, 2014, the Company completed an initial public offering (“IPO”) of its common stock. The Company sold an aggregate of 6,200,000 shares of common stock at a public offering price of $10.00 per share. Net proceeds were $54,583 , after deducting underwriting discounts and commissions of $3,290 and offering expenses of $4,127 . Upon the completion of the IPO, all outstanding shares of the Company’s convertible preferred stock were automatically converted into 1,691,884 shares of common stock and certain outstanding warrants were exercised for an additional 275,687 shares of common stock. In connection with the consummation of the IPO, the Company repaid outstanding debt with a principal balance of $15,000 , plus all accrued interest, to the holder of such debt, which was outstanding pursuant to a credit agreement referred to herein as the 2013 Credit Agreement. The significant increase in the shares outstanding beginning in May 2014 has impacted the comparability of the Company's net earnings (loss) per share calculations between interim 2015 and 2014 periods. April 2015 Follow-on Public Offering On April 28, 2015, the Company completed a follow-on public offering (the "April 2015 offering") of its common stock. The Company sold an aggregate of 5,376,622 shares of common stock at a public offering price of $7.70 per share. Net proceeds were approximately $37,754 , after deducting underwriting discounts and commissions and estimated offering expenses of approximately $3,646 . The Company incurred $257 of the total estimated offering expenses as of March 31, 2015, which have been capitalized as deferred offering costs in the accompanying balance sheets. The significant increase in the shares outstanding beginning in April 2015 is expected to impact the year-over-year comparability of the Company’s net (loss) earnings per share calculations for the next twelve months.	Description of Business and Basis of Preparation Organization SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) is a Delaware corporation formed on November 4, 1999 . SCYNEXIS is a pharmaceutical company, headquartered in Jersey City, New Jersey committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Historically, the Company also offered its services in drug discovery and development, primarily in the form of integrated research teams consisting of medicinal, computational, analytical, and process scientists working on a collaborative basis with its customers on research projects. These services were provided by the Company's contract research and development services business (the "Services Business") asset group. On July 21, 2015, the Company completed the sale of the Services Business asset group pursuant to an Asset Purchase Agreement (the "Agreement"), with an effective date of July 17, 2015, with Accuratus Lab Services, Inc. ("Accuratus"), a private-equity backed process chemistry, formulation, manufacturing and analytical development services provider. The material terms of the Services Business sale transaction are described in Note 20. Discontinued Operations As described above, the Company completed the sales of the Services Business on July 21, 2015. The accompanying audited financial statements reflect the retrospective adjustments for the periods presented to include the Services Business in Discontinued Operations. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include: the accounts receivable allowance; the valuation of the related-party deemed contribution; the fair value of the Company’s common stock used to measure stock-based compensation for options granted to employees and nonemployees and to determine the fair value of common stock warrants; the Services Business asset group's fair value less costs to sell, which was used to assess the Services Business asset group for impairment; the fair value of convertible preferred stock; the fair value of the Company’s derivative liability; the estimate of services and effort expended by third-party research and development service providers used to recognize research and development expense; and the estimated useful lives of property and equipment. Reverse Stock-splits On March 17, 2014, the Company amended its amended and restated certificate of incorporation to implement a 1-for-4 reverse stock split of its common stock. The reverse stock split did not cause an adjustment to the par value or the authorized shares of the common stock. As a result of the reverse stock split, the Company adjusted the share amounts under its employee incentive plans, outstanding options and common stock warrant agreements with third parties. On April 25, 2014, the Company amended its amended and restated certificate of incorporation to implement an additional 1-for-5.1 reverse stock split of its common stock. The reverse stock split did not cause an adjustment to the par value or the authorized shares of the common stock. As a result of the reverse stock split, the Company further adjusted the share amounts under its employee incentive plans, outstanding options and common stock warrant agreements with third parties. All disclosures of common shares and per common share data in the accompanying financial statements and related notes reflect these two reverse stock splits for all periods presented. Initial Public Offering On May 7, 2014, the Company completed an initial public offering (“IPO”) of its common stock. The Company sold an aggregate of 6,200,000 shares of common stock under the registration statement on Form S-1 declared effective by the SEC on May 2, 2014, at a public offering price of $10.00 per share. Net proceeds were $54,583 , after deducting underwriting discounts and commissions of $3,290 and offering expenses of $4,127 . Upon the completion of the IPO, all outstanding shares of the Company’s convertible preferred stock were automatically converted into 1,691,884 shares of common stock and certain outstanding warrants were exercised for an additional 275,687 shares of common stock. In connection with the consummation of the IPO, the Company repaid outstanding debt with a principal balance of $15,000 , plus all accrued interest, to the holder of such debt, which was outstanding pursuant to a credit agreement referred to herein as the 2013 Credit Agreement. The significant increase in the shares outstanding beginning in May 2014 has impacted the comparability of the Company's net loss per share calculations between 2013 and 2014 periods.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Assets of Discontinued Operations The Company considers assets to be of discontinued operations (i) when management or others having the authority to do so approve a plan to sell the assets, (ii) the assets are available for immediate sale in their present condition, (iii) the Company has initiated an active program to locate a buyer and other actions required to complete the plan to sell the assets, (iv) consummation of the transaction is probable, (v) the assets are being actively marketed for sale at a price that is reasonable in relation to their current fair value, and (vi) the transaction is expected to qualify for recognition as a completed sale, within one year. Following the classification of property and equipment as held for sale, the Company discontinues depreciating the assets and writes down the assets to the lower of carrying value or fair market value, if needed. As described in Note 13, on May 4, 2015, actions taken by the Company's board of directors caused the Company to meet the relevant criteria for reporting the Services Business as held for sale. Deferred Offering Costs Deferred offering costs are expenses directly related to the IPO or the April 2015 offering. These costs consist of legal, accounting, printing, and filing fees that the Company has capitalized, including fees incurred by the independent registered public accounting firm directly related to the offerings. The IPO deferred offering costs were offset against the IPO proceeds in May 2014 and were reclassified to additional paid-in capital upon completion of the IPO. Deferred costs associated with the April 2015 offering will be offset against the proceeds from the April 2015 offering and will be reclassified to additional paid-in capital upon completion of the April 2015 offering. Revenue Recognition and Deferred Revenue The Company has historically derived the majority of its revenue from providing contract research and development services under fee for service arrangements, which were provided by the Services Business that was sold in July 2015 (see Notes 13 and 14). The Company also has entered into collaboration arrangements in exchange for non-refundable upfront payments and consideration as services are performed. These arrangements include multiple elements, such as the sale of licenses and the provision of services. Under these arrangements, the Company also is entitled to receive development milestone payments and royalties in the form of a designated percentage of product sales. The Company classifies non-refundable upfront payments, milestone payments and royalties received under collaboration and licensing agreements as revenue within its statements of operations because the Company views such activities as being central to its business operations. Revenue is recognized when all of the following conditions are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) fees are fixed or determinable, and (iv) collection of fees is reasonably assured. The Company’s contract research and development services revenue is recognized in the period in which the services are performed. When entering into an arrangement, the Company first determines whether the arrangement includes multiple deliverables and is subject to accounting guidance in ASC subtopic 605-25, Multiple-Element Arrangements . If the Company determines that an arrangement includes multiple elements, it determines whether the arrangement should be divided into separate units of accounting and how the arrangement consideration should be measured and allocated among the separate units of accounting. An element qualifies as a separate unit of accounting when the delivered element has standalone value to the customer. The Company’s arrangements do not include a general right of return relative to delivered elements. Any delivered elements that do not qualify as separate units of accounting are combined with other undelivered elements within the arrangement as a single unit of accounting. If the arrangement constitutes a single combined unit of accounting, the Company determines the revenue recognition method for the combined unit of accounting and recognizes the revenue over the period from inception through the date the last deliverable within the single unit of accounting is delivered. Non-refundable upfront license fees are recorded as deferred revenue and recognized into revenue on a straight-line basis over the estimated period of the Company’s substantive performance obligations. If the Company does not have substantive performance obligations, the Company recognizes non-refundable upfront fees into revenue through the date the deliverable is satisfied. Analyzing the arrangement to identify deliverables requires the use of judgment and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. In arrangements that include license rights and other non-contingent deliverables, such as participation in a steering committee, these deliverables do not have standalone value because the non-contingent deliverables are dependent on the license rights. That is, the non-contingent deliverables would not have value without the license rights, and only the Company can perform the related services. Upfront license rights and non-contingent deliverables, such as participation in a steering committee, do not have standalone value as they are not sold separately and they cannot be resold. In addition, when non-contingent deliverables are sold with upfront license rights, the license rights do not represent the culmination of a separate earnings process. As such, the Company accounts for the license and the non-contingent deliverables as a single combined unit of accounting. In such instances, the license revenue in the form of non-refundable upfront payments is deferred and recognized over the applicable relationship period, which historically has been the estimated period of the Company’s substantive performance obligations or the period the rights granted are in effect. The Company recognizes contingent event-based payments under license agreements when the payments are received. The Company has not received any royalty payments to date. The Company will recognize a milestone payment as revenue when earned if it is substantive and the Company has no ongoing performance obligations related to the milestone. A milestone payment is considered substantive if it: 1) is commensurate with either the Company’s performance to achieve the milestone or the enhanced value of the delivered item as a result of a specific outcome from the Company’s performance to achieve the milestone; 2) relates solely to past performance; and 3) is reasonable relative to all of the deliverables and payment terms, including other potential milestone consideration, within the arrangement. Amounts received prior to satisfying all revenue recognition criteria are recorded as deferred revenue in the accompanying balance sheets. The Company’s deferred revenue includes non-refundable upfront payments received under certain licensing and collaboration arrangements that contain substantive prospective performance obligations that the Company is providing over respective defined service or estimated relationship periods. Such non-refundable upfront payments are recognized as revenue over these defined service or estimated relationship periods. The Company received non-refundable upfront payments under research services agreements supported by the Services Business of $313 , $1,500 and $500 in August 2012, August 2013 and January 2014, respectively, which are recognized as revenue over periods of six months, 70 months and 48 months, respectively. The Company recognized revenue in discontinued operations from these upfront payments of $96 and $93 for the three months ended March 31, 2015 and 2014, respectively. Collaboration Arrangements The Company assesses its contractual arrangements, and presents costs incurred and payments received under contractual arrangements, in accordance with FASB ASC 808, Collaborative Arrangements (Topic 808), when the Company determines that the contractual arrangement incudes a joint operating activity, has active participation by both parties, and both parties are subject to significant risks and rewards under the arrangement. When reimbursement payments are due to the Company under a collaborative arrangement within the scope of Topic 808, the Company determines the appropriate classification for each specific reimbursement payment in the statements of operations by considering (i) the nature of the arrangement, (ii) the nature of the Company’s business operations, and (iii) the contractual terms of the arrangement. The Company's August 2013 development, license, and supply agreement with R-Pharm, CJSC (“R-Pharm”), combined with the supplemental arrangement in November 2014, is a collaborative arrangement pursuant to Topic 808 and the Company’s previously described accounting policy. The reimbursements due from R-Pharm for specified research and development costs incurred by the Company are classified as a reduction to research and development expense in the accompanying statements of operations. The reimbursements due to the Company are recorded as a reduction of expense when (i) the reimbursable expenses have been incurred by the Company, (ii) persuasive evidence of a cost reimbursement arrangement exists, (iii) reimbursable costs are fixed or determinable, and (iv) the collection of the reimbursement payment is reasonably assured. The Company recorded receivables for unpaid reimbursement amounts due from R-Pharm of $420 and $226 as of March 31, 2015 and December 31, 2014, respectively, which are presented as other current assets in the accompanying balance sheets. Research and Development Major components of research and development costs include clinical trial activities and services, including related drug formulation, manufacturing, and other development, preclinical studies, cash compensation, stock-based compensation, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf, materials and supplies, legal services, and regulatory compliance. The Company is required to estimate its expenses resulting from its obligations under contracts with clinical research organizations, clinical site agreements, vendors, and consultants in connection with conducting SCY-078 clinical trials and preclinical development. The financial terms of these contracts are subject to negotiations which vary from contract to contract, and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company’s objective is to reflect the appropriate development and trial expenses in its financial statements by matching those expenses with the period in which the services and efforts are expended. For clinical trials, the Company accounts for these expenses according to the progress of the trial as measured by actual hours expended by CRO personnel, investigator performance or completion of specific tasks, patient progression, or timing of various aspects of the trial. For preclinical development services performed by outside service providers, the Company determines accrual estimates through financial models, taking into account development progress data received from outside service providers and discussions with applicable Company and service provider personnel. Reimbursements of certain research and development costs by parties under collaborative arrangements have been recorded as a reduction of research and development expense presented within the statement of operations. Such reimbursements were recognized under the collaboration arrangement with R-Pharm during the quarter ended March 31, 2015. Information about the Company’s research and development expenses and reimbursements due under collaboration arrangements for the three months ended March 31, 2015 and 2014, is presented as follows: Three Months Ended March 31, 2015 2014 Research and development expense, gross $ 3,981 $ 1,320 Less: Reimbursement of research and development expense 194 — Research and development expense, net of reimbursements $ 3,787 $ 1,320 Income Taxes The Company provides for deferred income taxes under the asset and liability method, whereby deferred income taxes result from temporary differences between the tax bases of assets and liabilities and their reported amounts in the financial statements. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that the Company believes is more likely than not to be realized. The Company recognizes uncertain tax positions when the positions will be more likely than not sustained based solely upon the technical merits of the positions. The Company applies intraperiod tax allocation guidance pursuant to FASB ASC 740, Income Taxes (Topic 740) to allocate income tax (expense) benefit between pre-tax income (loss) from continuing operations and discontinued operations. For periods in which the Company reports pre-tax income from discontinued operations for financial reporting purposes and pre-tax loss from continuing operations, the Company presents income from discontinued operations net of income tax expense attributable to its discontinued operations using the estimated annual effective tax rate of the Services Business. The Company also recognizes a corresponding income tax benefit on its loss from continuing operations for the same affected period. Effect of Recent Accounting Pronouncements In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity , or ASU 2014-08. Under ASU 2014-08, only disposals representing a strategic shift in operations that have a major effect on the Company’s operations and financial results should be presented as discontinued operations. Additionally, ASU 2014-08 requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. The amendments in ASU 2014-08 are effective for fiscal years, and interim periods within those years, beginning after December 15, 2014. The Company adopted this guidance in the first quarter of 2015 and has applied it for presentation and disclosure of the Services Business as discontinued operations (see Note 13). The Company will also apply, as applicable, the guidance to future dispositions or classifications as held for sale. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers: Topic 606, or ASU 2014-09. ASU 2014-09 establishes the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In applying the new revenue recognition model to contracts with customers, an entity: (1) identifies the contract(s) with a customer; (2) identifies the performance obligations in the contract(s); (3) determines the transaction price; (4) allocates the transaction price to the performance obligations in the contract(s); and (5) recognizes revenue when (or as) the entity satisfies a performance obligation. The accounting standards update applies to all contracts with customers except those that are within the scope of other topics in the FASB Accounting Standards Codification. The accounting standards update also requires significantly expanded quantitative and qualitative disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. This guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2016, which is effective for the Company for the year ending December 31, 2017. The FASB has proposed a delay in the effective date of the accounting standards update to fiscal years and interim periods within those years beginning on or after December 15, 2017, which is pending approval. The Company is currently evaluating the impact that the implementation of ASU 2014-09 will have on the Company’s financial statements. In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern , or ASU 2014-15. ASU 2014-15 will explicitly require management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Earlier adoption is permitted. The Company is not early adopting ASU 2014-15. The Company is currently evaluating the impact that the implementation of ASU 2014-15 will have on the Company’s financial statements, and the actual impact will be dependent upon the Company’s liquidity and the nature or significance of future events or conditions that exist upon adopting the updated standard. In January 2015, the FASB issued ASU No. 2015-01, Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items, or ASU 2015-01. ASU 2015-01 eliminates from GAAP the concept of extraordinary items. ASU 2015-01 is effective for fiscal years and interim periods beginning after December 15, 2015. Early adoption is permitted. The Company does not expect that the adoption of ASU 2015-01 will have a material impact on its financial statements. In April 2015, the FASB issued ASU No. 2015-03, Simplifying the Presentation of Debt Issuance Costs , or ASU 2015-03. Under ASU 2015-03, the costs of issuing debt will no longer be recorded as an intangible asset, except when incurred before receipt of the funding from the associated debt liability. Rather, debt issuance costs related to a recognized debt liability will be presented on the balance sheet as a direct deduction from the debt liability, similar to the presentation of debt discounts. The costs will continue to be amortized to interest expense using the effective interest method. ASU 2015-03 is effective for fiscal years and interim periods beginning after December 15, 2015, with early adoption permitted. ASU 2015-03 requires retrospective application to all prior periods presented in the financial statements. The Company does not expect that the adoption of ASU 2015-03 will have a material any impact on its financial statements. In April 2015, the FASB issued ASU No. 2015-05, Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement” , or ASU 2015-05 . ASU 2015-05 provides guidance to entities about whether a cloud computing arrangement includes a software license. Under ASU 2015-05, if a software cloud computing arrangement contains a software license, entities should account for the license element of the arrangement in a manner consistent with the acquisition of other software licenses. If the arrangement does not contain a software license, entities should account for the arrangement as a service contract. ASU 2015-05 also removes the requirement to analogize to ASC 840-10, to determine the asset acquired in a software licensing arrangement. For public companies, ASU 2015-05 is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2015, and early adoption is permitted. The Company does not expect that the adoption of ASU 2015-05 will have a material impact on its financial statements.	Summary of Significant Accounting Policies Assets of Discontinued Operations The Company considers assets to be of discontinued operations (i) when management or others having the authority to do so approve a plan to sell the assets, (ii) the assets are available for immediate sale in their present condition, (iii) the Company has initiated an active program to locate a buyer and other actions required to complete the plan to sell the assets, (iv) consummation of the transaction is probable, (v) the assets are being actively marketed for sale at a price that is reasonable in relation to their current fair value, and (vi) the transaction is expected to qualify for recognition as a completed sale, within one year. Following the classification of property and equipment as held for sale, the Company discontinues depreciating the assets and writes down the assets to the lower of carrying value or fair market value, if needed. As described in Note 20, on May 4, 2015, actions taken by the Company's board of directors caused the Company to meet the relevant criteria for reporting the Services Business as held for sale. Concentration of Credit Risk Financial instruments, which potentially expose the Company to concentrations of credit risk, consist principally of cash on deposit with a bank, which exceeds FDIC insured limits, and accounts receivable and unbilled services. Ongoing credit evaluations of customer’s financial condition are performed by the Company and collateral is not required. Revenue recognized from a non-refundable upfront license fee payment received from Waterstone Pharmaceuticals (HK Limited), or Waterstone, a licensing partner (see Note 18), accounted for 80% and 0% of the Company's total revenue in continuing operations for the years ended December 31, 2014 and 2013 , respectively. Revenue recognized from a non-refundable upfront payment from R-Pharm, CJSC (“R-Pharm”), a collaboration partner (see Note 18), accounted for 20% and 100% of the Company's total revenue in continuing operations for the years ended December 31, 2014 and 2013 , respectively. No other parties contributed to the Company's total revenue in continuing operations in 2014 or 2013 . One Services Business customer represented 31% and another customer represented 15% of accounts receivable and unbilled services included in assets of discontinued operations, net at December 31, 2014 . Two Services Business customers each represented 16% and one customer represented 14% of accounts receivable and unbilled services included in assets of discontinued operations, net at December 31, 2013 . No other Services Business customer accounted for 10% or more of accounts receivable and unbilled services included in assets of discontinued operations, net. One Services Business customer, which is a related-party (see Note 14), accounted for 41% and 43% of the Company’s total revenues in discontinued operations for the years ended December 31, 2014 and 2013 , respectively. Another customer of the Services Business accounted for 17% of the Company's total revenues in discontinued operations for the year ended December 31, 2014 . No other customer accounted for more than 10% of the Company’s total revenues in discontinued operations in 2014 or 2013 . Cash and Cash Equivalents The Company considers any highly liquid investments with a remaining maturity of three months or less when purchased to be cash and cash equivalents. Accounts Receivable and Unbilled Services Accounts receivable and unbilled services consist of amounts billed and unbilled under the Company’s Services Business contracts with its Services Business customers. The Company extends credit to customers without requiring collateral. Accounts receivable are stated at net realizable value. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance based on its history of collections and write-offs and the current status of all receivables. The Company does not accrue interest on trade receivables. Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the respective assets, which generally range from three to seven years. Leasehold improvements are amortized over the shorter of the useful life of the asset or the term of the related lease. Maintenance and repairs are charged against expense as incurred. Deferred Financing Costs Deferred financing costs were transaction costs associated with issuing debt as well as costs related to a deemed contribution for a guarantee from a related party. The Company recognized these costs in the balance sheet as noncurrent assets. Deferred financing costs were amortized over the life of the related debt. Other Assets Other assets consist primarily of the refundable long-term deposit on the leased building facility (included in assets of discontinued operations) and the refundable amount held by the Company’s employee dental plan insurance provider as required by its agreement. Deferred Offering Costs Deferred offering costs were expenses directly related to the IPO. These costs consisted of legal, accounting, printing, and filing fees that the Company capitalized, including fees incurred by the independent registered public accounting firm directly related to the offering. The deferred offering costs were offset against the IPO proceeds in May 2014 and were reclassified to additional paid-in capital upon completion of the IPO. As of December 31, 2014 and 2013 , the amount capitalized as deferred offering costs was $0 and $1,775 , respectively. Impairment of Long-Lived Assets Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When such events occur, the Company compares the carrying amounts of the assets to their undiscounted expected future cash flows. If the undiscounted cash flows are insufficient to recover the carrying value, an impairment loss is recorded for the difference between the carrying value and fair value of the asset. To date, no such impairment has occurred. Revenue Recognition and Deferred Revenue The Company has historically derived the majority of its revenue from providing contract research and development services under fee for service arrangements, which were provided by the Services Business that was sold in July 2015 (see Notes 19 and 20). The Company also has entered into collaboration arrangements in exchange for non-refundable upfront payments and consideration as services are performed. These arrangements include multiple elements, such as the sale of licenses and the provision of services. Under these arrangements, the Company also is entitled to receive development milestone payments and royalties in the form of a designated percentage of product sales. The Company classifies non-refundable upfront payments, milestone payments and royalties received under collaboration and licensing agreements as revenues within its statements of operations because the Company views such activities as being central to its business operations. Revenue is recognized when all of the following conditions are met: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred or services have been rendered; (iii) fees are fixed or determinable; and (iv) collection of fees is reasonably assured. The Company’s contract research and development services revenue is recognized in the period in which the services are performed. When entering into an arrangement, the Company first determines whether the arrangement includes multiple deliverables and is subject to accounting guidance in ASC subtopic 605-25, Multiple-Element Arrangements . If the Company determines that an arrangement includes multiple elements, it determines whether the arrangement should be divided into separate units of accounting and how the arrangement consideration should be measured and allocated among the separate units of accounting. An element qualifies as a separate unit of accounting when the delivered element has standalone value to the customer. The Company’s arrangements do not include a general right of return relative to delivered elements. Any delivered elements that do not qualify as separate units of accounting are combined with other undelivered elements within the arrangement as a single unit of accounting. If the arrangement constitutes a single combined unit of accounting, the Company determines the revenue recognition method for the combined unit of accounting and recognizes the revenue over the period from inception through the date the last deliverable within the single unit of accounting is delivered. Non-refundable upfront license fees are recorded as deferred revenue and recognized into revenue on a straight-line basis over the estimated period of the Company’s substantive performance obligations. If the Company does not have substantive performance obligations, the Company recognizes non-refundable upfront fees into revenue through the date the deliverable is satisfied. Analyzing the arrangement to identify deliverables requires the use of judgment and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. In arrangements that include license rights and other non-contingent deliverables, such as participation in a steering committee, these deliverables do not have standalone value because the non-contingent deliverables are dependent on the license rights. That is, the non-contingent deliverables would not have value without the license rights, and only the Company can perform the related services. Upfront license rights and non-contingent deliverables, such as participation in a steering committee, do not have standalone value as they are not sold separately and they cannot be resold. In addition, when non-contingent deliverables are sold with upfront license rights, the license rights do not represent the culmination of a separate earnings process. As such, the Company accounts for the license and the non-contingent deliverables as a single combined unit of accounting. In such instances, the license revenue in the form of non-refundable upfront payments is deferred and recognized over the applicable relationship period, which historically has been the estimated period of the Company’s substantive performance obligations or the period the rights granted are in effect. The Company recognizes contingent event-based payments under license agreements when the payments are received. The Company has not received any royalty payments to date. The Company will recognize a milestone payment as revenue when earned if it is substantive and the Company has no ongoing performance obligations related to the milestone. A milestone payment is considered substantive if it: 1) is commensurate with either the Company’s performance to achieve the milestone or the enhanced value of the delivered item as a result of a specific outcome from the Company’s performance to achieve the milestone; 2) relates solely to past performance; and 3) is reasonable relative to all of the deliverables and payment terms, including other potential milestone consideration, within the arrangement. Amounts received prior to satisfying all revenue recognition criteria are recorded as deferred revenue in the accompanying balance sheets. The Company’s deferred revenue includes non-refundable upfront payments received under certain licensing and collaboration arrangements that contain substantive prospective performance obligations that the Company is providing over respective defined service or estimated relationship periods. Such non-refundable upfront payments are recognized over these defined service or estimated relationship periods. The Company received a non-refundable upfront payment of $1,500 from R-Pharm in August 2013 which is being recognized over a period of 70 months. The Company recognized revenue in continuing operations from this upfront payment of $256 and $95 for the years ended December 31, 2014 and 2013 , respectively. The Company received a non-refundable upfront payments of $313 and $500 in August 2012 and January 2014, respectively, under research services agreements supported by the Services Business, which were being recognized over periods of six months and 48 months, respectively. The Company recognized revenue in discontinued operations from these upfront payments of $122 and $62 for the years ended December 31, 2014 and 2013 , respectively. Collaboration Arrangements The Company assesses its contractual arrangements, and presents costs incurred and payments received under contractual arrangements, in accordance with FASB ASC 808, Collaborative Arrangements (Topic 808), when the Company determines that the contractual arrangement incudes a joint operating activity, has active participation by both parties, and both parties are subject to significant risks and rewards under the arrangement. When reimbursement payments are due to the Company under a collaborative arrangement within the scope of Topic 808, the Company determines the appropriate classification for each specific reimbursement payment in the statements of operations by considering (i) the nature of the arrangement, (ii) the nature of the Company’s business operations, and (iii) the contractual terms of the arrangement. The Company has concluded that the August 2013 development, license, and supply agreement with R-Pharm, combined with the supplemental arrangement in November 2014, is a collaborative arrangement pursuant to Topic 808 and the Company’s previously described accounting policy. This agreement and supplemental arrangement is further described in Note 18. The reimbursements due from R-Pharm for specified research and development costs incurred by the Company are classified as a reduction to research and development expense in the accompanying statements of operations. The reimbursements due to the Company are recorded as a reduction of expense when (i) the reimbursable expenses have been incurred by the Company, (ii) persuasive evidence of a cost reimbursement arrangement exists, (iii) reimbursable costs are fixed or determinable, and (iv) the collection of the reimbursement payment is reasonably assured. Unpaid reimbursement amounts due from R-Pharm at period end are presented as an other current asset in the accompanying balance sheets. Research and Development Major components of research and development costs include clinical trial activities and services, including related drug formulation, manufacturing, and other development, preclinical studies, cash compensation, stock-based compensation, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf, materials and supplies, legal services, and regulatory compliance. The Company is required to estimate its expenses resulting from its obligations under contracts with clinical research organizations, clinical site agreements, vendors, and consultants in connection with conducting SCY-078 clinical trials and preclinical development. The financial terms of these contracts are subject to negotiations which vary from contract to contract, and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company’s objective is to reflect the appropriate development and trial expenses in its financial statements by matching those expenses with the period in which the services and efforts are expended. For clinical trials, the Company accounts for these expenses according to the progress of the trial as measured by actual hours expended by CRO personnel, investigator performance or completion of specific tasks, patient progression, or timing of various aspects of the trial. For preclinical development services performed by outside service providers, the Company determines accrual estimates through financial models, taking into account development progress data received from outside service providers and discussions with applicable Company and service provider personnel. Reimbursements of certain research and development costs by parties under collaborative arrangements have been recorded as a reduction of research and development expense presented within the statement of operations. Such reimbursements were made under the collaboration arrangement with R-Pharm, which is further described in Note 18. Information about the Company’s research and development expenses and reimbursements due under collaboration arrangements for the years ended December 31, 2014 and 2013 is presented as follows: Years Ended December 31, 2014 2013 Research and development expense, gross $ 8,513 $ 4,363 Less: Reimbursement of research and development expense 226 — Research and development expense, net of reimbursements $ 8,287 $ 4,363 Patent Expenses Costs related to filing and pursuing patent applications, as well as costs related to maintaining the Company's existing patent portfolio, are recorded as expense as incurred since recoverability of such expenditures is uncertain. Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Company’s principal or, in absence of a principal, most advantageous market for the specific asset or liability. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs when determining fair value. The three tiers are defined as follows: • Level 1 — Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; • Level 2 — Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and • Level 3 — Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions about the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances. Amortization of Deferred Financing Costs and Debt Discount Amortization of deferred financing costs and debt discount includes the amortization of debt discount related to the warrants issued with the convertible notes (Note 7), the amortization of issuance costs related to the convertible notes, and amortization of the deferred financing costs related to a deemed contribution for a guarantee from a related party. Comprehensive Loss The Company has no items of comprehensive income or loss other than net loss. Income Taxes The Company provides for deferred income taxes under the asset and liability method, whereby deferred income taxes result from temporary differences between the tax bases of assets and liabilities and their reported amounts in the financial statements. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that the Company believes is more likely than not to be realized. The Company recognizes uncertain tax positions when the positions will be more likely than not sustained based solely upon the technical merits of the positions. The Company applies intraperiod tax allocation guidance pursuant to FASB ASC 740, Income Taxes (Topic 740) to allocate income tax (expense) benefit between pre-tax income (loss) from continuing operations and discontinued operations. For periods in which the Company reports pre-tax income from discontinued operations for financial reporting purposes and pre-tax loss from continuing operations, the Company presents income from discontinued operations net of income tax expense attributable to its discontinued operations using the effective tax rate of the Services Business. The Company also recognizes a corresponding income tax benefit on its loss from continuing operations for the same affected period. Stock-Based Compensation The Company measures and recognizes compensation expense for all stock-based payment awards made to employees, officers, and directors based on the estimated fair values of the awards as of grant date. The value of the portion of the award that is ultimately expected to vest is recorded as expense over the requisite service periods. The Company also accounts for equity instruments issued to non-employees using a fair value approach. The Company values equity instruments and stock options granted to employees using the Black-Scholes valuation model. The measurement of non-employee share-based compensation is subject to periodic adjustments as the underlying equity instruments vest and is recognized as an expense over the term of the related financing or the period over which services are received. The Company estimated the fair value of common stock warrants granted to lenders at their intrinsic value, which was the estimated fair value of the common stock less the exercise price for the warrant. Deferred Rent The Company recognizes rent expense on a straight-line basis over the non-cancelable term of its operating lease and records the difference between cash rent payments and the recognition of rent expense as a deferred rent liability. The Company also records landlord-funded lease incentives, such as reimbursable leasehold improvements, as a deferred rent liability, which is amortized as a reduction of rent expense over the non-cancelable term of its operating lease. Basic and Diluted Net Loss per Share of Common Stock The Company uses the two-class method to compute net loss per share because the Company has issued securities, other than common stock, that contractually entitle the holders to participate in dividends and earnings of the Company. The two-class method requires earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings. Holders of each series of the Company’s convertible preferred stock were entitled to participate in dividends, when and if declared by the SCYNEXIS Board of Directors (the "board of directors" or the "board"), that were made to common stockholders, and as a result were considered participating securities. Under the two-class method, for periods with net income, basic net income per common share is computed by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income attributable to common stockholders is computed by subtracting from net income the portion of current year earnings that the participating securities would have been entitled to receive pursuant to their dividend rights had all of the year’s earnings been distributed. No such adjustment to earnings is made during periods with a net loss, as the holders of the participating securities have no obligation to fund losses. Diluted net loss per common share is computed under the two-class method by using the weighted average number of shares of common stock outstanding, plus, for periods with net income attributable to common stockholders, the potential dilutive effects of stock options and warrants. In addition, the Company analyzes the potential dilutive effect of the outstanding participating securities when calculating diluted earnings per share. Under the “treasury stock” method, it is assumed that the warrants and options were exercised at the beginning of the period and that the funds obtained from the exercise were used to reacquire the Company’s common stock at the average market price for the period and includes those securities when they are dilutive. Under the “if-converted” method, it is assumed that the outstanding participating securities convert into common stock at the beginning of the period. The Company reports the more dilutive of the approaches as its diluted net income or net loss per share during the period. Segment and Geographic Information Operating segments are defined as components of an enterprise (business activity from which it earns revenue and incurs expenses) about which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker (“CODM”) is the Chief Executive Officer. The CODM reviews consolidated operating results to make decisions about allocating resources and assessing performance for the entire Company. The Company views its operations and manages its business as one operating segment. All assets of the Company were held in the United States for the years ended December 31, 2014 and 2013 . Although all operations are based in the United States, the Company generated a portion of its revenue, including revenue in discontinued operations, from customers outside of the United States. All of the Company's revenue from continuing operations was generated from non-refundable upfront payments received under certain licensing and collaboration arrangements with partners located in Russia and China. Information about the Company’s revenue, including revenue in continuing operations and discontinued operations, from different geographic regions for the years ended December 31, 2014 and 2013 is presented as follows: Years Ended December 31, 2014 2013 United States $ 16,422 86 % $ 15,126 90 % Europe 1,235 7 % 1,626 10 % Other non-US 1,367 7 % 105 — Total $ 19,024 100 % $ 16,857 100 % All sales, including sales outside of the United States, are denominated in United States dollars. Effect of Recent Accounting Pronouncements In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity , or ASU 2014-08. Under ASU 2014-08, only disposals representing a strategic shift in operations that have a major effect on the Company’s operations and financial results should be presented as discontinued operations. Additionally, ASU 2014-08 requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. The amendments in ASU 2014-08 are effective for fiscal years, and interim periods within those years, beginning after December 15, 2014. However, ASU 2014-08 should not be applied to a component that is classified as held for sale before the effective date even if the component is disposed of after the effective date. Early adoption is permitted, but only for disposals (or classifications as held for sale) that have not been reported in financial statements previously issued. The Company adopted this guidance in the first quarter of 2015 and has applied it for presentation and disclosure of the Services Business as discontinued operations (see Note 20). The Company will also apply, as applicable, the guidance to future dispositions or classifications as held for sale. In May 2014, the Financial Accounting Standards Board (FASB) issued ASU No. 2014-09, Revenue from Contracts with Customers: Topic 606, or ASU 2014-09. ASU 2014-09 establishes the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes the most current revenue recognition guidance. This guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2016, which is effective for the Company for the year ending December 31, 2017. The Company is currently evaluating the impact that the implementation of ASU 2014-09 will have on the Company’s financial statements. In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern , or ASU 2014-15. ASU 2014-15 will explicitly require management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Earlier adoption is permitted. The Company is not early adopting ASU 2014-15. The Company is currently evaluating the impact that the implementation of ASU 2014-15 will have on the Company’s financial statements.

Allowance for Bad Debts

Allowance for Bad Debts	12 Months Ended
	Dec. 31, 2014
Receivables [Abstract]
Loans, Notes, Trade and Other Receivables Disclosure	Allowance for Bad Debts A summary of activity in the allowance for bad debts for the years ended December 31, 2014 and 2013 is as follows: Balance at Beginning of Period Additions Charged to Expense Deductions Balance at End of Period Year ended December 31, 2013 $ 251 $ — $ (88 ) $ 163 Year ended December 31, 2014 $ 163 $ — $ (163 ) $ — All activity in the allowance for bad debts for the years ended December 31, 2014 and 2013 was directly related to the Services Business, and, as such, is included in discounted operations in the accompanying statements of operations and in assets of discontinued operations on the accompanying balance sheets.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Current Assets	Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following: December 31, 2014 2013 Prepaid SCY-078 development services $ 109 $ — Prepaid insurance 295 97 Other prepaid expenses 70 141 Other receivable due from R-Pharm 226 — Other current assets 3 5 Total $ 703 $ 243

Property and Equipment

Property and Equipment	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment consists of the following: March 31, December 31, Equipment $ 8,698 $ 8,552 Furniture and fixtures 375 375 Leasehold improvements 13,209 13,193 Total property and equipment 22,282 22,120 Less accumulated depreciation 17,608 17,285 Property and equipment, net of accumulated depreciation 4,674 4,835 Property and equipment reclassified to assets of discontinued operations, net 4,674 4,835 Property and equipment, net of assets of discontinued operations $ — $ — Depreciation expense was $323 and $308 for the three months ended March 31, 2015 and 2014, respectively, with $282 and $282 included in income (loss) from discontinued operations, respectively.	Property and Equipment Property and equipment consists of the following: December 31, 2014 2013 Equipment $ 8,552 $ 9,577 Furniture and fixtures 375 378 Leasehold improvements 13,193 13,115 Total property and equipment 22,120 23,070 Less accumulated depreciation 17,285 17,669 Property and equipment, net of accumulated depreciation 4,835 5,401 Property and equipment reclassified to assets of discontinued operations, net 4,835 5,401 Property and equipment, net of assets of discontinued operations $ — $ — Depreciation expense was $1,238 and $1,329 for the years ended December 31, 2014 and 2013 , respectively, including $1,132 and $1,215 presented in discontinued operations in the accompanying statements of operations for the years ended December 31, 2014 and 2013 , respectively. As discussed in Notes 19 and 20, the Company met the relevant criteria for reporting the Service Business as held for sale on May 4, 2015, and as a result, the Company stopped recording depreciation expense on that date and assessed the property and equipment assets for impairment pursuant to FASB Topic 360, Property, Plant, and Equipment . In the quarter ended June 30, 2014, the Company’s insurance carrier remitted proceeds for the replacement cost of a fixed asset that was damaged by severe weather. The asset’s net book value was reduced upon occurrence of the damage. The proceeds received from the insurance recovery exceeded the net book value of the asset by $165 , which was recognized as a gain during the quarter ended June 30, 2014. The replacement asset was delivered, installed and placed in service during the quarter ended September 30, 2014. The fixed asset, and the resulting gain, was directly related to the Services Business and, therefore, is presented in discontinued operations in the accompanying statements of operations. Gain on Sale of Asset On May 17, 2012, the Company sold the rights to its HEOS software to a third party for consideration of $4,500 . The HEOS software asset was used in and was directly related to the operations of the Services Business. The Company received $3,500 on May 17, 2012 and recorded a gain on sale of asset of $3,412 within discontinued operations, net of transaction expenses. The remaining balance of $1,000 was held in escrow by the buyer until certain conditions were met. On May 17, 2013, the Company met all the contractual conditions and collected the $1,000 held in escrow. The Company recognized $988 , which is net of transaction expenses, as a gain on sale of asset included in discontinued operations in the accompanying financial statements.

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure	Accrued Expenses Accrued expenses consist of the following: December 31, 2014 2013 Accrued research and development expenses $ 293 $ 92 Accrued employee bonus compensation 1,464 — Interest payable — 23 Employee withholdings 156 61 Other accrued expenses 332 556 Total accrued expenses $ 2,245 $ 732 Severance Costs In June 2014, the Company reduced its workforce in an effort to reduce operating costs. Employee severance costs associated with this action were $379 , which were expensed in the quarter ended June 30, 2014. The severance costs are being paid out through the Company's normal payroll disbursements on a monthly basis from July 2014 to January 2015. As of December 31, 2014 , $362 had been paid out and the remaining costs of $17 are included in accrued expenses in the accompanying balance sheets. The Company has entered into certain compensatory arrangements and commitments with employees and officers, including severance and retention obligations, the material terms of which are described in Note 20.

Debt Obligations

Debt Obligations	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Debt Disclosure [Abstract]
Debt Obligations	Debt Obligations Credit Facility Agreement In April 2010, the Company entered into a $15,000 credit facility agreement with HSBC Bank (the “2010 Credit Agreement”). The agreement comprised a $5,000 term loan and a $10,000 revolving credit facility. Borrowings under the 2010 Credit Agreement carried interest at a rate of London InterBank Offered Rate plus 0.95% per annum. The 2010 Credit Agreement required interest-only payments through March 2013 and was guaranteed by a related party that has an investment in the Company. All outstanding borrowings under the agreement were originally due on March 11, 2013. The 2010 Credit Agreement contained no financial covenants. On March 8, 2013, the Company entered into an agreement to amend the 2010 Credit Agreement with HSBC Bank (the “2013 Credit Agreement”). The 2013 Credit Agreement required interest-only payments through December 2014 when all outstanding borrowings were due. Other significant terms of the 2010 Credit Agreement remained the same, which included the guarantee made by a related party that has an investment in the Company. The 2013 Credit Agreement represented a new loan, and the Company determined the value of the extended guarantee under the 2013 Credit Agreement to be $3,930 , which was amortized over the term of the 2013 Credit Agreement. Pursuant to an addendum dated April 29, 2014, upon completion of the IPO on May 7, 2014, the entire outstanding balance of the 2013 Credit Agreement, amounting to $15,000 plus accrued interest, was paid in full using the proceeds from the IPO. The payment on May 7, 2014, released the related party guarantor from all obligations, under and in relation to the 2013 Credit Agreement. The Company recorded a loss on the extinguishment of debt of $1,389 in the three month period ended June 30, 2014, as the remaining deferred financing costs associated with the 2013 Credit Agreement were written off. The Company had no outstanding debt as of March 31, 2015 and as of December 31, 2014. Amortization of deferred financing costs associated with the 2010 Credit Agreement and 2013 Credit Agreement was $0 and $536 for the three months ended March 31, 2015 and 2014, respectively. Note and Warrant Purchase Agreements In December 2011, the Company executed a Note and Warrant Purchase Agreement (the “December 2011 Note and Warrant Agreement”) to issue convertible notes in an aggregate amount not to exceed $15,000 . In 2011 and 2012, under the December 2011 Note and Warrant Agreement, the Company issued convertible notes (the “2011-2012 Notes”) with a total principal amount of $11,444 to related parties that held investments in the Company. The 2011-2012 Notes included warrants to purchase 26,000 shares of the Company’s common stock at $0.20 per share. The 2011-2012 Notes were convertible into shares of the Company’s stock under various methods as stipulated in the agreement. In June 2013, the Company executed another Note and Warrant Purchase Agreement (the “June 2013 Note and Warrant Agreement”) with certain existing lenders. Under the June 2013 Note and Warrant Agreement, the lenders agreed to loan to the Company up to $1,500 in exchange for convertible notes (the “June 2013 Notes”). The Company issued June 2013 Notes for an aggregate amount of $899 . In addition, the Company agreed to issue warrants to purchase shares of the Company’s common stock upon the request of a majority of the noteholders. The June 2013 Notes were convertible into shares of the Company’s stock using methods described in the agreement. In addition, the June 2013 Notes included conversion of the entire outstanding principal and interest balance into equity securities upon the closing of any equity financing at the option of the noteholders. On December 11, 2013, the noteholders elected to convert the June 2013 Notes into shares of Series D-2 convertible preferred stock. Also on December 11, 2013, the noteholders elected to convert the 2011-2012 Notes into shares of Series D-1 and Series D-2 convertible preferred stock. There was no outstanding principal or accrued interest associated with the 2011-2012 Notes and June 2013 Notes as of December 31, 2014 or as of March 31, 2015 .	Debt Obligations Credit Facility Agreement In April 2010, the Company entered into a $15,000 credit facility agreement with HSBC Bank (the “2010 Credit Agreement”). The agreement comprised a $5,000 term loan and a $10,000 revolving credit facility. Borrowings under the 2010 Credit Agreement carried interest at a rate of London InterBank Offered Rate plus 0.95% per annum. The 2010 Credit Agreement required interest-only payments through March 2013 and was guaranteed by a related party that has an investment in the Company. All outstanding borrowings under the agreement were originally due on March 11, 2013. The 2010 Credit Agreement contained no financial covenants. At the inception of the 2010 Credit Agreement, a deemed contribution in relation to the guarantee of the 2010 Credit Agreement was recognized as deferred financing costs and amortized over the life of the loan. The value of the guarantee was determined based on the difference between the loan’s stated interest rate and the interest rate that would apply if there had been no guarantee from the related party. The Company determined the value of the 2010 Credit Agreement guarantee to be $6,338 , which was amortized over the original life of the loan. On March 8, 2013, the Company entered into an agreement to amend the 2010 Credit Agreement with HSBC Bank (the “2013 Credit Agreement”). The 2013 Credit Agreement required interest-only payments through December 2014 when all outstanding borrowings were due. Other significant terms of the 2010 Credit Agreement remained the same, which included the guarantee made by a related party that has an investment in the Company. The 2013 Credit Agreement represented a new loan, and the Company determined the value of the extended guarantee under the 2013 Credit Agreement to be $3,930 , which was amortized over the term of the 2013 Credit Agreement. As of December 31, 2013 , both the $5,000 term loan and the $10,000 revolving credit facility were outstanding under the 2013 Credit Agreement. Pursuant to an addendum dated April 29, 2014, upon completion of the IPO on May 7, 2014, the entire outstanding balance of the 2013 Credit Agreement, amounting to $15,000 plus accrued interest, was paid in full using the proceeds from the IPO. The payment on May 7, 2014, released the related party guarantor from all obligations under and in relation to the 2013 Credit Agreement. The Company recorded a loss on the extinguishment of debt of $1,389 in the three month period ended June 30, 2014 as the remaining deferred financing costs associated with the 2013 Credit Agreement were written off. The Company had no outstanding debt as of December 31, 2014 . Amortization of deferred financing costs associated with the 2010 Credit Agreement and 2013 Credit Agreement was $755 and $2,317 for the years ended December 31, 2014 and 2013 , respectively. The weighted-average interest rate was 1.19% and 1.20% for the years ended December 31, 2014 and 2013 , respectively. Interest expense was $48 and $192 for the years ended December 31, 2014 and 2013 , respectively. Note and Warrant Purchase Agreements In December 2011, the Company executed a Note and Warrant Purchase Agreement (the “December 2011 Note and Warrant Agreement”) to issue convertible notes in an aggregate amount not to exceed $15,000 . In 2011 and 2012, under the December 2011 Note and Warrant Agreement, the Company issued convertible notes (the “2011-2012 Notes”) with a total principal amount of $11,444 to related parties that held investments in the Company. The 2011-2012 Notes included warrants to purchase 26,000 shares of the Company’s common stock at $0.20 per share. The 2011-2012 Notes were convertible into shares of the Company’s stock under various methods as stipulated in the agreement. In June 2013, the Company executed another Note and Warrant Purchase Agreement (the “June 2013 Note and Warrant Agreement”) with certain existing lenders. Under the June 2013 Note and Warrant Agreement, the lenders agreed to loan to the Company up to $1,500 in exchange for convertible notes (the “June 2013 Notes”). The Company issued June 2013 Notes for an aggregate amount of $899 . In addition, the Company agreed to issue warrants to purchase shares of the Company’s common stock upon the request of a majority of the noteholders. The June 2013 Notes were convertible into shares of the Company’s stock using methods described in the agreement. In addition, the June 2013 Notes included conversion of the entire outstanding principal and interest balance into equity securities upon the closing of any equity financing at the option of the noteholders. The 2011-2012 Notes and June 2013 Notes carried interest at a rate of 8% per annum and contained no financial covenants. The outstanding principal amount and unpaid accrued interest on the convertible notes issued under the December 2011 Note and Warrant Agreement and the June 2013 Note and Warrant Agreement were originally due on December 31, 2012 and December 31, 2013, respectively, contingent upon (i) the prior written consent of holders of at least 70% of the outstanding aggregated principal amount of the convertible notes issued under the same agreement, and (ii) the prior written consent of HSBC Bank for so long as any of the principal and interest related to the 2010 Credit Agreement or the 2013 Credit Agreement remained outstanding. On the date of issuance, the fair value of warrants issued in the year ended December 31, 2012 under the December 2011 Note and Warrant Agreement was $328 . The fair value of these warrants was accounted for as debt discount and amortized to expense over the stated term of the 2011-2012 Notes. The fair value of the obligation to issue warrants in connection with the June 2013 Notes was $1,168 . The fair value of the obligation to issue warrants was $269 above the face value of the June 2013 Notes and this excess was expensed at issuance. The $899 remaining amount of the fair value of the obligation to issue warrants was accounted for as a debt discount and was amortized to expense over the term of the June 2013 Notes. The amount of the discount related to the 2011-2012 Notes’ warrants and the June 2013 Notes’ obligation to issue warrants that was amortized to expense was $0 and $1,168 for the years ended December 31, 2014 and 2013 , respectively. On December 11, 2013, the noteholders elected to convert the June 2013 Notes into shares of Series D-2 convertible preferred stock. Under the election, the outstanding principal and accrued interest balance of $899 and $33 , respectively, was converted into 665,542 shares of Series D-2 convertible preferred stock at a conversion price of $1.40 per share. Consistent with the original terms of the June 2013 Notes, the conversion price was adjusted to $1.40 per share because the Company adjusted the conversion price of the 2011-2012 Notes in connection with the sale and issuance of shares of Series D-2 convertible preferred stock on December 11, 2013 (Note 9). Also on December 11, 2013, the noteholders elected to convert the 2011-2012 Notes into shares of Series D-1 and Series D-2 convertible preferred stock. Under the election, the outstanding principal and accrued interest balance of $11,444 and $1,640 , respectively, was converted into 6,054,255 shares of Series D-1 convertible preferred stock and 3,291,443 shares of Series D-2 preferred stock at a conversion price of $1.40 per share. The conversion price of the 2011-2012 Notes was adjusted to $1.40 per share in connection with the sale and issuance of shares of Series D-2 convertible preferred stock on December 11, 2013 (Note 9). Because the Company adjusted the original conversion price on the 2011-2012 Notes and the June 2013 Notes from $4.3125 to $1.40 , the Company recorded additional interest expense of $10,802 as a result of the beneficial conversion for the antidilution adjustment on the Series D-1 convertible preferred stock and the Series D-2 convertible preferred stock. The intrinsic value of the beneficial conversion feature was calculated by multiplying the incremental number of shares of Series D-1 and Series D-2 convertible preferred stock the investors received (as a result of the Company reducing the conversion price to $1.40 ) by the estimated fair value of the Series D-1 and the Series D-2 convertible preferred stock on the commitment date. Because the intrinsic value of the beneficial conversion feature was greater than the proceeds allocated to the 2011-2012 Notes and the June 2013 Notes, the amount recognized for the beneficial conversion feature was limited by the amount of the proceeds allocated to the convertible notes. Due to the previously described conversions to Series D-1 Preferred and Series D-2 Preferred, there was no outstanding principal or accrued interest associated with the 2011-2012 Notes and June 2013 Notes as of December 31, 2013 and as of December 31, 2014.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Leases During the first quarter of 2015, the Company leased its Durham, North Carolina facility and certain office equipment under long-term non-cancelable operating leases. The Company’s lease for its primary North Carolina facility was due to expire in 2019 . The lease agreement included a renewal option to extend the lease through March 31, 2024 . Rent expense was approximately $218 and $231 for the three months ended March 31, 2015 and 2014, respectively, including $178 and $200 presented in discontinued operations in the accompanying statements of operations for the three months ended March 31, 2015 and 2014 , respectively. Future minimum lease payments for all operating leases as of March 31, 2015 are as follows: 2015 (remaining 9 months) $ 826 2016 1,122 2017 1,140 2018 1,161 2019 291 Thereafter — Total $ 4,540 As a condition to the execution of the Agreement, Accuratus assumed the Company’s post-closing obligation under its facility lease in Durham, North Carolina and the Company is being released from any post-closing liability under the facility operating lease (see Note 14), including the future minimum lease payments included within the table immediately above. The Company and its retained employees will continue to operate from the Durham facility immediately after the closing for a period of up to six months pursuant to a facility license agreement between the Company and Accuratus dated July 17, 2015. The Company has relocated its corporate headquarters and operating activities to Jersey City, New Jersey, where in July 2015 it subleased a premises located at 101 Hudson Street, Jersey City, New Jersey. The material terms of the Jersey City, New Jersey sublease are described in Note 14. License Arrangement with Potential Future Expenditures As of March 31, 2015 , the Company had a license arrangement with Merck Sharp & Dohme Corp., or Merck, that involves potential future expenditures. Under the license arrangement, the Company exclusively licensed from Merck its rights to SCY-078 in the field of human health. SCY-078 is the Company's lead product candidate. Pursuant to the terms of the license agreement, Merck is eligible to receive milestone payments from the Company that could total $19,000 upon occurrence of specific events, including initiation of a phase 3 clinical study, new drug application, and marketing approvals in each of the U.S., major European markets and Japan. In addition, Merck is eligible to receive tiered royalties from the Company based on a percentage of worldwide net sales of SCY-078. The aggregate royalties are mid- to high-single digits. In December 2014, the Company and Merck entered into an amendment to the license agreement that defers the remittance of a milestone payment due to Merck, such that no amount will be due upon initiation of the first phase 2 clinical trial of a product containing the SCY-078 compound (the "Deferred Milestone"). The amendment also increases, in an amount equal to the Deferred Milestone, the milestone payment that will be due upon initiation of the first Phase 3 clinical trial of a product containing the SCY-078 compound. Except as described above, all other terms and provisions of the license agreement remain in full force and effect. The Company has two additional licensing agreements for other compounds that could require it to make payments of up to $2,300 upon achievement of certain milestones by the Company. Clinical Development Arrangement In June 2014, the Company entered into an agreement with a third-party clinical research organization to conduct a Phase 2 clinical trial for SCY-078. The scope of the services under the agreement can be modified at any time, and the agreement can be terminated by either party 30 days after receipt of written notice. Other Arrangements The Company entered into an agreement with a third party firm to assist the Company in exploring the divestiture of its Services Business (see Note 13). Pursuant to the terms of the agreement, in the event that the Company was able to complete a divestiture of its Services Business to a third-party, the Company was obligated to pay a success fee to the third party firm for the greater of $500 or 4% of the transaction consideration. As described in Note 13, the Company completed the sale of the Services Business pursuant to the Agreement, with an effective date of July 17, 2015. In May 2015, the Company's board of directors approved, and the Company communicated, the material terms of a compensatory plan (the "Compensatory Plan") for the non-executive employees of its Service Business. The compensatory plan is designed to promote the retention of services of such non-executive employees in connection with the potential sale of the Service Business. The Company's obligations under the Compensatory Plan were contingent upon the successful closing of the sale of the Services Business. The material terms of the Compensatory Plan are described in Note 14, Subsequent Events, below.	Commitments and Contingencies Leases During the year ended December 31, 2014, the Company leased its Durham, North Carolina facility and certain office equipment under long-term non-cancelable operating leases. The Company’s lease for its primary North Carolina facility was due to expire in 2019 . The lease agreement included a renewal option to extend the lease through March 31, 2024 . As described below and in Note 20, Accuratus assumed the Company's post-closing obligation under its Durham, North Carolina facility lease in July 2015. Rent expense was approximately $952 and $906 for the years ended December 31, 2014 and 2013 , respectively, including $827 and $781 presented in discontinued operations in the accompanying statements of operations for the years ended December 31, 2014 and 2013 , respectively. Future minimum lease payments for all operating leases as of December 31, 2014 , including future minimum lease payments that were assumed by Accuratus in July 2015, are as follows: 2015 $ 1,075 2016 1,104 2017 1,123 2018 1,156 2019 291 Thereafter — Total $ 4,749 As a condition to the execution of the Asset Purchase Agreement (the "Agreement"), Accuratus assumed the Company’s post-closing obligation under its facility lease in Durham, North Carolina and the Company is being released from any post-closing liability under the facility operating lease (see Note 20), including the future minimum lease payments included within the table immediately above totaling $4,718 . The Company and its retained employees will continue to operate from the Durham facility immediately after the closing for a period of up to six months pursuant to a facility license agreement between the Company and Accuratus dated July 17, 2015. The Company has relocated its corporate headquarters and operating activities to Jersey City, New Jersey, where in July 2015 it subleased a premises located at 101 Hudson Street, Jersey City, New Jersey. The material terms of the Jersey City, New Jersey sublease are described in Note 20. License Arrangements with Potential Future Expenditures As of December 31, 2014 , the Company had a license arrangement with Merck Sharp & Dohme Corp., or Merck, as amended, that involves potential future expenditures. Under the license arrangement, the Company exclusively licensed from Merck its rights to SCY-078 in the field of human health. SCY-078 is the Company's lead product candidate. Pursuant to the terms of the license agreement, Merck is eligible to receive milestone payments from the Company that could total $19,000 upon occurrence of specific events, including initiation of a phase 3 clinical study, new drug application, and marketing approvals in each of the U.S., major European markets and Japan. In addition, Merck is eligible to receive tiered royalties from the Company based on a percentage of worldwide net sales of SCY-078. The aggregate royalties are mid- to high-single digits. In December 2014, the Company and Merck entered into an amendment to the license agreement that defers the remittance of a milestone payment due to Merck, such that no amount will be due upon initiation of the first phase 2 clinical trial of a product containing the SCY-078 compound (the "Deferred Milestone"). The amendment also increases, in an amount equal to the Deferred Milestone, the milestone payment that will be due upon initiation of the first Phase 3 clinical trial of a product containing the SCY-078 compound. Except as described above, all other terms and provisions of the license agreement remain in full force and effect. The Company has two additional licensing agreements for other compounds that could require it to make payments of up to $2,300 upon achievement of certain milestones by the Company. Clinical Development Arrangement In June 2014, the Company entered into an agreement with a third-party clinical research organization to conduct a Phase 2 clinical trial for SCY-078. The Company had no such commitments as of December 31, 2013 . The scope of the services under the agreement can be modified at any time, and the agreement can be terminated by either party 30 days after receipt of written notice. Other Arrangements The Company entered into an agreement with a third party firm to assist the Company in exploring the divestiture of its Services Business (Note 19). Pursuant to the terms of the agreement, in the event that the Company was able to complete a divestiture of its Services Business to a third-party, the Company was obligated to pay a success fee to the third party firm for the greater of $500 or 4% of the transaction consideration. As described in Note 20, the Company completed the sale of the Services Business pursuant to an Asset Purchase Agreement, dated July 17, 2015. Compensatory Arrangements with Employees and Officers Subsequent to December 31, 2014, the Company has entered into certain compensatory arrangements and commitments with employees and officers, the material terms of which are described in Note 20.

Convertible Preferred Stock

Convertible Preferred Stock	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Temporary Equity Disclosure [Abstract]
Convertible Preferred Stock	Convertible Preferred Stock The Company issued multiple series of convertible preferred stock between 2000 and January 2014. In March 2014, the Company amended its amended and restated certificate of incorporation to require the automatic conversion of all series of convertible preferred stock into common stock upon the completion of a public offering of common stock with gross proceeds of at least $20,000 . In May 2014, upon completion of the IPO, all outstanding shares of convertible preferred stock were converted into an aggregate of 1,691,884 shares of common stock at their respective conversion prices. Warrants Associated with Preferred Stock Issuances In July 2006, the Company issued warrants to purchase 196,923 shares of Series C-1 Convertible Preferred Stock, which converted into the right to purchase 14,033 shares of our common stock in connection with our IPO, however, we refer to these warrants as our Series C-1 Preferred warrants. The Series C-1 Preferred warrants were issued conjunction with a loan financing agreement with an original exercise price of $3.25 per share of Series C-1 Preferred, which converted into an exercise price of $45.61 per share of common stock in connection with our IPO. These warrants remain outstanding as of March 31, 2015 and will expire on July 14, 2016 . The fair value at the date of grant for these instruments was $459 , which was recorded as a debt discount. The debt discount related to these warrants was fully amortized as of December 31, 2010. The Company determined that the warrants should be recorded as a derivative liability and stated at fair value at each reporting period. The Company recorded other income associated with the fair value adjustment for these warrants of $0 and $37 for three months ended March 31, 2015 and March 31, 2014 , respectively. On December 11, 2013, the Company entered into an agreement to sell 1,785,712 shares of Series D-2 Convertible Preferred Stock ("Series D-2 Preferred") at $1.40 per share for an aggregate price of $2,500 (the “Series D-2 Purchase Agreement”), less issuance costs of $95 . The Series D-2 Purchase Agreement included warrants to purchase 87,532 shares of the Company’s common stock at $0.20 per share. The fair value of the warrants on the date of issuance was $4,214 , which was recorded as a discount to the Series D-2 Preferred. The fair value of the warrants was $1,714 above the face amount of the Series D-2 Preferred and this excess was expensed to derivative fair value adjustment at issuance. As described in Note 7, the warrants were classified as a derivative liability and were stated at fair value at each reporting period end date prior to being exercised in May 2014 in conjunction with the Company’s IPO. On January 31, 2014, the Company sold 388,641 shares of Series D-2 Preferred to related parties under the Series D-2 Purchase Agreement at $1.40 per share, for an aggregate price of $544 . The sale also included warrants to purchase 19,048 shares of the Company’s common stock at $0.20 per share. The fair value of the warrants on the date of issuance was $906 . The fair value of the warrants was $362 above the face amount of the Series D-2 Preferred and this excess was expensed to derivative fair value adjustment at issuance. As described in Note 7, the warrants were classified as a derivative liability and were stated at fair value at each reporting period end date prior to being exercised in May 2014 in conjunction with the Company’s IPO.	Convertible Preferred Stock The Company issued multiple series of convertible preferred stock between 2000 and January 2014. Each issuance is briefly described as follows: Series A Convertible Preferred Stock (“Series A Preferred”) In 2000, the Company issued 31,407 shares of Series A Preferred at $7.96 per share to its initial employees and consultants. Series B Convertible Preferred Stock (“Series B Preferred”) In 2000, the Company issued 600,999 shares of Series B Preferred at $9.01 per share in exchange for $2,200 in equipment, intellectual property, and conversion of existing debt, and $3,215 in cash, and incurred issuance costs of $43 . Subsequently in 2000, the Company issued an additional 110,988 shares of Series B Preferred at $9.01 per share for cash. As part of the issuance of the Series C convertible preferred stock in June 2002, the holders of Series B Preferred agreed to modify the redemption feature of the Series B Preferred to eliminate this feature. As described below, 244,173 shares of Series B Preferred were mandatorily converted into common stock during 2012. Series C Convertible Preferred Stock (“Series C Preferred”) and Warrants The Company issued warrants to purchase 100,524 shares of Series C Preferred in conjunction with certain bridge loan financings during 2001 and the subsequent 2002 Series C Preferred financing. The warrants were issued with an exercise price of $0.01 per share. Two of the investors exercised such warrants during 2003. In 2002, the Company issued 2,867,154 shares of Series C Preferred for $24,000 in cash and the conversion of approximately $4,513 of 4.5% convertible notes and accrued interest, less issuance costs of approximately $86 . As described below, 197,045 shares of Series C Preferred were mandatorily converted into common stock during 2012. In January 2005, the remaining warrants to purchase 23,911 shares of Series C Preferred shares were exercised. Series C-1 Convertible Preferred Stock (“Series C-1 Preferred”) and Warrants In August 2004, the Company received cash of $3,200 for the issuance of 984,615 shares of Series C-1 Preferred. As described below, these Series C-1 Preferred shares were mandatorily converted into common stock during 2012. Series C-2 Convertible Preferred Stock (“Series C-2 Preferred”) In March 2008, the Company received cash of $13,500 for the issuance of 2,347,826 shares of Series C-2 Preferred. December 2013 Issuances of Series D-1 Convertible Preferred Stock (“Series D-1 Preferred) and Series D-2 Convertible Preferred Stock (“Series D-2 Preferred”) On December 11, 2013, the Company entered into an agreement to sell 1,785,712 shares of Series D-2 Convertible Preferred Stock ("Series D-2 Preferred") at $1.40 per share for an aggregate price of $2,500 (the “Series D-2 Purchase Agreement”), less issuance costs of $95 . The Series D-2 Preferred was convertible into shares of common stock at a conversion price of $28.56 per share and the fair value of the common stock on December 11, 2013 was $48.35 . A convertible financial instrument includes a beneficial conversion feature if its conversion price is lower than the Company’s stock price (i.e., it’s in the money) at the commitment date. Therefore, the Company determined that the sale of the Series D-2 Preferred resulted in a beneficial conversion feature with an intrinsic value of $4,232 , which the Company recorded as a reduction to additional paid-in capital upon the sale of the Series D-2 Preferred. The Company calculated the intrinsic value of the beneficial conversion feature as the difference between the estimated fair value of the common stock on December 11, 2013 of $48.35 per share and the effective conversion price per share of $0 multiplied by the number of shares of common stock issuable upon conversion of 87,532 . Concurrent with the sale of the Series D-2 Preferred, the Company modified the terms of the 2011-2012 Notes and the related warrants and the June 2013 Notes and related warrants (Note 7). Under the amendments, the outstanding principal and accrued interest balance was converted into Series D-1 Preferred and Series D-2 Preferred at a conversion price of $1.40 per share. As a result of the conversions, the Company issued 6,054,255 shares of Series D-1 Preferred and 3,956,985 shares of Series D-2 Preferred. January 2014 Issuance of Series D-2 Preferred On January 31, 2014, the Company sold 388,641 shares of Series D-2 Preferred to related parties under the Series D-2 Purchase Agreement at $1.40 per share, for an aggregate price of $544 . The Series D-2 Preferred was convertible into shares of common stock at a conversion price of $28.56 per share and the fair value of the common stock on January 31, 2014 was $47.74 . A convertible financial instrument includes a beneficial conversion feature if its conversion price is lower than the Company’s stock price (i.e., it’s in the money) at the commitment date. Therefore, the Company determined that the sale of the Series D-2 Preferred resulted in a beneficial conversion feature with an intrinsic value of $909 , which the Company recorded as a reduction to additional paid-in capital upon the sale of the Series D-2 Preferred. The Company calculated the intrinsic value of the beneficial conversion feature as the difference between the estimated fair value of the common stock on January 31, 2014 of $47.74 per share and the effective conversion price per share of $0 multiplied by the number of shares of common stock issuable upon conversion of 19,048 . Conversion of Convertible Preferred Stock In Conjunction with IPO In March 2014, the Company amended its amended and restated certificate of incorporation to require the automatic conversion of all series of convertible preferred stock into common stock upon the completion of a public offering of common stock with gross proceeds of at least $20,000 . There were no other changes in significant terms of the convertible preferred stock during the year ended December 31, 2014. In May 2014, upon completion of the IPO, all outstanding shares of convertible preferred stock were converted into an aggregate of 1,691,884 shares of common stock at their conversion prices. Warrants Associated with Preferred Stock Issuances In July 2006, the Company issued warrants to purchase 196,923 shares of Series C-1 Preferred with an exercise price of $3.25 per share of Series C-1 Preferred. As of December 31, 2014 , these warrants are equivalent to warrants to purchase 14,033 shares of common stock at an exercise price of $45.61 per share of common stock. These warrants remain outstanding as of December 31, 2014 and will expire on July 14, 2016 . The fair value at the date of grant for these instruments was $459 , which was recorded as a debt discount. The debt discount related to these warrants was fully amortized as of December 31, 2010. The Company determined that the warrants should be recorded as a derivative liability and stated at fair value at each reporting period. The Company recorded other income associated with the fair value adjustment for these warrants of $37 and $121 for the years ended December 31, 2014 and 2013 , respectively. The December 11, 2013 Series D-2 Purchase Agreement included warrants to purchase 87,532 shares of the Company’s common stock at $0.20 per share. The fair value of the warrants on the date of issuance was $4,214 , which was recorded as a discount to the Series D-2 Preferred. The fair value of the warrants was $1,714 above the face amount of the Series D-2 Preferred and this excess was expensed to derivative fair value adjustment at issuance. As described in Note 10, the warrants were classified as a derivative liability and were stated at fair value at each reporting period end date prior to being exercised in May 2014 (in conjunction with the Company’s IPO). The sale of Series D-2 Preferred on January 31, 2014 included warrants to purchase 19,048 shares of the Company’s common stock at $0.20 per share. The fair value of the warrants on the date of issuance was $906 . The fair value of the warrants was $362 above the face amount of the Series D-2 Preferred and this excess was expensed to derivative fair value adjustment at issuance. As described in Note 10, the warrants were classified as a derivative liability and were stated at fair value at each reporting period end date prior to being exercised in May 2014 (in conjunction with the Company’s IPO). Authorized, Issued, and Outstanding Convertible Preferred Shares Prior to IPO The following table summarizes authorized, issued and outstanding preferred shares as of May 7, 2014, immediately prior to the automatic conversion to shares of common stock: Authorized Issued and Outstanding Series A Preferred 31,410 31,407 Series B Preferred 711,987 467,814 Series C Preferred 2,967,678 2,770,633 Series C-1 Preferred 3,076,923 — Series C-2 Preferred 2,347,826 2,347,826 Series D-1 Preferred 10,000,000 6,054,255 Series D-2 Preferred 10,000,000 6,131,338 Total 29,135,824 17,803,273 Convertible Preferred Stock Activity The following table summarizes convertible preferred stock activity for the years ended December 31, 2014 and 2013 : Shares of Series A Convertible Preferred Stock Series B Convertible Preferred Stock Series C Convertible Preferred Stock Series C-1 Convertible Preferred Stock Series C-2 Convertible Preferred Stock Series D-1 Convertible Preferred Stock Series D-2 Convertible Preferred Stock Balance, December 31, 2012 31,407 467,814 2,770,633 — 2,347,826 — — Issuance of Series D-2 Preferred — — — — — — 1,785,712 Conversion of notes payable — — — — — 6,054,255 3,956,985 Balance, December 31, 2013 31,407 467,814 2,770,633 — 2,347,826 6,054,255 5,742,697 Issuance of Series D-2 Preferred — — — — — — 388,641 Automatic conversion to common stock (31,407 ) (467,814 ) (2,770,633 ) — (2,347,826 ) (6,054,255 ) (6,131,338 ) Balance, December 31, 2014 — — — — — — — Significant terms of the convertible preferred stock, prior to the automatic conversion in conjunction with the IPO, were as follows: Voting rights Each share had the right to vote equal to the number of shares of common stock into which it was convertible. Additionally, the approval of 65% of the Series B Preferred, Series C Preferred, and Series C-2 Preferred stockholders, voting as separate classes, was required to change any bylaws; issue stock or securities with a preference to Series B Preferred, Series C Preferred, and Series C-2 Preferred; change any rights, preferences and privileges of Series B Preferred, Series C Preferred, and Series C-2 Preferred; or change the number of directors outside a range. Furthermore, the approval of 65% of the Series C Preferred stockholders was required to liquidate, sell, or merge the Company. Approval of 70% of the Series D-1 Preferred and the Series D-2 Preferred (the “Series D Preferred”) stockholders, voting as a separate class, was required to change any bylaws; issue stock or securities with a preference to Series D Preferred; enter into a merger without loss of control by existing shareholders of the Company; or change any rights, preferences and privileges of Series D Preferred. Dividend rights Holders of Series D Preferred were entitled to receive 8% of the original issue price per annum as a dividend on a “when and if” declared basis in preference to any dividend paid to other convertible preferred or common stockholders. Such dividends were payable only when, and if, declared by the board of directors and were noncumulative. After payment of the 8% Series D Preferred dividend, holders of all series of convertible preferred stock were entitled to receive dividends declared by the board of directors in preference to any dividend paid to common stockholders. Each share of preferred stock was entitled to the same amount as would have been declared or paid thereon had the holder thereof elected to convert the same into shares of common stock. Liquidation rights Holders of Series D-1 Preferred and Series D-2 Preferred had a liquidation preference of two and three times the original issue price plus all declared and unpaid dividends adjusted for events of dilution, respectively. Holders of Series A Preferred, Series B Preferred, Series C Preferred, Series C-1 Preferred, and Series C-2 Preferred had liquidation preferences of $7.96 , $9.01 , $10.15 , $3.25 , and $5.75 per share, plus declared but unpaid dividends adjusted for events of dilution, respectively. Upon occurrence of a liquidation event, Series D-1 Preferred and Series D-2 Preferred would participate pari passu; then Series C-2 Preferred, Series C-1 Preferred, and Series C Preferred would participate pari passu; then Series B Preferred; then Series A Preferred would receive their liquidation preference; and the remaining assets would be distributed ratably to the preferred and common stockholders on an “as converted” basis. Conversion rights Each share of Series A Preferred was convertible into 0.20 shares of common stock. Each share of Series B Preferred and Series C Preferred was convertible into 0.28 shares of common stock as of the date of the IPO in May 2014. Each share of Series C-1 Preferred and Series C-2 Preferred was convertible into 0.07 shares of common stock as of the date of the IPO. Each share of Series D-1 Preferred and Series D-2 Preferred was convertible into 0.05 shares of common stock as of the date of the IPO. Series A Preferred, Series B Preferred, Series C Preferred, Series C-1 Preferred, Series C-2 Preferred, and Series D Preferred would all convert automatically into common stock at their respective conversion prices upon completion of a public offering of the common stock of the Company. The conversion price for Series B Preferred, Series C Preferred, Series C-1 Preferred, Series C-2 Preferred, and Series D Preferred were subject to adjustment if the Company issued additional shares of common stock at a price less than the Series B Preferred, Series C Preferred, Series C-1 Preferred, Series C-2 Preferred, and Series D Preferred conversion prices in effect at the time of the sale. With the sale of the Series D-2 Preferred on December 11, 2013 at a price of $1.40 per share, the antidilution provisions associated with the Series B Preferred, the Series C Preferred, the Series C-1 Preferred, and the Series C-2 Preferred were triggered. As of December 11, 2013, the conversion price of the Series B Preferred, the Series C Preferred, the Series C-1 Preferred, and the Series C-2 Preferred were reduced from $45.95 , $51.77 , $66.30 , and $117.30 , respectively, to $32.2912 , $36.2386 , $46.1101 , and $78.9623 , respectively. In December 2013, the Company recorded a deemed dividend as a reduction to additional paid-in capital of $6,402 as a result of the beneficial conversion for the antidilution adjustment on the outstanding shares of Series B Preferred, Series C Preferred, and Series C-2 Preferred. The intrinsic value of the beneficial conversion feature was calculated by multiplying the incremental number of shares of the respective convertible preferred stock the investors received (as a result of the Company reducing the original conversion price) by the estimated fair value of the common stock on the issuance date of the respective convertible preferred stock. A deemed dividend for the beneficial conversion feature on the conversion of the 2011-2012 Notes into shares of Series D-1 Preferred was recorded as additional interest expense (Note 7). No shares of Series C-1 Preferred are outstanding and, therefore, no beneficial conversion feature was recognized for the Series C-1 Preferred. With the sale of the Series D-2 Preferred on January 31, 2014 at a price of $1.40 per share, the antidilution provisions associated with the Series B Preferred, the Series C Preferred, the Series C-1 Preferred, and the Series C-2 Preferred were triggered again. As of January 31, 2014, the conversion price of the Series B Preferred, the Series C Preferred, the Series C-1 Preferred, and the Series C-2 Preferred were further reduced to $32.0076 , $35.8917 , $45.6062 , and $77.9382 , respectively. In January 2014, the Company recorded another deemed dividend as a reduction to additional paid-in capital of $214 as a result of the beneficial conversion for the antidilution adjustment on the outstanding shares of Series B Preferred, Series C Preferred, and Series C-2 Preferred. The intrinsic value of the beneficial conversion feature was calculated by multiplying the incremental number of shares of the respective convertible preferred stock the investors received (as a result of the Company reducing the original conversion price) by the estimated fair value of the common stock on the issuance date of the respective convertible preferred stock. No shares of Series C-1 Preferred are outstanding and, therefore, no beneficial conversion feature was recognized for the Series C-1 Preferred. In conjunction with the issuance of the 2011-2012 Notes and related warrants, the Company implemented a special mandatory conversion provision. Under this provision, preferred stockholders that met certain ownership criteria who elected not to purchase their pro rata amount of the convertible note round had their preferred shares converted into common stock in 2012. Redemption Upon liquidation, dissolution, or winding up of the Company, the holders of the Series D-2 Preferred would receive an amount equal to three times the original issue price plus all declared and unpaid dividends; the holders of the Series D-1 Preferred would receive an amount equal to two times the original issue price plus all declared and unpaid dividends; and the holders of the Series C-2 Preferred, Series C-1 Preferred, Series C Preferred, Series B Preferred, and the Series A Preferred would receive an amount equal to the original issue price plus all declared and unpaid dividends. In addition, after receiving their liquidation preference, the holders of all series of preferred stock share ratably with holders of common stock on an as-if-converted to common stock basis. An asset transfer or acquisition of the Company is a deemed liquidation event in that holders of all series of preferred stock are treated in the same manner as upon liquidation, dissolution, or winding up of the Company. As a result of the existence of this deemed liquidation feature, the Company determined that all series of preferred stock are redeemable. They are carried at liquidation value at each reporting period and excluded from stockholders’ deficit in the accompanying balance sheets.

Common Stock

Common Stock	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Equity [Abstract]
Common Stock	Common Stock Authorized, Issued, and Outstanding Common Shares The Company’s common stock has a par value of $0.001 per share and consists of 125,000,000 authorized shares at March 31, 2015 , and December 31, 2014 ; 8,527,210 and 8,512,103 shares were issued and outstanding at March 31, 2015 , and December 31, 2014 , respectively. The following table summarizes common stock share activity for the three months ended March 31, 2015 : Shares of Common Stock Balance, December 31, 2014 8,512,103 Common stock issued through employee stock purchase plan 15,107 Balance, March 31, 2015 8,527,210 Shares Reserved for Future Issuance The Company had reserved shares of common stock for future issuance as follows: March 31, December 31, Outstanding stock options 575,416 615,322 Outstanding Series C-1 Preferred warrants 14,033 14,033 For possible future issuance under 2014 Equity Incentive Plan (Note 8) 561,000 180,610 For possible future issuance under Employee Stock Purchase Plan (Note 8) 52,050 37,746 For possible future issuance under 2015 Inducement Plan (Note 8) 450,000 — Total common shares reserved for future issuance 1,652,499 847,711 Common Stock Warrants The Company had outstanding common stock warrants issued in connection with the Note and Warrant Purchase Agreements (Note 4) and in connection with certain convertible preferred stock agreements (Note 6). The December 2011 Note and Warrant Purchase Agreement included warrants to purchase 26,000 shares of the Company’s common stock at $0.20 per share. The warrants could be exercised for shares of common stock, in accordance with their terms. The number of shares of common stock that could be purchased by exercising the warrants would vary based on the event that occurred and would be calculated in accordance with the December 2011 Note and Warrant Purchase Agreements (Note 4). On December 11, 2013, holders of the June 2013 Notes exercised their rights under the June 2013 Note and Warrant Agreement to receive warrants to purchase shares of the Company’s common stock. As a result of this exercise, the Company issued warrants to purchase 88,987 shares of the Company’s common stock to the holders of the June 2013 Notes at an exercise price of $0.20 per share. These warrants were exercisable until June 28, 2018 , and were exercised in connection with the IPO. On December 11, 2013, in connection with the Series D-2 Convertible Preferred Stock offering, the Company issued warrants to purchase 87,532 shares of the Company’s common stock at an exercise price of $0.20 per share. These warrants were exercisable until December 11, 2018 , and were exercised in connection with the IPO. In addition, as a result of the conversion of the principal and interest outstanding on the 2011-2012 Notes into Series D-1 Preferred and Series D-2 Preferred (Note 4), in accordance with the amended terms of the agreement, the number of common shares underlying the warrants issued in connection with the 2011-2012 Notes was increased by 54,120 to a total of 80,120 . In connection with the consummation of the IPO in May 2014, the outstanding common stock warrants were exercised at an exercise price of $0.20 per share and the holders received 275,687 shares of common stock. All previously described warrants met the definition of a derivative financial instrument and were accounted for as derivatives. The warrants were stated at fair value at each reporting period end date prior to being exercised in May 2014 in conjunction with the Company’s IPO. The combined fair value of the common stock warrant derivative liabilities, including warrants issued with the sale of Series D-2 Preferred, was $12,200 as of December 31, 2013, and then decreased to $9,998 as of March 31, 2014. The combined fair value of the common stock warrant derivative liabilities continued to decrease in the second quarter of 2014 to $2,701 as of May 2, 2014, and this amount was settled to additional paid in capital on that date as the warrants were exercised in conjunction with the Company's IPO. The fair value adjustment of the long-term derivative liability was recorded as other income in the amounts of $0 and $3,108 for the three months ended March 31, 2015 and March 31, 2014 , respectively.	Common Stock Authorized, Issued, and Outstanding Common Shares The Company’s common stock has a par value of $0.001 per share and consists of 125,000,000 authorized shares and 70,000,000 authorized shares as of December 31, 2014 , and December 31, 2013 , respectively; 8,512,103 and 334,068 shares were issued and outstanding as of December 31, 2014 , and December 31, 2013 , respectively. The following table summarizes common stock share activity for the years ended December 31, 2014 and 2013 : Shares of Common Stock Balance, December 31, 2012 335,782 Exercise of stock options 220 Repurchase of common stock (1,934 ) Balance, December 31, 2013 334,068 Exercise of stock options 416 Conversion of preferred stock 1,691,884 Exercise of common stock warrants 275,687 Common stock issued through IPO 6,200,000 Common stock issued through employee stock purchase plan 10,048 Balance, December 31, 2014 8,512,103 Shares Reserved for Future Issuance The Company had reserved shares of common stock for future issuance as follows: As of As of December 31, December 31, For conversion of Series A Preferred, Series B Preferred, Series C Preferred, Series C-2 Preferred, Series D-1 Preferred, and Series D-2 Preferred and exercise of warrants to purchase Series C-1 Preferred and subsequent conversion of the shares purchased — 1,675,812 Outstanding stock options 615,322 137,610 Outstanding common stock warrants — 257,242 Outstanding Series C-1 convertible preferred stock warrants 14,033 13,879 For possible future issuance under stock option plan 180,610 49,734 For possible future issuance under employee stock purchase plan 37,746 — Total common shares reserved for future issuance 847,711 2,134,277 Liquidation Rights In the event of any liquidation or dissolution of the Company, the holders of the common stock are entitled to share ratably with holders of the series of outstanding preferred stock, on an as-if-converted to common stock basis, in the remaining assets of the Company legally available for distribution after the payment of the full liquidation preference for all series of the outstanding preferred stock. Dividends and Voting Rights The holders of the common stock are entitled to receive dividends if and when declared by the Company, but not until all dividends on the preferred stock have been either (i) paid or (ii) declared and the Company has set aside the funds to pay those dividends declared. The holders of the common stock have the right to one vote per share. Common Stock Warrants The Company had outstanding common stock warrants issued in connection with the Note and Warrant Purchase Agreements (Note 7) and in connection with certain convertible preferred stock agreements (Note 9). The December 2011 Note and Warrant Purchase Agreement included warrants to purchase 26,000 shares of the Company’s common stock at $0.20 per share. The warrants could be exercised for shares of common stock, in accordance with their terms. The number of shares of common stock that could be purchased by exercising the warrants would vary based on the event that occurred and would be calculated in accordance with the December 2011 Note and Warrant Purchase Agreements (Note 7). On December 11, 2013, holders of the June 2013 Notes exercised their rights under the June 2013 Note and Warrant Agreement to receive warrants to purchase shares of the Company’s common stock. As a result of this exercise, the Company issued warrants to purchase 88,987 shares of the Company’s common stock to the holders of the June 2013 Notes at an exercise price of $0.20 per share. These warrants were exercisable until June 28, 2018 , and would terminate unless exercised prior to an IPO. On December 11, 2013, in connection with the first Series D-2 Preferred offering, the Company issued warrants to purchase 87,532 shares of the Company’s common stock at an exercise price of $0.20 per share. These warrants were exercisable until December 11, 2018 , and would terminate unless exercised prior to an IPO. In addition, as a result of the conversion of the principal and interest outstanding on the 2011-2012 Notes into Series D-1 Preferred and Series D-2 Preferred (Note 7), in accordance with the amended terms of the agreement, the number of common shares underlying the warrants issued in connection with the 2011-2012 Notes was increased by 54,120 to a total of 80,120 . On January 31, 2014, in connection with the second Series D-2 Preferred offering, the Company issued warrants to purchase 19,048 shares of the Company’s common stock at $0.20 per share. In connection with the consummation of the IPO in May 2014, substantially all outstanding common stock warrants were exercised at an exercise price of $0.20 per share and the holders received 275,687 shares of common stock. All previously described warrants met the definition of a derivative financial instrument and were accounted for as derivatives. The combined fair value of the common stock warrant derivative liabilities, including warrants issued with the sale of Series D-2 Preferred, was $2,701 as of May 2, 2014, and this amount was settled to additional paid in capital on that date. The combined fair value of the common stock warrant derivative liabilities was $12,200 as of December 31, 2013 , which was recorded as a long-term derivative liability in the accompanying balance sheet. The fair value adjustment of the long-term derivative liability was recorded as other (income) expense in the amount of $(10,442) and $8,007 for years ended December 31, 2014 and 2013 , respectively. As discussed in Note 9, the fair value of the warrants issued in connection with the Company’s Series D-2 Preferred offering in January 2014 was $362 above the face amount of the Series D-2 Preferred. This excess was expensed in the year ended December 31, 2014 , and, as a result, the net fair value adjustment presented in the accompanying statements of operations for the year ended December 31, 2014 was income of $10,080 .

Stock-based Compensation

Stock-based Compensation	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based Compensation	Stock-based Compensation 2009 Stock Option Plan The Company had a share-based compensation plan (the “2009 Stock Option Plan”) under which the Company granted options to purchase shares of common stock to employees, directors, and consultants as either incentive stock options or nonqualified stock options. Incentive stock options could be granted with exercise prices not less than 100% to 110% of the fair market value of the common stock. Options granted under the plan generally vest over three to four years and expire in 10 years from the date of grant. 2014 Equity Incentive Plan In February 2014, the Company’s board of directors adopted the 2014 Equity Incentive Plan, or the 2014 Plan, which was subsequently ratified by its stockholders and became effective on May 2, 2014 (the “Effective Date”). The 2014 Plan is the successor to and continuation of the 2009 Stock Option Plan. As of the Effective Date, no additional awards will be granted under the 2009 Stock Option Plan, but all stock awards granted under the 2009 Stock Option Plan prior to the Effective Date will remain subject to the terms of the 2009 Stock Option Plan. All awards granted on and after the Effective Date will be subject to the terms of the 2014 Plan. The 2014 Plan provides for the grant of the following awards: (i) incentive stock options, (ii) nonstatutory stock options, (iii) stock appreciation rights, (iv) restricted stock awards, (v) restricted stock unit awards, and (vi) other stock awards. Employees, directors, and consultants are eligible to receive awards. Under the 2014 Plan, the aggregate number of shares of common stock that could be issued from and after the Effective Date (the “share reserve”) could not exceed the sum of (i) 257,352 new shares, (ii) the shares that represented the 2009 Stock Option Plan’s available reserve on the Effective Date, and (iii) any returning shares from the 2009 Stock Option Plan. Under the 2014 Plan, the share reserve will automatically increase on January 1 st of each year, for a period of not more than 10 years, commencing on January 1, 2015, and ending on January 1, 2024, in an amount equal to 4.0% of the total number of shares of capital stock outstanding on December 31 st of the preceding calendar year. The Company's board of directors may act prior to January 1 st of a given year to provide that there will be no increase in the share reserve or that the increase will be a lesser number of shares than would otherwise occur. On June 18, 2014, the Company’s board of directors and Compensation Committee approved an amendment of the 2014 Plan, subject to stockholder approval, to increase the aggregate number of shares of the Company’s common stock that may be issued under the 2014 Plan by an additional 351,653 shares. All other material terms of the 2014 Plan remained unchanged. The Company’s stockholders approved the 2014 Plan amendment on September 11, 2014. Pursuant to the terms of the 2014 Plan, on January 1, 2015, the Company automatically added 340,484 shares to the total number of shares of common stock available for future issuance under the 2014 Plan. In connection with the resignation of the Company's Chief Medical Officer, Dr. Carole Sable, effective as of February 20, 2015, the Company returned 57,452 shares to the total number shares of common stock available for future issuance under the 2014 Plan. The returned shares represent Dr. Sable's unvested shares as of the effective date of her resignation. On February 25, 2015, the Company's board of directors approved an amendment of the 2014 Plan, subject to stockholder approval at the Company's 2015 annual meeting of stockholders to be held on June 4, 2015, to increase the aggregate number of shares of common stock that may be issued pursuant to awards under the 2014 Plan by an additional 510,726 shares. All other material terms of the 2014 Plan otherwise remain unchanged. As of March 31, 2015 , there were 561,000 shares of common stock available for future issuance under the 2014 Plan. See Note 14 for certain events occurring after March 31, 2015 , that affected the number of shares of common stock available for future issuance under the 2014 Plan. 2015 Inducement Plan On March 26, 2015, the Company's board of directors adopted the 2015 Inducement Plan, or the 2015 Plan. The 2015 Plan provides for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other forms of equity compensation (collectively, stock awards), all of which may be granted to persons not previously employees or directors of the Company, or following a bona fide period of non-employment, as an inducement material to the individuals’ entering into employment with the Company within the meaning of NASDAQ Listing Rule 5635(c)(4). The 2015 Plan has a share reserve covering 450,000 shares of common stock. No awards had been granted under the 2015 Plan as of March 31, 2015 . 2014 Employee Stock Purchase Plan In February 2014, the Company’s board of directors adopted the 2014 Employee Stock Purchase Plan (“ESPP”), which was subsequently ratified by the Company’s stockholders and became effective on May 2, 2014 . The purpose of the ESPP is to provide means by which eligible employees of the Company and of certain designated related corporations may be given an opportunity to purchase shares of the Company’s common stock, and to seek and retain services of new and existing employees and to provide incentives for such persons to exert maximum efforts for the success of the Company. Common stock that may be issued under the ESPP will not exceed 47,794 shares, plus the number of shares of common stock that are automatically added on January 1 st of each year for a period of ten years, commencing on January 1, 2015, and ending on January 1, 2024, in an amount equal to the lesser of (i) 0.8% of the total number of shares of outstanding common stock on December 31 of the preceding calendar year, and (ii) 29,411 shares of common stock. Similar to the 2014 Plan, the Company's board of directors may act prior to January 1 st of a given year to provide that there will be no increase in the share reserve or that the increase will be a lesser number of shares than would otherwise occur. The ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code. In the quarterly period ended March 31, 2015 , the number of shares of common stock available for issuance under the ESPP was automatically increased by 29,411 shares pursuant to the terms of the ESPP and the Company issued 15,107 shares of common stock under the ESPP. As of March 31, 2015 , there were 52,050 shares of common stock available for future issuance under the ESPP. Compensation Cost The compensation cost that has been charged against income for stock awards under the 2009 Stock Option Plan, the 2014 Plan, and the ESPP was $296 and $110 , including $33 and $13 presented in discontinued operations in the accompanying statements of operations, for the three months ended March 31, 2015 and 2014 , respectively. The total income tax benefit recognized in the statements of operations for share-based compensation arrangements was $0 for the three months ended March 31, 2015 and 2014 . Cash received from options exercised was $0 and $5 for the three months ended March 31, 2015 and 2014 . Stock-based compensation expense related to stock options is included in the following line items in the accompanying statements of operations: Three Months Ended March 31, 2015 2014 Research and development $ 52 $ 62 Selling, general and administrative 211 35 Discontinued operations (within cost of revenue, see Note 13) 33 13 Total $ 296 $ 110	Stock-based Compensation 2009 Stock Option Plan The Company had a share-based compensation plan (the “2009 Stock Option Plan”) under which the Company granted options to purchase shares of common stock to employees, directors, and consultants as either incentive stock options or nonqualified stock options. Incentive stock options could be granted with exercise prices not less than 100% to 110% of the fair market value of the common stock. Options granted under the plan generally vest over three to four years and expire in 10 years from the date of grant. 2014 Equity Incentive Plan In February 2014, the Company’s board of directors adopted the 2014 Equity Incentive Plan, or the 2014 Plan, which was subsequently ratified by its stockholders and became effective on May 2, 2014 (the “Effective Date”). The 2014 Plan is the successor to and continuation of the 2009 Stock Option Plan. As of the Effective Date, no additional awards will be granted under the 2009 Stock Option Plan, but all stock awards granted under the 2009 Stock Option Plan prior to the Effective Date will remain subject to the terms of the 2009 Stock Option Plan. All awards granted on and after the Effective Date will be subject to the terms of the 2014 Plan. The 2014 Plan provides for the grant of the following awards: (i) incentive stock options, (ii) nonstatutory stock options, (iii) stock appreciation rights, (iv) restricted stock awards, (v) restricted stock unit awards, and (vi) other stock awards. Employees, directors, and consultants are eligible to receive awards. Under the 2014 Plan, the aggregate number of shares of common stock that could be issued from and after the Effective Date (the “share reserve”) could not exceed the sum of (i) 257,352 new shares, (ii) the shares that represented the 2009 Stock Option Plan’s available reserve on the Effective Date, and (iii) any returning shares from the 2009 Stock Option Plan. Under the 2014 Plan, the share reserve will automatically increase on January 1 st of each year, for a period of not more than 10 years, commencing on January 1, 2015 and ending on January 1, 2024, in an amount equal to 4.0% of the total number of shares of capital stock outstanding on December 31 st of the preceding calendar year. The board of directors may act prior to January 1 st of a given year to provide that there will be no increase in the share reserve or that the increase will be a lesser number of shares than would otherwise occur. On June 18, 2014, the Company’s board of directors and compensation committee approved an amendment of the 2014 Plan, subject to stockholder approval, to increase the aggregate number of shares of the Company’s common stock that may be issued under the 2014 Plan by an additional 351,653 shares. All other material terms of the 2014 Plan remained unchanged. The Company’s stockholders approved the 2014 Plan amendment on September 11, 2014. As of December 31, 2014 , there were 180,610 shares of common stock available for future issuance under the 2014 Plan. See Note 20 for certain events occurring after December 31, 2014 that affected the number of shares of common stock available for future issuance under the 2014 Plan. Option Valuation Method The fair value of a stock option is estimated using an option-pricing model that takes into account as of the grant date the exercise price and expected life of the option, the current price of the underlying stock and its expected volatility, expected dividends on the stock, and the risk-free interest rate for the expected term of the option. The Company has used the simplified method in calculating the expected term of all option grants based on the vesting period. Compensation costs related to share-based payment transactions are recognized in the financial statements upon satisfaction of the requisite service or vesting requirements. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company based its estimated forfeiture rate on historical forfeitures of all stock option grants. The Company has elected to use the Black-Scholes option-pricing model. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable rather than for use in estimating the fair value of stock options subject to vesting and transferability restrictions. Using the Black-Scholes option-pricing model, the weighted-average fair value of options granted during 2014 and 2013 was $6.24 and $25.09 per option, respectively. The aggregate fair value of options granted during 2014 and 2013 was $3,249 and $290 , respectively. The assumptions used to estimate fair value and the resulting grant date fair values are as follows: Employees Nonemployees Years Ended December 31, Years Ended December 31, 2014 2013 2014 2013 Expected dividend yield — — — — Weighted average expected volatility 68.57% 65.49% 64.10% 65.49% Weighted average risk-free interest rate 2.05% 2.41% 1.75% 2.37% Weighted average expected term (in years) 6.04 6.49 5.30 5.00 Forfeiture rate 5.00% 5.00% 5.00% 5.00% The activity of the plan for the years ended December 31, 2014 and 2013 is summarized as follows: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding — January 1, 2013 154,277 $ 23.05 5.02 $ 213 Granted 11,525 50.39 Exercised (220 ) 21.01 Canceled (27,972 ) 20.81 Outstanding — December 31, 2013 137,610 $ 25.86 5.23 $ 3,097 Exercisable — December 31, 2013 115,475 $ 23.26 4.50 $ 2,898 Vested or expected to vest — December 31, 2013 136,002 $ 25.70 5.18 $ 3,084 Outstanding — January 1, 2014 137,610 $ 25.86 5.23 $ 3,097 Granted 520,887 $ 9.53 (1) Exercised (416 ) $ 20.40 Canceled (42,759 ) $ 9.57 Outstanding — December 31, 2014 615,322 $ 9.55 9.48 $ 265 Exercisable — December 31, 2014 192,916 $ 9.44 9.48 $ 88 Vested or expected to vest —December 31, 2014 572,926 $ 9.55 9.48 $ 247 (1) The weighted average exercise price table takes into consideration the effect of the option award modifications approved by the Company's board of directors on June 18, 2014, and approved by the Company's shareholders on September 11, 2014. These option award modifications are described in further detail below. The intrinsic values in the table above represent the total intrinsic value (the difference between the Company’s estimated fair value of common stock as of December 31, 2014 and 2013, and the exercise price multiplied by the number of options). The intrinsic value amounts presented above can be positive or negative based on the average exercise price being greater or less than the estimated fair value of common stock as of December 31, 2014 and 2013. Information as of December 31, 2014, concerning currently outstanding and vested options is as follows: Outstanding Exercisable Exercise Price Number of Shares Weighted- Average Remaining Contractual Life (in years) Number of Shares Weighted- Average Remaining Contractual Life (in years) $6.77 8,000 9.47 — 0.00 7.70 5,944 9.76 5,944 9.76 8.03 5,700 9.50 5,700 9.50 8.73 35,114 9.45 3,494 9.45 9.64 543,374 9.47 176,248 9.47 10.81 17,190 9.93 1,530 9.93 Total 615,322 Total 192,916 The total fair value of shares vested during the years ended December 31, 2014 and 2013 was $458 and $801 , respectively. Unvested shares as of December 31, 2014 and 2013 are as follows: As of December 31, 2014 As of December 31, 2013 Exercise Price Number of Unvested Shares Exercise Price Number of Unvested Shares $6.77 8,000 $20.40 563 7.70 — 24.48 7,318 8.03 — 25.50 — 8.73 31,620 25.91 — 9.64 367,127 30.60 4,307 10.81 15,660 55.08 9,947 Total 422,407 Total 22,135 As of December 31, 2014 and 2013, there was approximately $2,683 and $404 , respectively, of total unrecognized compensation cost related to unvested share-based compensation arrangements granted under the plan. That cost is expected to be recognized over weighted-average periods of 3.2 and 1.8 years for the years ended December 31, 2014 and 2013, respectively. The aggregate intrinsic value of the options exercised during the years ended December 31, 2014 and 2013 was $11 and $6 , respectively. Option Grants On June 18, 2014, the Company’s board of directors approved the grant of options to purchase 396,573 shares of common stock at a per share exercise price of $9.64 to certain of the Company’s executive officers and employees. No compensation cost associated with these option grants was recognized during the three month period ended June 30, 2014 because the grants were subject to and contingent upon stockholder approval of the previously described June 18, 2014 amendment to the 2014 Plan. The Company did not believe stockholder approval was perfunctory. The Company’s stockholders approved the 2014 Plan amendment on September 11, 2014, which was considered to be the measurement date for the determination of stock compensation expense. The fair value of each option grant award was estimated using the Black-Scholes option-pricing model, consistent with and in accordance with the Company’s existing accounting policy for stock compensation. Using the Black-Scholes option-pricing model, the fair value of all September 11, 2014 option grants was $3.76 per option. The aggregate fair value of options granted on September 11, 2014 was determined to be $1,490 , which is being recognized as expense, after adjusting for estimated pre-vesting forfeitures, over a 45 month vesting period. Option Amendments During the year ended December 31, 2014 , the Company's board of directors approved the following with respect to the 2009 Stock Option Plan: • On April 29, 2014, the exercise price per share of certain options to purchase 53,404 shares of common stock under the 2009 Stock Option Plan was lowered to an amount equal to $10.00 per share. The original exercise prices of such options ranged from $20.40 to $61.20 per share, with a weighted average exercise price of $54.87 per share. • On June 18, 2014, the exercise price per share of all outstanding options to purchase shares of common stock under the 2009 Stock Option Plan was lowered to an amount equal to $9.64 per share, the closing stock price on June 18, 2014. This modification lowered the exercise price of outstanding options to purchase 110,346 shares of common stock, including those options to purchase common stock that were previously modified on April 29, 2014. These outstanding stock options had exercise prices that ranged from $20.40 to $61.20 per share, with a weighted average exercise price of $41.87 per share. • Also on June 18, 2014, the contractual term of all outstanding options to purchase shares of common stock under the 2009 Stock Option Plan was extended to June 17, 2024. The Company determined the additional compensation cost associated with the previously described modifications pursuant to applicable guidance in FASB ASC Topic 718, Compensation—Stock Compensation . The additional compensation cost was determined by calculating the difference between (a) the estimated fair value of each option award immediately prior to the modifications and (b) the estimated fair value of each option award immediately after the modifications. The fair value of each option award immediately prior to and immediately after modification was estimated using the Black-Scholes option-pricing model, consistent with and in accordance with the Company’s existing accounting policy for stock compensation. Using the Black-Scholes option-pricing model, the weighted-average fair value of outstanding 2009 Stock Option Plan option awards was $3.08 per option immediately prior to modification on June 18, 2014 and was $5.87 per option immediately after modification. The additional compensation cost was determined to be $293 , of which $130 was associated with services previously performed and, therefore, was expensed in the quarter ended June 30, 2014. The remaining additional compensation cost is being recognized as remaining services are performed. Also on June 18, 2014, the board of directors approved modifications to the exercise price and contractual term of all outstanding option awards under the Company’s Stock Option Plan previously adopted by the Company in 1999 (the “1999 Stock Option Plan”). The modifications to the exercise price and contractual term are consistent with those previously described for outstanding options under the 2009 Stock Option Plan. In addition, the 1999 Stock Option Plan option awards were modified to provide that the holder may exercise vested shares under the option for the contractual term of the option even in the event the holder terminates services with the Company other than for cause. The modifications lowered the exercise price of outstanding options to purchase 73,087 shares of common stock, which had exercise prices that ranged from $20.40 to $25.50 per share, with a weighted average exercise price of $21.50 per share. Pursuant to the terms of the 1999 Stock Option Plan, any amendments that modify the terms of the options awards require approval or consent of the Company’s shareholders. No additional compensation cost associated with the options under the 1999 Stock Option Plan was recognized during the quarter ended June 30, 2014 because the amendments were subject to and contingent upon stockholder approval. The Company did not believe stockholder approval was perfunctory. The Company’s stockholders approved the 1999 Stock Option Plan modifications on September 11, 2014, which was considered to be the measurement date for the determination of additional stock compensation expense. Consistent with the accounting guidance and methodology previously described for the 2009 Plan amendment, the Company determined the additional compensation cost associated with the 1999 Stock Option Plan modifications pursuant to FASB ASC Topic 718. The weighted-average fair value of outstanding 1999 Stock Option Plan option awards was $0.78 per option immediately prior to modification on September 11, 2014 and was $3.78 per option immediately after modification. The additional compensation cost was determined to be $225 , all of which was associated with services previously performed and, therefore, was fully expensed in the quarter ended September 30, 2014. See Note 20 for certain events occurring after December 31, 2014, that resulted in additional amendments to outstanding stock option awards. 2014 Employee Stock Purchase Plan In February 2014, the Company’s board of directors adopted the 2014 Employee Stock Purchase Plan (“ESPP”), which was subsequently ratified by the Company’s stockholders and became effective on May 2, 2014 . The purpose of the ESPP is to provide means by which eligible employees of the Company and of certain designated related corporations may be given an opportunity to purchase shares of the Company’s common stock, and to seek and retain services of new and existing employees and to provide incentives for such persons to exert maximum efforts for the success of the Company. Common stock that may be issued under the ESPP will not exceed 47,794 shares, plus the number of shares of common stock that are automatically added on January 1 st of each year for a period of ten years, commencing on January 1, 2015 and ending on January 1, 2024, in an amount equal to the lesser of (i) 0.8% of the total number of shares of outstanding common stock on December 31 of the preceding calendar year, and (ii) 29,411 shares of common stock. Similar to the 2014 Plan, the board of directors may act prior to January 1 st of a given year to provide that there will be no increase in the share reserve or that the increase will be a lesser number of shares than would otherwise occur. The ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code. In September 2014, the Company issued 10,048 shares of common stock under the ESPP. As of December 31, 2014 , there were 37,746 shares of common stock available for future issuance under the ESPP. Compensation Cost The compensation cost that has been charged against income for stock awards under the 2009 Stock Option Plan, the 2014 Plan, and the ESPP was $1,201 and $180 for the years ended December 31, 2014 and 2013 , respectively. The total income tax benefit recognized in the statements of operations for share-based compensation arrangements was $0 for both the years ended December 31, 2014 and 2013 . Cash received from options exercised was $9 and $5 for the years ended December 31, 2014 and 2013 , respectively. Stock-based compensation expense related to stock options is included in the following line items in the accompanying statements of operations: Years Ended December 31, 2014 2013 Research and development $ 394 28 Selling, general and administrative 648 107 Discontinued operations 159 45 Total stock-based compensation expense $ 1,201 $ 180

Income Taxes

Income Taxes	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company applies intraperiod tax allocation guidance pursuant to FASB ASC 740, Income Taxes (Topic 740) to allocate income tax (expense) benefit between pre-tax income (loss) from continuing operations and discontinued operations. For periods in which the Company reports pre-tax income from discontinued operations for financial reporting purposes and pre-tax loss from continuing operations, the Company presents income from discontinued operations net of income tax expense attributable to its discontinued operations using the estimated annual effective tax rate of the Services Business. The Company also recognizes a corresponding income tax benefit on its loss from continuing operations for the same affected period. The Company did not record a federal or state income tax benefit for the three months ended March 31, 2015 after applying the intraperiod tax allocation policy described above. The Company recorded an income tax benefit for the three months ended March 31, 2014 after applying the intraperiod tax allocation policy described above.	Income Taxes The Company’s financial statements include total tax benefit of $1,166 and $575 on net losses from continuing operations before taxes of $6,769 and $31,906 for the years ended December 31, 2014 and 2013 , respectively. Reconciliations of the differences between the benefit for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows: Years Ended December 31, 2014 2013 Amount Percent of Pretax Income Amount Percent of Pretax Income Income taxes from continuing operations at statutory rate $ (2,301 ) 34.0 % $ (10,848 ) 34.0 % State income taxes (471 ) 7.0 % (116 ) 0.5 % Beneficial conversion feature on convertible notes — — % 3,673 (11.5 )% Stock warrant derivative liability (3,427 ) 50.6 % 2,686 (8.4 )% Debt discount amortization — — % 392 (1.2 )% Deemed contribution interest — — % 1,516 (4.8 )% Provision to return adjustments — — % (190 ) 0.6 % Stock-based compensation 268 (4.0 )% 41 (0.1 )% Expiration of capital losses carryforward. — — % 1,511 (4.7 )% Change in statutory state income tax rate — — % 936 (2.9 )% Change in reserve for uncertain tax positions — — % 623 (2.0 )% R&D tax credits (320 ) 4.7 % — — % Other (190 ) 2.8 % (5 ) — % Increase (decrease) in valuation allowance 5,275 (77.9 )% (794 ) 2.5 % Total $ (1,166 ) 17.2 % $ (575 ) 1.8 % The components of deferred tax assets and liabilities are as follows: December 31, 2014 2013 Current deferred tax assets: Accrued expenses $ 1,052 $ 612 Stock-based compensation 336 241 Assets of discontinued operations, net of liabilities 1,882 1,938 Other 15 25 3,285 2,816 Noncurrent deferred tax assets (liabilities) Net operating loss carryforwards 29,981 26,286 Research and development credits 2,684 2,373 Deferred financing costs — (800 ) 32,665 27,859 Total deferred tax assets 35,950 30,675 Valuation allowance (35,950 ) (30,675 ) Net deferred tax assets $ — $ — As of December 31, 2014 and 2013 , the Company had federal net operating loss ("NOL") carryforwards of approximately $81,687 and $71,757 , respectively, North Carolina net economic loss ("NEL") carryforwards of approximately $85,790 and $75,990 , respectively, and Pennsylvania NOL carryforwards of approximately $0 and $80 , respectively. The federal NOL and North Carolina NEL carryforwards begin to expire in 2020 and 2015 , respectively. As of December 31, 2014 , the Company had federal research and development credit carryforwards of $2,371 and North Carolina credit carryforwards of $150 , which begin to expire in 2020 and 2015 , respectively. As of December 31, 2014 and 2013 , the Company has concluded that it is more likely than not that the Company will not realize the benefit of its deferred tax assets due to its history of losses. Accordingly, the net deferred tax assets have been fully reserved. In accordance with Section 382 of the Internal Revenue Code of 1986, as amended, a change in equity ownership of greater than 50% within a three-year period results in an annual limitation on the Company’s ability to utilize its NOL carryforwards created during the tax periods prior to the change in ownership. The Company has determined that ownership changes have occurred and as a result, a portion of the Company’s NOL carryforwards are limited. Because the Company has incurred cumulative net operating losses since inception, all tax years remain open to examination by U.S. federal and state income tax authorities. The Company adopted FASB Accounting Standards Codification 740-10-25-5, Income Taxes , formerly FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes , as amended, on January 1, 2009. The difference between the tax benefit recognized in the financial statements and the tax benefit claimed in the tax return is referred to as an unrecognized tax benefit. The following is a tabular reconciliation of the total amounts of unrecognized tax benefits: December 31, 2014 2013 Unrecognized tax benefit—January 1 $ 623 $ — Additions for tax positions of current period — 333 Additions for tax positions of prior periods — 290 Other — — Unrecognized tax benefit—December 31 $ 623 $ 623 None of the unrecognized tax benefits would, if recognized, affect the effective tax rate because the Company has recorded a valuation allowance to fully offset federal and state deferred tax assets. The Company has no tax positions for which it is reasonably possible that the total amount of unrecognized tax benefits will significantly increase or decrease within the coming year. The Company has $0 provided for interest and penalties associated with uncertain tax positions.

Net Loss Per Share

Net Loss Per Share	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share The Company uses the two-class method to compute net loss per share because the Company has issued securities, other than common stock, that contractually entitle the holders to participate in dividends and earnings of the Company. The two-class method requires earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings. Holders of each series of the Company’s convertible preferred stock were entitled to participate in dividends, when and if declared by the Company's board of directors, that were made to common stockholders, and as a result were considered participating securities. Under the two-class method, for periods with net income, basic net income per common share is computed by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income attributable to common stockholders is computed by subtracting from net income the portion of current year earnings that the participating securities would have been entitled to receive pursuant to their dividend rights had all of the year’s earnings been distributed. No such adjustment to earnings is made during periods with a net loss, as the holders of the participating securities have no obligation to fund losses. Diluted net loss per common share is computed under the two-class method by using the weighted average number of shares of common stock outstanding, plus, for periods with net income attributable to common stockholders, the potential dilutive effects of stock options and warrants. In addition, the Company analyzes the potential dilutive effect of the outstanding participating securities when calculating diluted earnings per share. Under the “treasury stock” method, it is assumed that the warrants and options were exercised at the beginning of the period and that the funds obtained from the exercise were used to reacquire the Company’s common stock at the average market price for the period and includes those securities when they are dilutive. Under the “if-converted” method, it is assumed that the outstanding participating securities convert into common stock at the beginning of the period. The Company reports the more dilutive of the approaches as its diluted net income or net loss per share during the period. The following table summarizes the computation of basic and diluted net loss per share attributable to the Company’s common stockholders: Three Months Ended March 31, 2015 2014 Income (loss) attributable to common stock - basic: Loss from continuing operations $ (5,931 ) $ 45 Deemed dividend for beneficial conversion feature on Series D-2 Preferred — (909 ) Deemed dividend for antidilution adjustments to convertible preferred stock — (214 ) Accretion of convertible preferred stock — (510 ) Loss from continuing operations attributable to common stock - basic (5,931 ) (1,588 ) Income (loss) from discontinued operations, net of income tax expense, attributable to common stock - basic (453 ) 367 Net loss attributable to common stock - basic $ (6,384 ) $ (1,221 ) Income (loss) attributable to common stock - diluted: Loss from continuing operations attributable to common stock - basic $ (5,931 ) $ (1,588 ) Derivative fair value adjustment — (2,783 ) Loss from continuing operations attributable to common stock - diluted (5,931 ) (4,371 ) Income (loss) from discontinued operations, net of income tax expense, attributable to common stock - diluted (453 ) 367 Net loss attributable to common stock - diluted $ (6,384 ) $ (4,004 ) Weighted-average common shares outstanding: Weighted-average common shares outstanding - basic 8,516,467 334,086 Allocation of common stock warrants as participating securities — 274,988 Weighted-average common shares outstanding - diluted 8,516,467 609,074 Income (loss) per share - basic: Continuing operations $ (0.70 ) $ (4.75 ) Discontinued operations (0.05 ) 1.10 Net loss per share - basic $ (0.75 ) $ (3.65 ) Income (loss) per share - diluted: Continuing operations $ (0.70 ) $ (7.17 ) Discontinued operations (0.05 ) 0.60 Net loss per share - diluted $ (0.75 ) $ (6.57 ) The following securities, presented on a common stock equivalent basis, have been excluded from the calculation of weighted average common shares outstanding because their effect is anti-dilutive. Three Months Ended March 31, 2015 2014 Convertible preferred stock: Series A Preferred — 6,149 Series B Preferred — 131,685 Series C Preferred — 783,515 Series C-2 Preferred — 173,213 Series D-1 Preferred — 296,773 Series D-2 Preferred — 300,549 Series C-1 Preferred warrants 14,033 14,033 Stock options 575,416 184,240 ESPP 40,334 —	Net Loss Per Share The following table summarizes the computation of basic and diluted net loss per share attributable to the Company’s common stockholders: Years Ended 2014 2013 Income (loss) attributable to common stock - basic: Loss from continuing operations $ (5,603 ) $ (31,331 ) Deemed dividend for beneficial conversion feature on Series D-2 Preferred (909 ) (4,232 ) Deemed dividend for antidilution adjustments to convertible preferred stock (214 ) (6,402 ) Accretion of convertible preferred stock (510 ) (5,714 ) Loss from continuing operations attributable to common stock - basic (7,236 ) (47,679 ) Income from discontinued operations, net of income tax expense, attributable to common stock - basic 1,369 870 Net loss attributable to common stock - basic $ (5,867 ) $ (46,809 ) Income (loss) attributable to common stock - diluted: Loss from continuing operations attributable to common stock - basic $ (7,236 ) $ (47,679 ) Derivative fair value adjustment (10,080 ) — Loss from continuing operations attributable to common stock - diluted (17,316 ) (47,679 ) Income from discontinued operations, net of income tax expense, attributable to common stock - diluted 1,369 870 Net loss attributable to common stock - diluted $ (15,947 ) $ (46,809 ) Weighted-average common shares outstanding: Weighted-average common shares outstanding - basic 5,663,311 335,612 Allocation of common stock warrants as participating securities 273,776 — Weighted-average common shares outstanding - diluted 5,937,087 335,612 Income (loss) per share - basic: Continuing operations $ (1.28 ) $ (142.06 ) Discontinued operations 0.24 2.59 Net loss per share - basic $ (1.04 ) $ (139.47 ) Income (loss) per share - diluted: Continuing operations $ (2.92 ) $ (142.06 ) Discontinued operations 0.23 2.59 Net loss per share - diluted $ (2.69 ) $ (139.47 ) The following securities, presented on a common stock equivalent basis, have been excluded from the calculation of weighted average common shares outstanding because their effect is anti-dilutive. As discussed in Note 9, in May 2014, upon completion of the IPO, all outstanding shares of the convertible preferred stock were converted into shares of common stock at their conversion prices. Therefore, as of December 31, 2014 , the convertible preferred stock securities were no longer outstanding and will have no impact on net income or net loss per share. Years Ended 2014 2013 Convertible preferred stock: Series A Preferred 6,149 6,149 Series B Preferred 131,685 130,529 Series C Preferred 783,515 776,016 Series C-2 Preferred 173,213 170,967 Series D-1 Preferred 296,773 296,773 Series D-2 Preferred 300,549 281,500 Warrants to purchase Series C-1 Preferred 14,033 13,878 Warrants to purchase common stock — 257,242 Stock options 615,322 137,610 ESPP 65,401 — Convertible notes — —

Related-Party Transactions

Related-Party Transactions	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Related Party Transactions [Abstract]
Related-Party Transactions	Related-Party Transactions The Company had transactions with related parties as follows: Three Months Ended March 31, 2015 2014 Revenue $ 987 $ 1,822 Sanofi owns 100% of a subsidiary that is a customer of the Company's Services Business, which is presented in discontinued operations in the accompanying statements of operations (see Note 13). Both Sanofi and the subsidiary have an investment in the Company. The Company’s related-party revenue with the subsidiary composed 31% and 39% of total revenue included in discontinued operations for the three months ended March 31, 2015 and 2014, respectively.	Related-Party Transactions The Company had transactions with related parties as follows: Years Ended December 31, 2014 2013 Revenue $ 7,288 $ 7,288 Selling, general and administrative expense $ 500 $ — Research Services Agreement with a Related-Party Sanofi owns 100% of a subsidiary, Merial, which is a customer of the Services Business, presented in discontinued operations in the accompanying statements of operations (Note 19). Both Sanofi and the subsidiary have an investment in the Company. The Company’s related-party revenue with Merial composed 41% and 43% of total revenue in discontinued operations for the years ended December 31, 2014 and 2013 , respectively. This related-party revenue was recognized in connection with contract research and development services the Company provided to Merial on a fee-for-service basis under an agreement that expired on December 31, 2014. As described in Note 18, the Company entered into a new agreement with Merial in December 2014 under which the Services Business will provide contract research and screening services on a fee-for-service basis over a term of two years, ending on December 31, 2016. Success Fee Paid to a Related Party In 2013, Burrill Securities, an affiliate of Burrill Biotechnology Capital Fund, L.P., a holder of the Company’s capital stock, assisted the Company with the identification of certain strategic alternatives to an IPO. Pursuant to the related engagement letter, as amended, the Company was required to pay Burrill Securities a success fee if the Company consummated a strategic transaction or an IPO prior to November 17, 2014. In May 2014, in connection with the closing of the Company's IPO, it paid a $500 success fee to Burrill Securities and the fee was recognized as general and administrative expense in the accompanying statements of operations.

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Compensation and Employee Benefit Plans	Employee Benefit Plan The Company has a 401(k) retirement plan, which covers all U.S. employees scheduled for and working more than 20 hours per week. The Company may provide a discretionary match with a maximum amount of 50% of the first 6% of eligible participant’s compensation, which vests ratably over four years . Contributions under the plan during were approximately $239 during both years ended December 31, 2014 and 2013 , including $176 and $173 presented in discontinued operations in the accompanying statements of operations for the years ended December 31, 2014 and 2013 , respectively.

Gain on Sale of Asset

Gain on Sale of Asset	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Other Income and Expenses [Abstract]
Property and Equipment	Property and Equipment Property and equipment consists of the following: March 31, December 31, Equipment $ 8,698 $ 8,552 Furniture and fixtures 375 375 Leasehold improvements 13,209 13,193 Total property and equipment 22,282 22,120 Less accumulated depreciation 17,608 17,285 Property and equipment, net of accumulated depreciation 4,674 4,835 Property and equipment reclassified to assets of discontinued operations, net 4,674 4,835 Property and equipment, net of assets of discontinued operations $ — $ — Depreciation expense was $323 and $308 for the three months ended March 31, 2015 and 2014, respectively, with $282 and $282 included in income (loss) from discontinued operations, respectively.	Property and Equipment Property and equipment consists of the following: December 31, 2014 2013 Equipment $ 8,552 $ 9,577 Furniture and fixtures 375 378 Leasehold improvements 13,193 13,115 Total property and equipment 22,120 23,070 Less accumulated depreciation 17,285 17,669 Property and equipment, net of accumulated depreciation 4,835 5,401 Property and equipment reclassified to assets of discontinued operations, net 4,835 5,401 Property and equipment, net of assets of discontinued operations $ — $ — Depreciation expense was $1,238 and $1,329 for the years ended December 31, 2014 and 2013 , respectively, including $1,132 and $1,215 presented in discontinued operations in the accompanying statements of operations for the years ended December 31, 2014 and 2013 , respectively. As discussed in Notes 19 and 20, the Company met the relevant criteria for reporting the Service Business as held for sale on May 4, 2015, and as a result, the Company stopped recording depreciation expense on that date and assessed the property and equipment assets for impairment pursuant to FASB Topic 360, Property, Plant, and Equipment . In the quarter ended June 30, 2014, the Company’s insurance carrier remitted proceeds for the replacement cost of a fixed asset that was damaged by severe weather. The asset’s net book value was reduced upon occurrence of the damage. The proceeds received from the insurance recovery exceeded the net book value of the asset by $165 , which was recognized as a gain during the quarter ended June 30, 2014. The replacement asset was delivered, installed and placed in service during the quarter ended September 30, 2014. The fixed asset, and the resulting gain, was directly related to the Services Business and, therefore, is presented in discontinued operations in the accompanying statements of operations. Gain on Sale of Asset On May 17, 2012, the Company sold the rights to its HEOS software to a third party for consideration of $4,500 . The HEOS software asset was used in and was directly related to the operations of the Services Business. The Company received $3,500 on May 17, 2012 and recorded a gain on sale of asset of $3,412 within discontinued operations, net of transaction expenses. The remaining balance of $1,000 was held in escrow by the buyer until certain conditions were met. On May 17, 2013, the Company met all the contractual conditions and collected the $1,000 held in escrow. The Company recognized $988 , which is net of transaction expenses, as a gain on sale of asset included in discontinued operations in the accompanying financial statements.

Fair Value Measurements

Fair Value Measurements	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The carrying amounts of certain financial instruments, including cash and cash equivalents, accounts receivable, unbilled services, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their respective fair values due to the short-term nature of such instruments. Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made. As of March 31, 2015 , and December 31, 2014 , there were no assets or liabilities measured at fair value on a recurring basis. The Company’s derivative liabilities were the only balance sheet amounts that were measured at fair value on a recurring basis. The fair value of these warrant derivatives was based on a valuation of the Company’s common stock. In order to determine the fair value of the Company’s common stock, the Company used a probability-weighted expected return method, or PWERM. Significant inputs for the PWERM included an estimate of the Company’s equity value, a weighted average cost of capital and an estimated probability and timing for each valuation scenario. A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows: Three Months Ended March 31, 2014 Balance at beginning of period $ 12,237 Issuance of warrants 544 Excess of fair value of warrants over proceeds 362 Adjustment to fair value (3,145 ) Balance at end of period $ 9,998 The fair value of the common stock warrant derivative liabilities decreased from the March 31, 2014 balance presented in the table above during the second quarter of 2014, to $2,701 as of May 2, 2014. The May 2, 2014 balance was then settled to additional paid in capital on that date as the common stock warrants were exercised in conjunction with the IPO.	Fair Value Measurements The carrying amounts of certain financial instruments, including cash and cash equivalents, accounts receivable, unbilled services, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their respective fair values due to the short-term nature of such instruments. As of December 31, 2013, the Company estimated that the fair value of its obligation under the 2013 Credit Agreement was $13,023 . The fair value of debt fell within Level 3 of the fair value hierarchy as it was significantly driven by the creditworthiness of the Company, which was an unobservable input. Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made. As of December 31, 2014 , there were no assets or liabilities measured at fair value on a recurring basis. The following table summarizes the conclusions reached as of December 31, 2013 : Balance as of December 31, 2013 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Derivative liability — Series C-1 warrants $ 37 $ — $ — $ 37 Derivative liability — common stock warrants 12,200 — — 12,200 Total derivative liability $ 12,237 $ — $ — $ 12,237 The Company’s derivative liabilities were the only balance sheet amounts that were measured at fair value on a recurring basis. The fair value of these warrant derivatives was based on a valuation of the Company’s common stock. In order to determine the fair value of the Company’s common stock, the Company used a probability-weighted expected return method, or PWERM. Significant inputs for the PWERM included an estimate of the Company’s equity value, a weighted average cost of capital and an estimated probability and timing for each valuation scenario. A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows: Years Ended December 31, 2014 2013 Balance at beginning of period $ 12,237 $ 683 Issuance of warrants 544 5,382 Excess of fair value of warrants over proceeds 362 (1,714 ) Adjustment to fair value (10,442 ) 7,886 Reclassification to additional paid-in capital upon exercise of warrants (2,701 ) — Balance at end of period $ — $ 12,237

Significant Agreements

Significant Agreements	12 Months Ended
	Dec. 31, 2014
Research and Development [Abstract]
Research, Development, and Computer Software Disclosure	18. Significant Agreements R-Pharm Collaboration Arrangement In August 2013, the Company entered into a development, license, and supply agreement (the “original agreement”) with R-Pharm, granting it exclusive rights to develop and commercialize SCY-078, the Company's lead antifungal compound, in the field of human health in Russia and certain smaller non-core markets. The Company received an upfront payment of $1,500 , which composes the substantial majority of its deferred revenue balance as of December 31, 2013, and is entitled to receive payments on contingent events, including 1) a development milestone payment of $3,000 upon the first registration of SCY-078 in any country covered by the agreement; 2) sales-based payments of up to $15,000 upon R-Pharm’s achievement of specified targets for cumulative net sales of SCY-078; and 3) percentage royalties of up to the mid-teens on SCY-078 net sales. The Company deferred the upfront payment received and is recognizing it over the estimated relationship period of 70 months, which includes the product development period and an additional period during which the Company is required to participate in a product development committee. The development milestone payment is considered substantive and will be recognized when R-Pharm achieves certain specified milestones. The sales-based payments will not be recognized until the Company 1) receives the payments, and 2) has no continuing performance obligations. If the Company has any continuing performance obligations when the sales-based payments are received, those payments will be deferred and recognized over the remaining period of continuing performance obligations. Royalties will be recognized when payment is received. The original agreement also included terms whereby R-Pharm would reimburse the Company for certain research and development costs associated with Phase 2 and Phase 3 clinical trials of oral SCY-078 and the development of an IV formulation of SCY-078. However, these cost reimbursement terms required that the clinical trials and the IV formulation development follow a global development plan that was agreed upon by both parties in August 2013. Subsequent to August 2013, modifications were made to the global development plan that caused the clinical trial cost reimbursement terms in the original agreement to no longer be enforceable. As a result, the Company concluded that persuasive evidence of a cost reimbursement arrangement did not exist under the original agreement with R-Pharm. Further, the IV formulation development cost reimbursement terms in the original agreement did not specify which IV formulation and development costs were reimbursable by R-Pharm. Because of this lack of specificity, the Company concluded that the reimbursable fees due from R-Pharm were not determinable under the original agreement. In November 2014, the Company entered into a supplemental arrangement with R-Pharm, whereby R-Pharm was informed of the modified IV formulation development plan and R-Pharm agreed to reimburse the Company for specifically identified IV formulation development and manufacturing costs incurred by the Company. The specifically identified costs were defined as all costs incurred by the Company under a separate arrangement between the Company and a third-party service provider, whereby the third-party service provider is performing certain IV formulation and development services. The Company concluded that the original agreement, when combined with the November 2014 supplemental arrangement, provided persuasive evidence of a cost reimbursement arrangement between the Company and R-Pharm as of December 31, 2014. Therefore, the Company recognized a $226 receivable due from R-Pharm for reimbursable costs incurred by the Company during the year ended December 31, 2014. The presentation and disclosure associated with this cost reimbursement receivable is in accordance with the Company's research and development expenses accounting policy described in Note 2. The agreement with R-Pharm relates to the Company's continuing operations and was not associated with the sale of the Services Business in July 2015 (Note 20). Elanco Licensing Agreement The Company entered into a licensing agreement with Elanco Animal Health (Elanco) in December 2013. The agreement includes an upfront payment of $500 and multi-year contract research and development services with fees of $2,750 annually for the first two years and $3,000 annually for the second two years , and entitles the Company to 1) development milestone payments of up to $1,500 for each compound Elanco and the Company decide to develop; 2) a one-time payment of up to $2,000 for the first regulatory approval of any product in the U.S.; 3) a one-time payment of $4,000 for the first commercial sale of a product in the U.S. and a one-time payment of $1,500 for the first commercial sale of a product in the European Union; 4) one-time payments of up to $15,000 for reaching specified annual sales of a product; and 5) mid-single-digit percentage royalties on net annual sales. The Company has deferred the upfront payment, which it received in January 2014, and is recognizing the revenue over the research and development period of four years . The Elanco Licensing Agreement is directly related to the Services Business and was assigned to Accuratus in conjunction with the sale of the Services Business in July 2015 (Note 20). Revenue from the agreement is included in discontinued operations in the accompanying statements of operations. Waterstone Licensing Agreement On October 29, 2014, the Company entered into a license agreement with Waterstone Pharmaceutical (HK Limited), or Waterstone, under which the Company granted Waterstone an exclusive, worldwide license to develop and commercialize SCY-635 for the treatment of viral diseases in humans. In addition, under the same agreement, the Company granted Waterstone an option for an exclusive, worldwide license to develop and commercialize two additional compounds of the Company, SCY-575 and SCY-116, for the treatment of viral diseases in humans. The option is exercisable for a period of 18 months from the date of the agreement. In addition, the Company agreed that during the term of the agreement, it would not develop or commercialize, or grant any right or license to any third party to develop or commercialize, in Asia (excluding Japan), any cyclophilin inhibitor for treatment of viral diseases in humans. The agreement expires upon Waterstone’s last royalty payment, which is the later of ten years from the last registration of the product, or the last to expire of the patents. Either party may terminate the agreement if the other party breaches and fails to remedy the breach after receiving notice from the nonbreaching party. Specifically, the Company has the ability to terminate the agreement if the Company determines that Waterstone failed to make reasonable progress in the development and commercialization of SCY-635 or the optioned compounds. If the Company gives Waterstone notice of failure to make reasonable progress, Waterstone will have the opportunity to correct the deficiencies. If Waterstone fails to do so, the Company has the right to terminate the license. The Company received a non-refundable upfront license fee payment of $1,000 in November 2014 for SCY-635, and may receive an additional upfront payment of $500 if Waterstone exercises its option for the two additional compounds. The Company is also entitled to receive certain payments on contingent future events, including 1) a development milestone payment of $4,000 upon the first registration of a product, and 2) royalties based on a specified percentage of net sales (which percentage is in the mid-single digits), varying based on whether the product contains SCY-635 or one of the two additional compounds. The Company analyzed the license agreement and concluded that, as of December 31, 2014, it had no remaining substantive obligations to perform under the arrangement. As a result, the Company recognized revenue of $ 1,000 from the non-refundable upfront payment in the year ended December 31, 2014. The development milestone payment and the royalties will be recognized as revenue if and when the Company receives the payments. The Waterstone Licensing Agreement relates to the Company's continuing operations and was not associated with the sale of the Services Business in July 2015 (Note 20). Merial Research Services Agreement In December 2014, the Company entered into an agreement with Merial, a related party (Note 14), under which the Company will provide contract research and screening services in the field of animal health that primarily target parasites. Prior to the execution of this agreement, the Company provided contract research and development services for Merial on a fee-for-service basis under a separate agreement that expired on December 31, 2014. The agreement is a non-exclusive arrangement in the animal health field and is on a fee-for-service basis. The Company will not receive any contingent payments based on the progression to development and commercialization of any compounds arising from this agreement. Any intellectual property created in connection the Company's performance of the services shall be the sole property of Merial. The term of the agreement is two years, beginning January 1, 2015 and ending on December 31, 2016, and the total service fee due from Merial over the term of the agreement is $7,900 , payable in equal quarterly installments. The agreement also provides for an option to extend the term for one additional year. Either party may terminate the agreement in the event of breach of material obligation by the other party if such breach is not remedied after written notice from the non-breaching party. Either party may terminate this agreement if the other party makes an assignment for the benefit of creditors, becomes subject to bankruptcy proceedings, subject to appointment of a receiver, or admits inability to pay its debts. Further, within six months of any change of control the Company, Merial shall either (i) consent to continue the agreement pursuant to its terms, (ii) agree to an assignment of the agreement to a third-party acceptable to Merial, or (iii) the parties shall implement another solution acceptable to Merial, provided, however, if no resolution acceptable to Merial has been implemented within six months of the change of control, Merial may terminate the agreement immediately. If Merial believes in good faith that the Company acted in any way that may subject Merial to liability under anti-corruption laws, Merial shall have the unilateral right to terminate this agreement. At termination or expiration of the agreement for any reason, upon Merial’s request, the Company must transfer all agreement intellectual property to Merial. The Merial Research Services Agreement is directly related to the Services Business and was assigned to Accuratus in conjunction with the sale of the Services Business in July 2015 (Note 20). Revenue from the agreement is included in discontinued operations in the accompanying statements of operations.

Discontinued Operations

Discontinued Operations	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Discontinued Operations As part of the Company's strategic objective to focus its resources on the development of SCY-078, the Company's board of directors directed the Company's management to explore the divestiture of the Services Business in order to simplify the Company's business model and to allow the Company's Chief Executive Officer to focus on the execution of the Company's strategic objectives. The Company engaged a third-party firm to assist in the evaluation of several divestiture options (i.e., a third-party sale, spin-off, management buy-out or shut-down process). The Company did not meet the relevant criteria for reporting the service business as held for sale as of March 31, 2015, pursuant to FASB Topic 205-20, Presentation of Financial Statements--Discontinued Operations , and FASB Topic 360, Property, Plant, and Equipment . On May 4, 2015, the Company's board of directors completed its evaluation of the various divestiture options and directed management to pursue a plan to sell the Service Business to Accuratus, representing a strategic shift in the Company's operations. On this date, the Company met the relevant criteria for and began reporting the Services Business as held for sale and in discontinued operations. Accordingly, the accompanying financial statements have been retrospectively recast to reflect the Services Business in discontinued operations. On July 21, 2015, the Company completed the sale of the Services Business to Accuratus pursuant to the Agreement, with an effective date of July 17, 2015 (see Note 14). As a condition to the execution of the Agreement, Accuratus assumed the Company’s post-closing obligation under its facility lease in Durham, North Carolina (see Note 5). The Company and its retained employees will continue to operate from the Durham facility immediately after the closing for a period of up to six months pursuant to a facility license agreement. In addition, under a Transition Services Agreement, Accuratus will provide accounting, IT, payroll, personnel and human resources support, and equity compensation plan administration support services to the Company at rates ranging from one hundred to two hundred dollars per hour for a period of time not to extend beyond December 31, 2015. The Company and Accuratus also entered into a Commitment to Services Agreement (the "Services Agreement") pursuant to which Accuratus will provide the Company with certain contract research and development services for 18 months (the "Initial Term") following the closing of the sale of the Services Business for a minimum purchase obligation of at least $3,300 due from the Company over the Initial Term of the Services Agreement. The purpose of the Services Agreement is to replace services that were previously provided internally by employees of the Company prior to the sale of the Services Business. The employees performing these services became employees of Accuratus in connection with this sale transaction. The following table presents a reconciliation of the carrying amounts of assets and liabilities of the Services Business to the amounts presented net in the accompanying balance sheets: March 31, 2015 December 31, 2014 Carrying amounts of assets included as part of discontinued operations: Accounts and unbilled receivables, net $ 1,053 $ 1,501 Prepaid expenses and other current assets 258 289 Property and equipment, net 4,674 4,835 Other assets 64 76 Assets of discontinued operations, net $ 6,049 $ 6,701 Carrying amounts of liabilities included as part of discontinued operations: Accounts payable and accrued expenses $ 689 $ 681 Deferred revenue 445 445 Deferred rent 1,237 1,294 Liabilities related to assets of discontinued operations $ 2,371 $ 2,420 The following table presents revenue, (expenses), gains, and (losses) attributable to discontinued operations: Three Months Ended March 31, 2015 2014 Major line items constituting income (loss) of discontinued operations: Total revenue $ 3,232 $ 4,640 Cost of revenue (3,231 ) (3,960 ) Research and development (431 ) — Selling, general and administrative (23 ) — Income tax expense — (313 ) Income (loss) from discontinued operations, net $ (453 ) $ 367 The following table presents depreciation, capital expenditures, and significant operating and investing non-cash items related to the discontinued operations: Three Months Ended March 31, 2015 2014 Depreciation expense $ 282 $ 282 Purchases of property and equipment $ (171 ) $ (74 ) Stock-based compensation $ 33 $ 13 Changes in deferred rent $ (57 ) $ (15 ) Equipment purchases in accounts payable and accrued expenses $ 25 $ 204	Discontinued Operations As part of the Company's strategic objective to focus its resources on the development of SCY-078, the Company's board of directors directed the Company's management to explore the divestiture of the Services Business in order to simplify the Company's business model and to allow the Company's Chief Executive Officer to focus on the execution of the Company's strategic objectives. The Company engaged a third-party firm to assist in the evaluation of several divestiture options (i.e., a third-party sale, spin-off, management buy-out or shut-down process). The Company did not meet the relevant criteria for reporting the service business as held for sale as of December 31, 2014, pursuant to FASB Topic 205-20, Presentation of Financial Statements--Discontinued Operations , and FASB Topic 360, Property, Plant, and Equipment . On May 4, 2015, the Company's board of directors completed its evaluation of the various divestiture options and directed management to pursue a plan to sell the Service Business to Accuratus, representing a strategic shift in the Company's operations. On this date, the Company met the relevant criteria for and began reporting the Services Business as held for sale and in discontinued operations. Accordingly, the accompanying financial statements have been retrospectively recast to reflect the Services Business in discontinued operations. On July 21, 2015, the Company completed the sale of the Services Business to Accuratus pursuant to the Agreement, with an effective date of July 17, 2015 (see Note 20). The Services Business has been presented separately as discontinued operations in the Company's Statements of Operations for both years presented. The following table presents a reconciliation of the carrying amounts of assets and liabilities of the Services Business to assets of discontinued operations, net in the accompanying balance sheets: December 31, 2014 2013 Carrying amounts of assets included as part of discontinued operations: Accounts and unbilled receivables, net $ 1,501 $ 1,062 Prepaid expenses and other current assets 289 246 Property and equipment, net 4,835 5,401 Other assets 76 89 Assets of discontinued operations, net $ 6,701 $ 6,798 Carrying amounts of liabilities included as part of discontinued operations: Accounts payable and accrued expenses $ 681 $ 737 Deferred revenue 445 225 Deferred rent 1,294 1,481 Liabilities related to assets of discontinued operations $ 2,420 $ 2,443 The following table presents revenue, (expenses), gains, and (losses) attributable to discontinued operations: Years Ended December 31, 2014 2013 Major line items constituting income of discontinued operations: Total revenue $ 17,768 $ 16,762 Cost of revenue (15,446 ) (16,305 ) Selling, general and administrative 48 — Gain on insurance recovery 165 — Gain on sale of asset — 988 Income tax expense (1,166 ) (575 ) Income from discontinued operations $ 1,369 $ 870 The following table presents depreciation, capital expenditures, and significant operating and investing non-cash items related to the discontinued operations: Years Ended December 31, 2014 2013 Depreciation expense $ 1,132 $ 1,215 Purchases of property and equipment (704 ) (431 ) Proceeds from insurance recovery 216 — Gain on insurance recovery (165 ) — Gain on sale of asset, net of transaction expenses — (988 ) Proceeds from sale of asset, net of transaction expenses — 988 Stock-based compensation 159 45 Changes in deferred rent (187 ) (53 ) Equipment purchases in accounts payable and accrued expenses 34 15 Impairment of fixed asset 51 —

Subsequent Events

Subsequent Events	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events The Company evaluated subsequent events through May 15, 2015, the date on which the March 31, 2015 financial statements were originally issued. There are no significant events that require disclosure in these financial statements, except as follows: April 2015 Stock Option Grants On April 1, 2015, the Company granted options to purchase 425,967 shares of common stock to officers and other key employees, including an award to Dr. Marco Taglietti, the Company's new Chief Executive Officer, to purchase 330,000 shares of the Company's common stock. All options granted on April 1, 2015, shall have a 10 -year term. For Dr. Taglietti's grant, one-fourth of the shares subject to the option shall vest on the one-year anniversary of the date of grant with the remainder vesting in equal monthly installments for thirty-six months thereafter, provided Dr. Taglietti continues to provide service to the Company. For all other April 1, 2015 officer and key employee grants, the shares subject to the options shall vest in equal monthly installments for 48 months as measured from the date of grant. April 2015 Follow-on Public Offering On April 28, 2015, the Company completed a follow-on public offering of its common stock. The Company sold an aggregate of 5,376,622 shares of common stock at a public offering price of $7.70 per share. Net proceeds were approximately $37,754 , after deducting underwriting discounts and commissions and estimated offering expenses of approximately $3,646 . Compensatory Plan with Service Business Employees In connection with the Company's planned sale of its service business (see Note 13), the Company designed a compensatory plan to promote the retention of services of non-executive employees supporting the service business. The Company's board of directors adopted, and the Company communicated, the material terms of the plan in May 2015 to all non-executive employees of the service business. The Company's obligations under the compensatory plan are contingent upon the successful closing of the potential sale of the service business. The compensatory plan terms provide for certain cash compensation payments, as well as modifications to the terms of currently outstanding stock options held by such non-executive employees, as more completely described below. Certain non-executive service business employees will receive a cash incentive payment upon the closing of the potential sale transaction (the "Services Business Plan"). All non-executive employees of the service business will be eligible to receive a cash retention compensation payment from the Company on the earlier of (i) the six month anniversary of the closing of the potential sale transaction, provided that they remain employed by the successor of the service business as of such date, or (ii) the date of termination of such employee by the successor of the service business without good cause. Maximum cash compensation payments could total approximately $1,300 under the compensatory plan, if all service business employees remain eligible pursuant to the plan's terms. In addition, the stock options held by each non-executive employee of the service business will be modified immediately prior to the closing of the potential sale transaction to provide: (i) accelerated vesting of all unvested stock options as of the closing of the potential sale transaction and (ii) an extension to the existing 90-day post-employment option exercise period, which varies for each employee based upon years of service, with a maximum exercise period of 48 months. As of May 1, 2015, the non-executive employees of the service business held outstanding options to purchase 55,964 shares of the Company's common stock at a weighted average exercise price of $9.62 , including unvested options to purchase 33,274 shares at a weighted average exercise price of $9.62 . Further, in the event a non-executive employee of the service business is not offered a comparable position by the potential purchaser, the Company intends to provide severance payments to such employees, which are not currently estimable. Compensatory Arrangement with Executive Officer On May 12, 2015, Charles F. Osborne, Jr., notified the Company that he will be resigning from the Company, including in his capacity as Chief Financial Officer, effective June 30, 2015. The Company's compensation committee of the board of directors approved a compensatory arrangement for Mr. Osborne that provides for certain payments and benefits, including (i) a cash payment of approximately $138,000 upon the effective date of his resignation; (ii) cash severance payments totaling approximately $179,000 , which is equal to seven months of Mr. Osborne's current base salary, paid over seven months commencing with the first payroll period following the resignation date; (iii) payment of the COBRA premiums for continued medical, dental, and vision group health coverage for a period up to seven months after the resignation date; and (iv) the vesting and exercisability of all outstanding options to purchase the Company's common stock held by Mr. Osborne will be accelerated in full on the effective date of resignation and the post-employment option exercise period will be extended from 90-days to 36 months. As of June 30, 2015, Mr. Osborne will hold outstanding options to purchase an aggregate of 74,490 shares of the Company's common stock at a weighted average exercise price of $9.53 , including unvested options to purchase 50,814 shares at a weighted average exercise price of $9.49 . The Company updated its evaluation of subsequent events through October 30, 2015, the date on which the March 31, 2015, financial statements were reissued. There are no additional significant events that require disclosure in these interim financial statements, except as follows: 2014 Equity Incentive Plan Activity The Company's board of directors recently took certain actions that affected the number of outstanding stock options and options available for grant under the 2014 Equity Incentive Plan, or the 2014 Plan, as follows: • On June 4, 2015, the Company's stockholders approved an amendment of the 2014 Plan to increase the aggregate number of shares of common stock that may be issued pursuant to awards under the 2014 Plan by an additional 510,726 shares. All other material terms of the 2014 Plan otherwise remain unchanged. • On June 4, 2015, the Company granted options to purchase 125,000 shares of common stock to David Angulo, M.D., the new Chief Medical Officer, under the 2015 Inducement Plan. The options have a ten -year term, with one-fourth of the shares subject to the option vesting on the one-year anniversary of the date of grant and the remainder vesting in equal monthly installments for thirty-six months thereafter, provided Dr. Angulo continues to provide service to the Company. • On October 1, 2015, the Company granted options to purchase 60,000 shares of common stock to a newly hired vice president under the 2015 Inducement Plan. The options have a ten-year term, with one-fourth of the shares subject to the option vesting on the one-year anniversary of the date of grant and the remainder vesting in equal monthly installments for thirty-six months thereafter, provided the vice president continues to provide service to the Company. Compensatory Arrangement with Executive Officer On July 21, 2015, Yves J. Ribeill, Ph.D., President and a member of the Company’s board of directors, resigned as President. Dr. Ribeill will continue to serve on the Company's board of directors. The Company and Dr. Ribeill entered into an agreement, effective July 21, 2015, for certain payments and benefits (the “Separation Agreement”), pursuant to which Dr. Ribeill will receive: (i) a cash payment of approximately $100 upon the effective date of his resignation; (ii) cash severance payments totaling approximately $900 , paid over 12 months commencing with the first payroll period following the resignation date; (iii) a payment representing a contribution Dr. Ribeill can use towards continuing COBRA premiums for medical, dental, and vision group health coverage after the resignation date, and (iv) the vesting and exercisability of all outstanding options held by Dr. Ribeill will be accelerated in full on the effective date of resignation, with the exception of options granted pursuant to the 1999 Plan, and the post-employment option exercise period will be extended from 90 -days to 48 months. As of July 23, 2015, Dr. Ribeill held 84,613 vested options and 183,268 unvested options to purchase shares of the Company’s common stock at a weighted average exercise price of $9.61 and $9.41 per share, respectively. Sale of the Services Business On July 21, 2015, the Company completed the sale of the Company’s Services Business pursuant to the Agreement, with an effective date of July 17, 2015, with Accuratus, a private-equity backed process chemistry, formulation, manufacturing and analytical development services provider, for an aggregate purchase price of $3,875 , subject to a working capital adjustment of $824 , which reduced the proceeds at closing. In addition, a portion of the consideration payable at closing equal to $500 was withheld and is subject to an escrow for a period of 12 months from the date of closing to satisfy indemnification obligations of the Company in connection with breaches of any representation and warranties and other customary obligations under the terms of the Agreement. The net cash consideration received by us upon closing in July 2015 was $2,549 , after adjusting for the items described above and a nominal escrow fee. As discussed in Note 13, the Company met the relevant criteria for reporting the Service Business as held for sale on May 4, 2015 (the "Measurement Date"), and as a result, assessed the asset group for impairment pursuant to FASB Topic 360, Property, Plant, and Equipment . The net carrying value of the Services Business asset group was compared to its fair value as of May 4, 2015. The Company determined that the selling price paid by Accuratus to acquire the Services Business asset group was the best estimate of fair value, which the Company concluded was a Level 2 input. The Company determined that the Services Business asset group's net carrying value exceeded its fair value by $572 on the Measurement Date. The Company also estimated selling costs directly attributable to the sale of the Services Business to be $778 . As a result, the Company recorded a $1,350 impairment charge on property and equipment assets classified as held for sale in the quarterly period ended June 30, 2015. As a condition to the execution of the Agreement, Accuratus is assuming the Company’s post-closing obligation under its facility lease in Durham, North Carolina (see Note 5). The Company and its retained employees will continue to operate from the Durham facility immediately after the closing for a period of up to six months pursuant to a facility license and a transition services agreement. In addition, under a Transition Services Agreement, Accuratus will provide accounting, IT, payroll, personnel and human resources support, and equity compensation plan administration support services to the Company at rates ranging from one hundred to two hundred dollars per hour for a period of time not to extend beyond December 31, 2015. The Services Business Plan provided that in the event a non-executive employee of the Services Business was not offered a comparable position by Accuratus, the Company would provide severance payments to such employees. The Company terminated certain employees in June 2015 (the "June 2015 Terminated Employees") who became eligible for severance benefits totaling approximately $999 pursuant to the terms of the Services Business Plan. The Services Business Plan also provided for certain amendments to the terms of the outstanding stock option awards held by the June 2015 Terminated Employees, which are described in below. In connection with the sale of the Services Business, each of the Company’s non-executive officer employees principally providing services to the Services Business have either accepted continued employment with Accuratus or has terminated in connection with the transaction contemplated by the Agreement. Pursuant to the Services Business Plan, as described above, the Company paid cash totaling approximately $215 to certain non-executive employees of the Services Business as an incentive payment upon the closing of the sale transaction in July 2015. In addition, all non-executive employees of the Services Business will be eligible to receive a cash retention compensation payment from the Company on the earlier of (i) the six month anniversary of the closing of the sale transaction, provided that they remain employed by Accuratus as of such date, or (ii) the date of termination of such employee by Accuratus without good cause. Maximum cash retention compensation payments could total approximately $814 under the Services Business Plan, if all service business employees remain eligible pursuant to the terms of the Services Business Plan. The Company incurred these obligations on the date of the sale of the Services Business in July 2015; therefore, the compensation expense associated with these will be recognized during the quarterly period ended September 30, 2015. In addition, the stock options held by each non-executive employee of the Services Business were modified immediately prior to the closing of the sale transaction in July 2015 to provide: (i) accelerated vesting of all unvested stock options as of the closing of the sale transaction and (ii) an extension to the existing 90-day post-employment option exercise period, which varies for each employee based upon years of service, with a maximum exercise period of 48 months. As of June 30, 2015, the non-executive employees of the Services Business held outstanding options to purchase 37,517 shares of the Company's common stock at a weighted average exercise price of $9.62 per share, including unvested options to purchase 23,052 shares at a weighted average exercise price of $9.61 per share. The incremental stock compensation expense associated with these modifications will be recognized during the quarterly period ended September 30, 2015. The Company entered into an agreement with a third party firm to assist the Company in exploring the divestiture of its Services Business. Pursuant to the terms of the agreement, in the event that the Company was able to complete a divestiture of the Services Business to a third-party, the Company was obligated to pay a success fee to the third party firm for the greater of $500 or 4% of the transaction consideration. The Company paid and expensed an initial retainer of $50 prior to the closing of the Service Business sale transaction, and then paid a $450 remaining success fee due to the third party firm in July 2015 in connection with the closing of the sale transaction. Commitment to Services Agreement On July 17, 2015, the Company and Accuratus also entered into the Services Agreement pursuant to which Accuratus will provide the Company with certain contract research and development services for the Initial Term following the closing of the sale of the Services Business for a minimum purchase obligation on the part of the Company of at least $3,300 over the Initial Term of the Services Agreement (see Note 13). The purpose of the Services Agreement is to replace services that were previously provided internally by employees of the Company prior to the sale of the Services Business. The employees performing these services became employees of Accuratus in connection with this sale transaction. Compensatory Arrangement with Employees of the Company's Continuing Operations In connection with the Company's relocation of its continuing operations to Jersey City, New Jersey, the Company designed a compensatory plan to promote the retention of services of non-executive employees supporting its continuing operations (the "Retention Plan"). The Company's board of directors adopted, and the Company communicated, the material terms of the Retention Plan prior to June 30, 2015, to all non-executive employees supporting the Company's continuing operations. The Retention Plan terms provide for certain cash compensation payments and severance payments, as well as modifications to the terms of currently outstanding stock options held by such non-executive employees, as more completely described below. The Company has concluded that the Retention Plan meets the definition of an exit and disposal activity pursuant to FASB ASC 420-- Exit and Disposal Cost Obligations as of June 30, 2015, and all related expenses incurred have been or will be presented in continuing operations in the statements of operations. The Retention Plan provides that non-executive employees are eligible to receive cash bonuses, severance payments and related benefit premiums that could total a maximum of approximately $1,161 , provided that all employees remain employed through December 31, 2015 and are not terminated for cause. The Retention Plan also provides that if the Company and an employee agree upon a services termination date earlier than December 31, 2015 (the "Release Date"), the employee will remain eligible for all terms of the Retention Plan. The Company will accrue this obligation over the remaining future service period required by the employees through the earlier of the Release Date or December 31, 2015. The Retention Plan also includes certain amendments to the terms of the eligible employees' outstanding stock option awards, which are described in detail below. Option Amendments Subsequent to March 30, 2015, the following events resulted in the amendment to terms of outstanding stock option awards: • On June 4, 2015, the Company's board of directors approved an extension to the existing 90 -day post-employment option exercise period to a period ranging from 36 to 48 months for three directors who resigned from the board effective June 4, 2015. The directors held outstanding options to purchase 48,283 shares of the Company's common stock at a weighted average exercise price of $9.01 per share. All outstanding options were fully vested prior to June 4, 2015. • The outstanding stock options held by the June 2015 Terminated Employees were modified to provide: (i) accelerated vesting of all unvested stock options as of their termination date and (ii) an extension to the existing 90-day post-employment option exercise period, which varies for each employee based upon years of service, with a maximum exercise period of 48 months. As of June 30, 2015, the June 2015 terminated employees held outstanding options to purchase 17,715 shares of the Company's common stock at a weighted average exercise price of $9.64 per share, including aggregate unvested options to purchase 8,331 shares at a weighted average exercise price of $9.64 per share. • The Company's compensation committee of the board of directors approved the following modifications to Mr. Osborne's outstanding options to purchase the Company's common stock: (i) accelerated vesting of all unvested stock options as of June 30, 2015, and (ii) an extension to the existing 90-day post-employment option exercise period to 36 months. As of June 30, 2015, Mr. Osborne held outstanding options to purchase an aggregate of 74,490 shares of the Company's common stock at a weighted average exercise price of $9.53 per share, including unvested options to purchase 50,814 shares at a weighted average exercise price of $9.49 per share. • Pursuant to the terms of the Retention Plan, all stock options held by non-executive employees eligible under the Retention Plan were modified to provide: (i) accelerated vesting of all unvested stock options as of December 31, 2015, and (ii) an extension to the existing 90-day post-employment option exercise period, which varies for each employee based upon years of service, with a maximum exercise period of 48 months. As of June 30, 2015, the retained employees eligible for participation in the Retention Plan held outstanding options to purchase 121,550 shares of the Company's common stock at a weighted average exercise price of $9.13 per share, including aggregate unvested options to purchase 85,990 shares at a weighted average exercise price of $8.95 per share. The Company determined the additional compensation cost associated with the previously described modifications pursuant to applicable guidance in FASB ASC Topic 718, Compensation—Stock Compensation .The additional compensation cost was determined by calculating the difference between (a) the estimated fair value of each option award immediately prior to the modifications and (b) the estimated fair value of each option award immediately after the modifications. The fair value of each option award immediately prior to and immediately after modification was estimated using the Black-Scholes option-pricing model to determine an incremental fair value, consistent with and in accordance with the Company’s existing accounting policy for stock compensation (see Note 2). Using the Black-Scholes option-pricing model, the weighted-average incremental fair value of outstanding modified option awards was $3.54 per option share. The total additional compensation cost associated with the previously described modifications was determined to be $819 , of which $466 was associated with services previously performed and, therefore, was expensed in the quarter ended June 30, 2015. The remaining additional compensation cost is associated with future service periods and will be recognized as those services are performed. New Facilities Lease On July 13, 2015, the Company entered into a sublease (the "Sublease") that became effective July 22, 2015, to sublet certain premises consisting of 10,141 square feet of space (the "Subleased Premises") located at 101 Hudson Street, Jersey City, New Jersey from Optimer Pharmaceutical, Inc. The term of the Sublease commences on August 1, 2015 (the "Commencement Date") and is scheduled to expire on July 30, 2018. No base rent is due under the Sublease until one month after the Commencement Date. Under the Sublease, the Company is obligated to pay monthly base rent of approximately $25 per month, which amount increases by 3% annually on each anniversary of the Commencement Date. In addition, the Company was required to fund a security deposit with the sublandlord in the amount of $74 .	Subsequent Events The Company evaluated subsequent events through March 30, 2015, the date on which the December 31, 2014 financial statements were originally issued. There are no significant events that require disclosure in these financial statements, except as follows: 2014 Equity Incentive Plan Activity The following events occurred with respect to the 2014 Plan subsequent to December 31, 2014. • Pursuant to the terms of the 2014 Plan (Note 11), on January 1, 2015, the Company automatically added 340,484 shares to the total number shares of common stock available for future issuance under the 2014 Plan. • In connection with the resignation of the Company's Chief Medical Officer, Dr. Carole Sable, effective as of February 20, 2015, the Company returned 57,452 shares to the total number shares of common stock available for future issuance under the 2014 Plan. The returned shares represent Dr. Sable's unvested shares as of the effective date of her resignation. • In February 2015, the board of directors appointed Marco Taglietti, M.D. as Chief Executive Officer of the Company, effective as of April 1, 2015. In connection with Dr. Taglietti’s appointment as Chief Executive Officer, Dr. Taglietti will be granted an option to purchase 330,000 shares of the Company's common stock, subject to approval by the board of directors. The option shall be granted as of the effective date of Dr. Taglietti's employment, shall have a ten-year term and one-fourth of the shares subject to the option shall vest on the one-year anniversary of the date of grant with the remainder vesting in equal monthly installments for thirty-six months thereafter, provided Dr. Taglietti continues to provide service to the Company. In addition, on the first anniversary of the Dr. Taglietti’s employment, subject to the approval of the board of directors, Dr. Taglietti will be granted an additional option to purchase 80,000 shares of the Company's common stock. The additional option shall have a ten-year term and the shares subject to the option shall vest in equal monthly installments for forty-eight months as measured from the date of grant, provided Dr. Taglietti continues to provide service to the Company. • On February 25, 2015, the Company's board of directors approved an amendment of the 2014 Plan, subject to stockholder approval at the Company's 2015 annual meeting of stockholders, to increase the aggregate number of shares of common stock that may be issued pursuant to awards under the 2014 Plan by an additional 510,726 shares. All other material terms of the 2014 Plan otherwise remain unchanged. Inducement Award Plan Approval On March 26, 2015, the Company's board of directors adopted the 2015 Inducement Plan, or the 2015 Plan. The 2015 Plan provides for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other forms of equity compensation (collectively, stock awards), all of which may be granted to persons not previously employees or directors of the Company, or following a bona fide period of non-employment, as an inducement material to the individuals’ entering into employment with the Company within the meaning of NASDAQ Listing Rule 5635(c)(4). The 2015 Plan has a share reserve covering 450,000 shares of common stock. The Company updated its evaluation of subsequent events through October 30, 2015, the date on which the December 31, 2014, financial statements were reissued. There are no additional significant events that require disclosure in these financial statements, except as follows: April 2015 Follow-On Public Offering On April 28, 2015, the Company completed a follow-on public offering (the "April 2015 Offering") of its common stock. The Company sold an aggregate of 5,376,622 shares of common stock at a public offering price of $7.70 per share. Net proceeds were approximately $38,012 , after deducting underwriting discounts and commissions and offering expenses of approximately $3,388 . Equity Compensation Plan Activity The Company's board of directors recently took certain actions that affected the number of outstanding stock options and options available for grant under the 2014 Equity Incentive Plan, or the 2014 Plan, as follows: • On April 1, 2015, the Company granted options to purchase 425,967 shares of common stock to officers and other key employees, including an award to Dr. Taglietti to purchase 330,000 shares of common stock. All options granted on April 1, 2015, have a ten -year term. For Dr. Taglietti's grant, one-fourth of the shares subject to the option vest on the one-year anniversary of the date of grant with the remainder vesting in equal monthly installments for thirty-six months thereafter, provided Dr. Taglietti continues to provide service to the Company. For all other April 1, 2015 officer and key employee grants, the shares subject to the options vest in equal monthly installments for forty-eight months as measured from the date of grant. • On June 4, 2015, the Company's stockholders approved an amendment of the 2014 Plan to increase the aggregate number of shares of common stock that may be issued pursuant to awards under the 2014 Plan by an additional 510,726 shares. All other material terms of the 2014 Plan otherwise remain unchanged. • On June 4, 2015, the Company granted options to purchase 125,000 shares of common stock to David Angulo, M.D., the new Chief Medical Officer, under the 2015 Inducement Plan. The options have a ten -year term, with one-fourth of the shares subject to the option vesting on the one-year anniversary of the date of grant and the remainder vesting in equal monthly installments for thirty-six months thereafter, provided Dr. Angulo continues to provide service to the Company. • On October 1, 2015, the Company granted options to purchase 60,000 shares of common stock to a newly hired vice president under the 2015 Inducement Plan. The options have a ten-year term, with one-fourth of the shares subject to the option vesting on the one-year anniversary of the date of grant and the remainder vesting in equal monthly installments for thirty-six months thereafter, provided the vice president continues to provide service to the Company. Departure of Chief Financial Officer Charles F. Osborne, Jr., the Company's former chief financial officer, resigned effective June 30, 2015. The Company's compensation committee of the board of directors approved a compensatory arrangement for Mr. Osborne that provided for certain payments and benefits, including: (i) a cash payment of approximately $138 upon his resignation on June 30, 2015; (ii) cash severance payments totaling approximately $179 , which is equal to seven months of Mr. Osborne’s current base salary, paid over seven months commencing with the first payroll period following the resignation date; (iii) a payment representing a contribution Mr. Osborne can use towards continuing COBRA premiums for medical, dental, and vision group health coverage for a period up to seven months after the resignation date; and (iv) certain amendments to the terms of Mr. Osborne's outstanding stock option awards as described below. Sale of the Services Business On July 21, 2015, the Company completed the sale of the Services Business pursuant to an Asset Purchase Agreement, with an effective date of July 17, 2015, with Accuratus for an aggregate purchase price of $3,875 , subject to a working capital adjustment of $824 , which reduced the proceeds at closing. In addition, a portion of the consideration payable at closing equal to $500 was withheld and is subject to an escrow for a period of 12 months from the date of closing to satisfy indemnification obligations of the Company in connection with breaches of any representation and warranties and other customary obligations under the terms of the Agreement. The net cash consideration received by the Company upon closing in July 2015 was $2,549 , after adjusting for the items described above and a nominal escrow fee. As discussed in Note 19, the Company met the relevant criteria for reporting the Service Business as held for sale on May 4, 2015 (the "Measurement Date"), and as a result, assessed the asset group for impairment pursuant to FASB Topic 360, Property, Plant, and Equipment . The net carrying value of the Services Business asset group was compared to its fair value as of May 4, 2015. The Company determined that the selling price paid by Accuratus to acquire the Services Business asset group was the best estimate of fair value, which the Company concluded was a Level 2 input. The Company determined that the Services Business asset group's net carrying value exceeded its fair value by $572 on the Measurement Date. The Company also estimated selling costs directly attributable to the sale of the Services Business to be $778 . As a result, the Company recorded a $1,350 impairment charge on property and equipment assets classified as held for sale in the quarterly period ended June 30, 2015. As a condition to the execution of the Agreement, Accuratus assumed the Company’s post-closing obligation under its facility lease in Durham, North Carolina. Certain of the Company's retained employees will continue to operate from the Durham facility immediately after the closing for a period of up to six months pursuant to a facility license and a transition services agreement. In addition, under a Transition Services Agreement, Accuratus has provided or is providing accounting, IT, payroll, personnel and human resources support, and equity compensation plan administration support services to the Company at rates ranging from one hundred to two hundred dollars per hour for a period of time not to extend beyond December 31, 2015. The Company entered into an agreement with a third party firm to assist the Company in exploring the divestiture of its Services Business. Pursuant to the terms of the agreement, in the event that the Company was able to complete a divestiture of the Services Business to a third party, the Company was obligated to pay a success fee to the third party firm for the greater of $500 or 4% of the transaction consideration. The Company paid and expensed an initial retainer prior to the closing of the Service Business sale transaction, and then paid a $450 remaining success fee due to the third party firm in July 2015 in connection with the closing of the sale transaction. The Company also entered into certain compensatory arrangements with its continuing employees and with terminated employees in connection with the sales of the Services Business as described below. Compensatory Plan with Services Business Employees In connection with the Company's sale of its Services Business, the Company designed a compensatory plan to promote the retention of services of its non-executive employees supporting that business (the "Services Business Plan"). The Company's board of directors adopted, and the Company communicated, the material terms of the Services Business Plan prior to June 30, 2015, to all non-executive employees of the Services Business. The Services Business Plan terms provide for certain cash compensation payments, as well as modifications to the terms of currently outstanding stock options held by such non-executive employees, as more completely described below, upon the successful closing of the sale of the Services Business. The sale closed in July 2015. The Services Business Plan meets the definition of an exit and disposal activity pursuant to FASB ASC 420-- Exit and Disposal Cost Obligations and all related expenses incurred have been or will be presented in discontinued operations in the statements of operations in the periods incurred. The Services Business Plan provided that in the event a non-executive employee of the Services Business was not offered a comparable position by Accuratus, the Company would provide severance payments to such employees. The Company terminated certain employees in June 2015 (the "June 2015 Terminated Employees") who became eligible for severance benefits totaling approximately $999 pursuant to the terms of the Services Business Plan. The Services Business Plan also provided for certain amendments to the terms of the outstanding stock option awards held by the June 2015 Terminated Employees, which are described in below. In July 2015, pursuant to the Services Business Plan, the Company paid cash totaling approximately $215 to certain non-executive employees of the Services Business representing an incentive payment upon the closing of the sale of the Services Business. In addition, all non-executive employees of the Services Business will be eligible to receive a cash retention compensation payment from the Company on the earlier of (i) the six month anniversary of the closing of the sale transaction, provided that they remain employed by Accuratus as of such date, or (ii) the date of termination of such employee by Accuratus without good cause. Maximum cash retention compensation payments could total approximately $814 under the Services Business Plan, if all service business employees remain eligible pursuant to the terms of the Services Business Plan. The Company incurred these obligations on the date of the sale of the Services Business in July 2015; therefore, the compensation expense associated with these obligations were recognized during the quarterly period ended September 30, 2015. The Services Business Plan also includes certain amendments to the terms of the eligible employees' outstanding stock option awards, which are described in detail below. Compensatory Arrangement with Employees of the Company's Continuing Operations In connection with the Company's relocation of its continuing operations to Jersey City, New Jersey, the Company designed a compensatory plan to promote the retention of services of non-executive employees supporting its continuing operations (the "Retention Plan"). The Company's board of directors adopted, and the Company communicated, the material terms of the Retention Plan prior to June 30, 2015, to all non-executive employees supporting the Company's continuing operations. The Retention Plan terms provide for certain cash compensation payments and severance payments, as well as modifications to the terms of currently outstanding stock options held by such non-executive employees, as more completely described below. The Company has concluded that the Retention Plan meets the definition of an exit and disposal activity pursuant to FASB ASC 420-- Exit and Disposal Cost Obligations as of June 30, 2015, and all related expenses incurred have been or will be presented in continuing operations in the statements of operations. The Retention Plan provides that non-executive employees are eligible to receive cash bonuses, severance payments and related benefit premiums that could total a maximum of approximately $1,161 , provided that all employees remain employed through December 31, 2015 and are not terminated for cause. The Retention Plan also provides that if the Company and an employee agree upon a services termination date earlier than December 31, 2015 (the "Release Date"), the employee will remain eligible for all terms of the Retention Plan. The Company will accrue this obligation over the remaining future service period required by the employees through the earlier of the Release Date or December 31, 2015. The Retention Plan also includes certain amendments to the terms of the eligible employees' outstanding stock option awards, which are described in detail below. Option Amendments Subsequent to March 30, 2015, the following events resulted in the amendment to terms of outstanding stock option awards: • On June 4, 2015, the Company's board of directors approved an extension to the existing 90 -day post-employment option exercise period to a period ranging from 36 to 48 months for three directors who resigned from the board effective June 4, 2015. The directors held outstanding options to purchase 48,283 shares of the Company's common stock at a weighted average exercise price of $9.01 per share. All outstanding options were fully vested prior to June 4, 2015. • The outstanding stock options held by the June 2015 Terminated Employees were modified to provide: (i) accelerated vesting of all unvested stock options as of their termination date and (ii) an extension to the existing 90-day post-employment option exercise period, which varies for each employee based upon years of service, with a maximum exercise period of 48 months. As of June 30, 2015, the June 2015 terminated employees held outstanding options to purchase 17,715 shares of the Company's common stock at a weighted average exercise price of $9.64 per share, including aggregate unvested options to purchase 8,331 shares at a weighted average exercise price of $9.64 per share. • The Company's compensation committee of the board of directors approved the following modifications to Mr. Osborne's outstanding options to purchase the Company's common stock: (i) accelerated vesting of all unvested stock options as of June 30, 2015, and (ii) an extension to the existing 90-day post-employment option exercise period to 36 months. As of June 30, 2015, Mr. Osborne held outstanding options to purchase an aggregate of 74,490 shares of the Company's common stock at a weighted average exercise price of $9.53 per share, including unvested options to purchase 50,814 shares at a weighted average exercise price of $9.49 per share. • Pursuant to the terms of the Retention Plan, all stock options held by non-executive employees eligible under the Retention Plan were modified to provide: (i) accelerated vesting of all unvested stock options as of December 31, 2015, and (ii) an extension to the existing 90-day post-employment option exercise period, which varies for each employee based upon years of service, with a maximum exercise period of 48 months. As of June 30, 2015, the retained employees eligible for participation in the Retention Plan held outstanding options to purchase 121,550 shares of the Company's common stock at a weighted average exercise price of $9.13 per share, including aggregate unvested options to purchase 85,990 shares at a weighted average exercise price of $8.95 per share. The Company determined the additional compensation cost associated with the previously described modifications pursuant to applicable guidance in FASB ASC Topic 718, Compensation—Stock Compensation .The additional compensation cost was determined by calculating the difference between (a) the estimated fair value of each option award immediately prior to the modifications and (b) the estimated fair value of each option award immediately after the modifications. The fair value of each option award immediately prior to and immediately after modification was estimated using the Black-Scholes option-pricing model to determine an incremental fair value, consistent with and in accordance with the Company’s existing accounting policy for stock compensation (see Note 2). Using the Black-Scholes option-pricing model, the weighted-average incremental fair value of outstanding modified option awards was $3.54 per option share. The total additional compensation cost associated with the previously described modifications was determined to be $819 , of which $466 was associated with services previously performed and, therefore, was expensed in the quarter ended June 30, 2015. The remaining additional compensation cost is associated with future service periods and will be recognized as those services are performed. Commitment to Services Agreement On July 17, 2015, the Company and Accuratus also entered into the Services Agreement pursuant to which Accuratus is providing the Company with certain contract research and development services for 18 months (the "Initial Term") following the closing of the sale of the Services Business for a minimum purchase obligation on the part of the Company of at least $3,300 over the Initial Term of the Services Agreement. The purpose of the Services Agreement is to replace services that were previously provided internally by employees of the Company prior to the sale of the Services Business. The employees performing these services became employees of Accuratus in connection with this sale transaction. New Facilities Lease On July 13, 2015, the Company entered into a sublease (the "Sublease") that became effective July 22, 2015, to sublet certain premises consisting of 10,141 square feet of space (the "Subleased Premises") located at 101 Hudson Street, Jersey City, New Jersey from Optimer Pharmaceutical, Inc. The term of the Sublease commenced on August 1, 2015 (the "Commencement Date") and is scheduled to expire on July 30, 2018. No base rent was due under the Sublease until one month after the Commencement Date. Under the Sublease, the Company is obligated to pay monthly base rent of approximately $25 per month, which amount increases by 3% annually on each anniversary of the Commencement Date. In addition, the Company was required to fund a security deposit with the sublandlord in the amount of $74 . Compensatory Arrangement with Executive Officer On July 21, 2015, Yves J. Ribeill, Ph.D., President and a member of the Company’s board of directors, resigned as President. Dr. Ribeill will continue to serve on the board of directors. The Company and Dr. Ribeill entered into an agreement, effective July 21, 2015, for certain payments and benefits (the “Separation Agreement”), pursuant to which Dr. Ribeill will receive: (i) a cash payment of approximately $100 upon the effective date of his resignation; (ii) cash severance payments totaling approximately $900 , paid over 12 months commencing with the first payroll period following the resignation date; (iii) a payment representing a contribution Dr. Ribeill can use towards continuing COBRA premiums for medical, dental, and vision group health coverage after the resignation date, and (iv) the vesting and exercisability of all outstanding options held by Dr. Ribeill will be accelerated in full on the effective date of resignation, with the exception of options granted pursuant to the 1999 Plan, and the post-employment option exercise period will be extended from 90 -days to 48 months. As of July 23, 2015, Dr. Ribeill held 84,613 vested options and 183,268 unvested options to purchase shares of the Company’s common stock at a weighted average exercise price of $9.61 and $9.41 per share, respectively.

Summary of Significant Accoun29

Summary of Significant Accounting Policies (Policies)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Assets of Discontinued Operations	Assets of Discontinued Operations The Company considers assets to be of discontinued operations (i) when management or others having the authority to do so approve a plan to sell the assets, (ii) the assets are available for immediate sale in their present condition, (iii) the Company has initiated an active program to locate a buyer and other actions required to complete the plan to sell the assets, (iv) consummation of the transaction is probable, (v) the assets are being actively marketed for sale at a price that is reasonable in relation to their current fair value, and (vi) the transaction is expected to qualify for recognition as a completed sale, within one year. Following the classification of property and equipment as held for sale, the Company discontinues depreciating the assets and writes down the assets to the lower of carrying value or fair market value, if needed. As described in Note 13, on May 4, 2015, actions taken by the Company's board of directors caused the Company to meet the relevant criteria for reporting the Services Business as held for sale.	Assets of Discontinued Operations The Company considers assets to be of discontinued operations (i) when management or others having the authority to do so approve a plan to sell the assets, (ii) the assets are available for immediate sale in their present condition, (iii) the Company has initiated an active program to locate a buyer and other actions required to complete the plan to sell the assets, (iv) consummation of the transaction is probable, (v) the assets are being actively marketed for sale at a price that is reasonable in relation to their current fair value, and (vi) the transaction is expected to qualify for recognition as a completed sale, within one year. Following the classification of property and equipment as held for sale, the Company discontinues depreciating the assets and writes down the assets to the lower of carrying value or fair market value, if needed. As described in Note 20, on May 4, 2015, actions taken by the Company's board of directors caused the Company to meet the relevant criteria for reporting the Services Business as held for sale.
Concentration of Credit Risk		Concentration of Credit Risk Financial instruments, which potentially expose the Company to concentrations of credit risk, consist principally of cash on deposit with a bank, which exceeds FDIC insured limits, and accounts receivable and unbilled services. Ongoing credit evaluations of customer’s financial condition are performed by the Company and collateral is not required.
Cash and Cash Equivalents		Cash and Cash Equivalents The Company considers any highly liquid investments with a remaining maturity of three months or less when purchased to be cash and cash equivalents.
Accounts Receivable and Unbilled Services		Accounts Receivable and Unbilled Services Accounts receivable and unbilled services consist of amounts billed and unbilled under the Company’s Services Business contracts with its Services Business customers. The Company extends credit to customers without requiring collateral. Accounts receivable are stated at net realizable value. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance based on its history of collections and write-offs and the current status of all receivables. The Company does not accrue interest on trade receivables.
Property and Equipment		Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the respective assets, which generally range from three to seven years. Leasehold improvements are amortized over the shorter of the useful life of the asset or the term of the related lease. Maintenance and repairs are charged against expense as incurred.
Deferred Financing Costs		Deferred Financing Costs Deferred financing costs were transaction costs associated with issuing debt as well as costs related to a deemed contribution for a guarantee from a related party. The Company recognized these costs in the balance sheet as noncurrent assets. Deferred financing costs were amortized over the life of the related debt. Deferred Offering Costs Deferred offering costs were expenses directly related to the IPO. These costs consisted of legal, accounting, printing, and filing fees that the Company capitalized, including fees incurred by the independent registered public accounting firm directly related to the offering. The deferred offering costs were offset against the IPO proceeds in May 2014 and were reclassified to additional paid-in capital upon completion of the IPO. As of December 31, 2014 and 2013 , the amount capitalized as deferred offering costs was $0 and $1,775 , respectively.
Other Assets		Other Assets Other assets consist primarily of the refundable long-term deposit on the leased building facility (included in assets of discontinued operations) and the refundable amount held by the Company’s employee dental plan insurance provider as required by its agreement.
Impairment of Long-Lived Assets		Impairment of Long-Lived Assets Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When such events occur, the Company compares the carrying amounts of the assets to their undiscounted expected future cash flows. If the undiscounted cash flows are insufficient to recover the carrying value, an impairment loss is recorded for the difference between the carrying value and fair value of the asset. To date, no such impairment has occurred.
Revenue Recognition and Deferred Revenue	Revenue Recognition and Deferred Revenue The Company has historically derived the majority of its revenue from providing contract research and development services under fee for service arrangements, which were provided by the Services Business that was sold in July 2015 (see Notes 13 and 14). The Company also has entered into collaboration arrangements in exchange for non-refundable upfront payments and consideration as services are performed. These arrangements include multiple elements, such as the sale of licenses and the provision of services. Under these arrangements, the Company also is entitled to receive development milestone payments and royalties in the form of a designated percentage of product sales. The Company classifies non-refundable upfront payments, milestone payments and royalties received under collaboration and licensing agreements as revenue within its statements of operations because the Company views such activities as being central to its business operations. Revenue is recognized when all of the following conditions are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) fees are fixed or determinable, and (iv) collection of fees is reasonably assured. The Company’s contract research and development services revenue is recognized in the period in which the services are performed. When entering into an arrangement, the Company first determines whether the arrangement includes multiple deliverables and is subject to accounting guidance in ASC subtopic 605-25, Multiple-Element Arrangements . If the Company determines that an arrangement includes multiple elements, it determines whether the arrangement should be divided into separate units of accounting and how the arrangement consideration should be measured and allocated among the separate units of accounting. An element qualifies as a separate unit of accounting when the delivered element has standalone value to the customer. The Company’s arrangements do not include a general right of return relative to delivered elements. Any delivered elements that do not qualify as separate units of accounting are combined with other undelivered elements within the arrangement as a single unit of accounting. If the arrangement constitutes a single combined unit of accounting, the Company determines the revenue recognition method for the combined unit of accounting and recognizes the revenue over the period from inception through the date the last deliverable within the single unit of accounting is delivered. Non-refundable upfront license fees are recorded as deferred revenue and recognized into revenue on a straight-line basis over the estimated period of the Company’s substantive performance obligations. If the Company does not have substantive performance obligations, the Company recognizes non-refundable upfront fees into revenue through the date the deliverable is satisfied. Analyzing the arrangement to identify deliverables requires the use of judgment and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. In arrangements that include license rights and other non-contingent deliverables, such as participation in a steering committee, these deliverables do not have standalone value because the non-contingent deliverables are dependent on the license rights. That is, the non-contingent deliverables would not have value without the license rights, and only the Company can perform the related services. Upfront license rights and non-contingent deliverables, such as participation in a steering committee, do not have standalone value as they are not sold separately and they cannot be resold. In addition, when non-contingent deliverables are sold with upfront license rights, the license rights do not represent the culmination of a separate earnings process. As such, the Company accounts for the license and the non-contingent deliverables as a single combined unit of accounting. In such instances, the license revenue in the form of non-refundable upfront payments is deferred and recognized over the applicable relationship period, which historically has been the estimated period of the Company’s substantive performance obligations or the period the rights granted are in effect. The Company recognizes contingent event-based payments under license agreements when the payments are received. The Company has not received any royalty payments to date. The Company will recognize a milestone payment as revenue when earned if it is substantive and the Company has no ongoing performance obligations related to the milestone. A milestone payment is considered substantive if it: 1) is commensurate with either the Company’s performance to achieve the milestone or the enhanced value of the delivered item as a result of a specific outcome from the Company’s performance to achieve the milestone; 2) relates solely to past performance; and 3) is reasonable relative to all of the deliverables and payment terms, including other potential milestone consideration, within the arrangement. Amounts received prior to satisfying all revenue recognition criteria are recorded as deferred revenue in the accompanying balance sheets. The Company’s deferred revenue includes non-refundable upfront payments received under certain licensing and collaboration arrangements that contain substantive prospective performance obligations that the Company is providing over respective defined service or estimated relationship periods. Such non-refundable upfront payments are recognized as revenue over these defined service or estimated relationship periods. The Company received non-refundable upfront payments under research services agreements supported by the Services Business of $313 , $1,500 and $500 in August 2012, August 2013 and January 2014, respectively, which are recognized as revenue over periods of six months, 70 months and 48 months, respectively. The Company recognized revenue in discontinued operations from these upfront payments of $96 and $93 for the three months ended March 31, 2015 and 2014, respectively.	Revenue Recognition and Deferred Revenue The Company has historically derived the majority of its revenue from providing contract research and development services under fee for service arrangements, which were provided by the Services Business that was sold in July 2015 (see Notes 19 and 20). The Company also has entered into collaboration arrangements in exchange for non-refundable upfront payments and consideration as services are performed. These arrangements include multiple elements, such as the sale of licenses and the provision of services. Under these arrangements, the Company also is entitled to receive development milestone payments and royalties in the form of a designated percentage of product sales. The Company classifies non-refundable upfront payments, milestone payments and royalties received under collaboration and licensing agreements as revenues within its statements of operations because the Company views such activities as being central to its business operations. Revenue is recognized when all of the following conditions are met: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred or services have been rendered; (iii) fees are fixed or determinable; and (iv) collection of fees is reasonably assured. The Company’s contract research and development services revenue is recognized in the period in which the services are performed. When entering into an arrangement, the Company first determines whether the arrangement includes multiple deliverables and is subject to accounting guidance in ASC subtopic 605-25, Multiple-Element Arrangements . If the Company determines that an arrangement includes multiple elements, it determines whether the arrangement should be divided into separate units of accounting and how the arrangement consideration should be measured and allocated among the separate units of accounting. An element qualifies as a separate unit of accounting when the delivered element has standalone value to the customer. The Company’s arrangements do not include a general right of return relative to delivered elements. Any delivered elements that do not qualify as separate units of accounting are combined with other undelivered elements within the arrangement as a single unit of accounting. If the arrangement constitutes a single combined unit of accounting, the Company determines the revenue recognition method for the combined unit of accounting and recognizes the revenue over the period from inception through the date the last deliverable within the single unit of accounting is delivered. Non-refundable upfront license fees are recorded as deferred revenue and recognized into revenue on a straight-line basis over the estimated period of the Company’s substantive performance obligations. If the Company does not have substantive performance obligations, the Company recognizes non-refundable upfront fees into revenue through the date the deliverable is satisfied. Analyzing the arrangement to identify deliverables requires the use of judgment and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. In arrangements that include license rights and other non-contingent deliverables, such as participation in a steering committee, these deliverables do not have standalone value because the non-contingent deliverables are dependent on the license rights. That is, the non-contingent deliverables would not have value without the license rights, and only the Company can perform the related services. Upfront license rights and non-contingent deliverables, such as participation in a steering committee, do not have standalone value as they are not sold separately and they cannot be resold. In addition, when non-contingent deliverables are sold with upfront license rights, the license rights do not represent the culmination of a separate earnings process. As such, the Company accounts for the license and the non-contingent deliverables as a single combined unit of accounting. In such instances, the license revenue in the form of non-refundable upfront payments is deferred and recognized over the applicable relationship period, which historically has been the estimated period of the Company’s substantive performance obligations or the period the rights granted are in effect. The Company recognizes contingent event-based payments under license agreements when the payments are received. The Company has not received any royalty payments to date. The Company will recognize a milestone payment as revenue when earned if it is substantive and the Company has no ongoing performance obligations related to the milestone. A milestone payment is considered substantive if it: 1) is commensurate with either the Company’s performance to achieve the milestone or the enhanced value of the delivered item as a result of a specific outcome from the Company’s performance to achieve the milestone; 2) relates solely to past performance; and 3) is reasonable relative to all of the deliverables and payment terms, including other potential milestone consideration, within the arrangement. Amounts received prior to satisfying all revenue recognition criteria are recorded as deferred revenue in the accompanying balance sheets. The Company’s deferred revenue includes non-refundable upfront payments received under certain licensing and collaboration arrangements that contain substantive prospective performance obligations that the Company is providing over respective defined service or estimated relationship periods. Such non-refundable upfront payments are recognized over these defined service or estimated relationship periods. The Company received a non-refundable upfront payment of $1,500 from R-Pharm in August 2013 which is being recognized over a period of 70 months. The Company recognized revenue in continuing operations from this upfront payment of $256 and $95 for the years ended December 31, 2014 and 2013 , respectively. The Company received a non-refundable upfront payments of $313 and $500 in August 2012 and January 2014, respectively, under research services agreements supported by the Services Business, which were being recognized over periods of six months and 48 months, respectively. The Company recognized revenue in discontinued operations from these upfront payments of $122 and $62 for the years ended December 31, 2014 and 2013 , respectively.
Collaborative Arrangement, Accounting Policy	Collaboration Arrangements The Company assesses its contractual arrangements, and presents costs incurred and payments received under contractual arrangements, in accordance with FASB ASC 808, Collaborative Arrangements (Topic 808), when the Company determines that the contractual arrangement incudes a joint operating activity, has active participation by both parties, and both parties are subject to significant risks and rewards under the arrangement. When reimbursement payments are due to the Company under a collaborative arrangement within the scope of Topic 808, the Company determines the appropriate classification for each specific reimbursement payment in the statements of operations by considering (i) the nature of the arrangement, (ii) the nature of the Company’s business operations, and (iii) the contractual terms of the arrangement. The Company's August 2013 development, license, and supply agreement with R-Pharm, CJSC (“R-Pharm”), combined with the supplemental arrangement in November 2014, is a collaborative arrangement pursuant to Topic 808 and the Company’s previously described accounting policy. The reimbursements due from R-Pharm for specified research and development costs incurred by the Company are classified as a reduction to research and development expense in the accompanying statements of operations. The reimbursements due to the Company are recorded as a reduction of expense when (i) the reimbursable expenses have been incurred by the Company, (ii) persuasive evidence of a cost reimbursement arrangement exists, (iii) reimbursable costs are fixed or determinable, and (iv) the collection of the reimbursement payment is reasonably assured.	Collaboration Arrangements The Company assesses its contractual arrangements, and presents costs incurred and payments received under contractual arrangements, in accordance with FASB ASC 808, Collaborative Arrangements (Topic 808), when the Company determines that the contractual arrangement incudes a joint operating activity, has active participation by both parties, and both parties are subject to significant risks and rewards under the arrangement. When reimbursement payments are due to the Company under a collaborative arrangement within the scope of Topic 808, the Company determines the appropriate classification for each specific reimbursement payment in the statements of operations by considering (i) the nature of the arrangement, (ii) the nature of the Company’s business operations, and (iii) the contractual terms of the arrangement. The Company has concluded that the August 2013 development, license, and supply agreement with R-Pharm, combined with the supplemental arrangement in November 2014, is a collaborative arrangement pursuant to Topic 808 and the Company’s previously described accounting policy. This agreement and supplemental arrangement is further described in Note 18. The reimbursements due from R-Pharm for specified research and development costs incurred by the Company are classified as a reduction to research and development expense in the accompanying statements of operations. The reimbursements due to the Company are recorded as a reduction of expense when (i) the reimbursable expenses have been incurred by the Company, (ii) persuasive evidence of a cost reimbursement arrangement exists, (iii) reimbursable costs are fixed or determinable, and (iv) the collection of the reimbursement payment is reasonably assured. Unpaid reimbursement amounts due from R-Pharm at period end are presented as an other current asset in the accompanying balance sheets.
Research and Development	Research and Development Major components of research and development costs include clinical trial activities and services, including related drug formulation, manufacturing, and other development, preclinical studies, cash compensation, stock-based compensation, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf, materials and supplies, legal services, and regulatory compliance. The Company is required to estimate its expenses resulting from its obligations under contracts with clinical research organizations, clinical site agreements, vendors, and consultants in connection with conducting SCY-078 clinical trials and preclinical development. The financial terms of these contracts are subject to negotiations which vary from contract to contract, and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company’s objective is to reflect the appropriate development and trial expenses in its financial statements by matching those expenses with the period in which the services and efforts are expended. For clinical trials, the Company accounts for these expenses according to the progress of the trial as measured by actual hours expended by CRO personnel, investigator performance or completion of specific tasks, patient progression, or timing of various aspects of the trial. For preclinical development services performed by outside service providers, the Company determines accrual estimates through financial models, taking into account development progress data received from outside service providers and discussions with applicable Company and service provider personnel. Reimbursements of certain research and development costs by parties under collaborative arrangements have been recorded as a reduction of research and development expense presented within the statement of operations.	Research and Development Major components of research and development costs include clinical trial activities and services, including related drug formulation, manufacturing, and other development, preclinical studies, cash compensation, stock-based compensation, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf, materials and supplies, legal services, and regulatory compliance. The Company is required to estimate its expenses resulting from its obligations under contracts with clinical research organizations, clinical site agreements, vendors, and consultants in connection with conducting SCY-078 clinical trials and preclinical development. The financial terms of these contracts are subject to negotiations which vary from contract to contract, and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company’s objective is to reflect the appropriate development and trial expenses in its financial statements by matching those expenses with the period in which the services and efforts are expended. For clinical trials, the Company accounts for these expenses according to the progress of the trial as measured by actual hours expended by CRO personnel, investigator performance or completion of specific tasks, patient progression, or timing of various aspects of the trial. For preclinical development services performed by outside service providers, the Company determines accrual estimates through financial models, taking into account development progress data received from outside service providers and discussions with applicable Company and service provider personnel. Reimbursements of certain research and development costs by parties under collaborative arrangements have been recorded as a reduction of research and development expense presented within the statement of operations. Such reimbursements were made under the collaboration arrangement with R-Pharm, which is further described in Note 18.
Patent Expense		Patent Expenses Costs related to filing and pursuing patent applications, as well as costs related to maintaining the Company's existing patent portfolio, are recorded as expense as incurred since recoverability of such expenditures is uncertain.
Fair Value of Financial Instruments		Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Company’s principal or, in absence of a principal, most advantageous market for the specific asset or liability. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs when determining fair value. The three tiers are defined as follows: • Level 1 — Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; • Level 2 — Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and • Level 3 — Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions about the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances.
Amortization of Deferred Financing Costs and Debt Discount		Amortization of Deferred Financing Costs and Debt Discount Amortization of deferred financing costs and debt discount includes the amortization of debt discount related to the warrants issued with the convertible notes (Note 7), the amortization of issuance costs related to the convertible notes, and amortization of the deferred financing costs related to a deemed contribution for a guarantee from a related party.
Comprehensive Loss		Comprehensive Loss The Company has no items of comprehensive income or loss other than net loss.
Income Taxes	Income Taxes The Company provides for deferred income taxes under the asset and liability method, whereby deferred income taxes result from temporary differences between the tax bases of assets and liabilities and their reported amounts in the financial statements. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that the Company believes is more likely than not to be realized. The Company recognizes uncertain tax positions when the positions will be more likely than not sustained based solely upon the technical merits of the positions. The Company applies intraperiod tax allocation guidance pursuant to FASB ASC 740, Income Taxes (Topic 740) to allocate income tax (expense) benefit between pre-tax income (loss) from continuing operations and discontinued operations. For periods in which the Company reports pre-tax income from discontinued operations for financial reporting purposes and pre-tax loss from continuing operations, the Company presents income from discontinued operations net of income tax expense attributable to its discontinued operations using the estimated annual effective tax rate of the Services Business. The Company also recognizes a corresponding income tax benefit on its loss from continuing operations for the same affected period.	Income Taxes The Company provides for deferred income taxes under the asset and liability method, whereby deferred income taxes result from temporary differences between the tax bases of assets and liabilities and their reported amounts in the financial statements. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that the Company believes is more likely than not to be realized. The Company recognizes uncertain tax positions when the positions will be more likely than not sustained based solely upon the technical merits of the positions. The Company applies intraperiod tax allocation guidance pursuant to FASB ASC 740, Income Taxes (Topic 740) to allocate income tax (expense) benefit between pre-tax income (loss) from continuing operations and discontinued operations. For periods in which the Company reports pre-tax income from discontinued operations for financial reporting purposes and pre-tax loss from continuing operations, the Company presents income from discontinued operations net of income tax expense attributable to its discontinued operations using the effective tax rate of the Services Business. The Company also recognizes a corresponding income tax benefit on its loss from continuing operations for the same affected period.
Stock-Based Compensation		Stock-Based Compensation The Company measures and recognizes compensation expense for all stock-based payment awards made to employees, officers, and directors based on the estimated fair values of the awards as of grant date. The value of the portion of the award that is ultimately expected to vest is recorded as expense over the requisite service periods. The Company also accounts for equity instruments issued to non-employees using a fair value approach. The Company values equity instruments and stock options granted to employees using the Black-Scholes valuation model. The measurement of non-employee share-based compensation is subject to periodic adjustments as the underlying equity instruments vest and is recognized as an expense over the term of the related financing or the period over which services are received. The Company estimated the fair value of common stock warrants granted to lenders at their intrinsic value, which was the estimated fair value of the common stock less the exercise price for the warrant.
Lease policy		Deferred Rent The Company recognizes rent expense on a straight-line basis over the non-cancelable term of its operating lease and records the difference between cash rent payments and the recognition of rent expense as a deferred rent liability. The Company also records landlord-funded lease incentives, such as reimbursable leasehold improvements, as a deferred rent liability, which is amortized as a reduction of rent expense over the non-cancelable term of its operating lease.
Basic and Diluted Net Loss per Share of Common Stock		Basic and Diluted Net Loss per Share of Common Stock The Company uses the two-class method to compute net loss per share because the Company has issued securities, other than common stock, that contractually entitle the holders to participate in dividends and earnings of the Company. The two-class method requires earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings. Holders of each series of the Company’s convertible preferred stock were entitled to participate in dividends, when and if declared by the SCYNEXIS Board of Directors (the "board of directors" or the "board"), that were made to common stockholders, and as a result were considered participating securities. Under the two-class method, for periods with net income, basic net income per common share is computed by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income attributable to common stockholders is computed by subtracting from net income the portion of current year earnings that the participating securities would have been entitled to receive pursuant to their dividend rights had all of the year’s earnings been distributed. No such adjustment to earnings is made during periods with a net loss, as the holders of the participating securities have no obligation to fund losses. Diluted net loss per common share is computed under the two-class method by using the weighted average number of shares of common stock outstanding, plus, for periods with net income attributable to common stockholders, the potential dilutive effects of stock options and warrants. In addition, the Company analyzes the potential dilutive effect of the outstanding participating securities when calculating diluted earnings per share. Under the “treasury stock” method, it is assumed that the warrants and options were exercised at the beginning of the period and that the funds obtained from the exercise were used to reacquire the Company’s common stock at the average market price for the period and includes those securities when they are dilutive. Under the “if-converted” method, it is assumed that the outstanding participating securities convert into common stock at the beginning of the period. The Company reports the more dilutive of the approaches as its diluted net income or net loss per share during the period.
Segment and Geographic Information		Segment and Geographic Information Operating segments are defined as components of an enterprise (business activity from which it earns revenue and incurs expenses) about which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker (“CODM”) is the Chief Executive Officer. The CODM reviews consolidated operating results to make decisions about allocating resources and assessing performance for the entire Company. The Company views its operations and manages its business as one operating segment. All assets of the Company were held in the United States for the years ended December 31, 2014 and 2013 . Although all operations are based in the United States, the Company generated a portion of its revenue, including revenue in discontinued operations, from customers outside of the United States
Effect of Recent Accounting Pronouncements	Effect of Recent Accounting Pronouncements In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity , or ASU 2014-08. Under ASU 2014-08, only disposals representing a strategic shift in operations that have a major effect on the Company’s operations and financial results should be presented as discontinued operations. Additionally, ASU 2014-08 requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. The amendments in ASU 2014-08 are effective for fiscal years, and interim periods within those years, beginning after December 15, 2014. The Company adopted this guidance in the first quarter of 2015 and has applied it for presentation and disclosure of the Services Business as discontinued operations (see Note 13). The Company will also apply, as applicable, the guidance to future dispositions or classifications as held for sale. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers: Topic 606, or ASU 2014-09. ASU 2014-09 establishes the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In applying the new revenue recognition model to contracts with customers, an entity: (1) identifies the contract(s) with a customer; (2) identifies the performance obligations in the contract(s); (3) determines the transaction price; (4) allocates the transaction price to the performance obligations in the contract(s); and (5) recognizes revenue when (or as) the entity satisfies a performance obligation. The accounting standards update applies to all contracts with customers except those that are within the scope of other topics in the FASB Accounting Standards Codification. The accounting standards update also requires significantly expanded quantitative and qualitative disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. This guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2016, which is effective for the Company for the year ending December 31, 2017. The FASB has proposed a delay in the effective date of the accounting standards update to fiscal years and interim periods within those years beginning on or after December 15, 2017, which is pending approval. The Company is currently evaluating the impact that the implementation of ASU 2014-09 will have on the Company’s financial statements. In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern , or ASU 2014-15. ASU 2014-15 will explicitly require management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Earlier adoption is permitted. The Company is not early adopting ASU 2014-15. The Company is currently evaluating the impact that the implementation of ASU 2014-15 will have on the Company’s financial statements, and the actual impact will be dependent upon the Company’s liquidity and the nature or significance of future events or conditions that exist upon adopting the updated standard. In January 2015, the FASB issued ASU No. 2015-01, Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items, or ASU 2015-01. ASU 2015-01 eliminates from GAAP the concept of extraordinary items. ASU 2015-01 is effective for fiscal years and interim periods beginning after December 15, 2015. Early adoption is permitted. The Company does not expect that the adoption of ASU 2015-01 will have a material impact on its financial statements. In April 2015, the FASB issued ASU No. 2015-03, Simplifying the Presentation of Debt Issuance Costs , or ASU 2015-03. Under ASU 2015-03, the costs of issuing debt will no longer be recorded as an intangible asset, except when incurred before receipt of the funding from the associated debt liability. Rather, debt issuance costs related to a recognized debt liability will be presented on the balance sheet as a direct deduction from the debt liability, similar to the presentation of debt discounts. The costs will continue to be amortized to interest expense using the effective interest method. ASU 2015-03 is effective for fiscal years and interim periods beginning after December 15, 2015, with early adoption permitted. ASU 2015-03 requires retrospective application to all prior periods presented in the financial statements. The Company does not expect that the adoption of ASU 2015-03 will have a material any impact on its financial statements. In April 2015, the FASB issued ASU No. 2015-05, Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement” , or ASU 2015-05 . ASU 2015-05 provides guidance to entities about whether a cloud computing arrangement includes a software license. Under ASU 2015-05, if a software cloud computing arrangement contains a software license, entities should account for the license element of the arrangement in a manner consistent with the acquisition of other software licenses. If the arrangement does not contain a software license, entities should account for the arrangement as a service contract. ASU 2015-05 also removes the requirement to analogize to ASC 840-10, to determine the asset acquired in a software licensing arrangement. For public companies, ASU 2015-05 is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2015, and early adoption is permitted. The Company does not expect that the adoption of ASU 2015-05 will have a material impact on its financial statements.	Effect of Recent Accounting Pronouncements In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity , or ASU 2014-08. Under ASU 2014-08, only disposals representing a strategic shift in operations that have a major effect on the Company’s operations and financial results should be presented as discontinued operations. Additionally, ASU 2014-08 requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. The amendments in ASU 2014-08 are effective for fiscal years, and interim periods within those years, beginning after December 15, 2014. However, ASU 2014-08 should not be applied to a component that is classified as held for sale before the effective date even if the component is disposed of after the effective date. Early adoption is permitted, but only for disposals (or classifications as held for sale) that have not been reported in financial statements previously issued. The Company adopted this guidance in the first quarter of 2015 and has applied it for presentation and disclosure of the Services Business as discontinued operations (see Note 20). The Company will also apply, as applicable, the guidance to future dispositions or classifications as held for sale. In May 2014, the Financial Accounting Standards Board (FASB) issued ASU No. 2014-09, Revenue from Contracts with Customers: Topic 606, or ASU 2014-09. ASU 2014-09 establishes the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes the most current revenue recognition guidance. This guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2016, which is effective for the Company for the year ending December 31, 2017. The Company is currently evaluating the impact that the implementation of ASU 2014-09 will have on the Company’s financial statements. In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern , or ASU 2014-15. ASU 2014-15 will explicitly require management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Earlier adoption is permitted. The Company is not early adopting ASU 2014-15. The Company is currently evaluating the impact that the implementation of ASU 2014-15 will have on the Company’s financial statements.
Deferred Offering Costs	Deferred Offering Costs Deferred offering costs are expenses directly related to the IPO or the April 2015 offering. These costs consist of legal, accounting, printing, and filing fees that the Company has capitalized, including fees incurred by the independent registered public accounting firm directly related to the offerings. The IPO deferred offering costs were offset against the IPO proceeds in May 2014 and were reclassified to additional paid-in capital upon completion of the IPO. Deferred costs associated with the April 2015 offering will be offset against the proceeds from the April 2015 offering and will be reclassified to additional paid-in capital upon completion of the April 2015 offering.

Summary of Significant Accoun30

Summary of Significant Accounting Policies (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Schedule of Research and Development Expenses and Reimbursements	Such reimbursements were recognized under the collaboration arrangement with R-Pharm during the quarter ended March 31, 2015. Information about the Company’s research and development expenses and reimbursements due under collaboration arrangements for the three months ended March 31, 2015 and 2014, is presented as follows: Three Months Ended March 31, 2015 2014 Research and development expense, gross $ 3,981 $ 1,320 Less: Reimbursement of research and development expense 194 — Research and development expense, net of reimbursements $ 3,787 $ 1,320	Information about the Company’s research and development expenses and reimbursements due under collaboration arrangements for the years ended December 31, 2014 and 2013 is presented as follows: Years Ended December 31, 2014 2013 Research and development expense, gross $ 8,513 $ 4,363 Less: Reimbursement of research and development expense 226 — Research and development expense, net of reimbursements $ 8,287 $ 4,363
Schedule of Segment Reporting Information, by Segment		Information about the Company’s revenue, including revenue in continuing operations and discontinued operations, from different geographic regions for the years ended December 31, 2014 and 2013 is presented as follows: Years Ended December 31, 2014 2013 United States $ 16,422 86 % $ 15,126 90 % Europe 1,235 7 % 1,626 10 % Other non-US 1,367 7 % 105 — Total $ 19,024 100 % $ 16,857 100 %

Allowance for Bad Debts (Tables

Allowance for Bad Debts (Tables)	12 Months Ended
	Dec. 31, 2014
Receivables [Abstract]
Schedule of Accounts, Notes, Loans and Financing Receivable	A summary of activity in the allowance for bad debts for the years ended December 31, 2014 and 2013 is as follows: Balance at Beginning of Period Additions Charged to Expense Deductions Balance at End of Period Year ended December 31, 2013 $ 251 $ — $ (88 ) $ 163 Year ended December 31, 2014 $ 163 $ — $ (163 ) $ —

Prepaid Expenses and Other Cu32

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure	Prepaid expenses and other current assets consist of the following: December 31, 2014 2013 Prepaid SCY-078 development services $ 109 $ — Prepaid insurance 295 97 Other prepaid expenses 70 141 Other receivable due from R-Pharm 226 — Other current assets 3 5 Total $ 703 $ 243

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Summary of Property and Equipment	Property and equipment consists of the following: March 31, December 31, Equipment $ 8,698 $ 8,552 Furniture and fixtures 375 375 Leasehold improvements 13,209 13,193 Total property and equipment 22,282 22,120 Less accumulated depreciation 17,608 17,285 Property and equipment, net of accumulated depreciation 4,674 4,835 Property and equipment reclassified to assets of discontinued operations, net 4,674 4,835 Property and equipment, net of assets of discontinued operations $ — $ —	Property and equipment consists of the following: December 31, 2014 2013 Equipment $ 8,552 $ 9,577 Furniture and fixtures 375 378 Leasehold improvements 13,193 13,115 Total property and equipment 22,120 23,070 Less accumulated depreciation 17,285 17,669 Property and equipment, net of accumulated depreciation 4,835 5,401 Property and equipment reclassified to assets of discontinued operations, net 4,835 5,401 Property and equipment, net of assets of discontinued operations $ — $ —

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities	Accrued expenses consist of the following: December 31, 2014 2013 Accrued research and development expenses $ 293 $ 92 Accrued employee bonus compensation 1,464 — Interest payable — 23 Employee withholdings 156 61 Other accrued expenses 332 556 Total accrued expenses $ 2,245 $ 732

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Future Minimum Lease Payments	Future minimum lease payments for all operating leases as of March 31, 2015 are as follows: 2015 (remaining 9 months) $ 826 2016 1,122 2017 1,140 2018 1,161 2019 291 Thereafter — Total $ 4,540	Future minimum lease payments for all operating leases as of December 31, 2014 , including future minimum lease payments that were assumed by Accuratus in July 2015, are as follows: 2015 $ 1,075 2016 1,104 2017 1,123 2018 1,156 2019 291 Thereafter — Total $ 4,749

Convertible Preferred Stock (Ta

Convertible Preferred Stock (Tables)	12 Months Ended
	Dec. 31, 2014
Temporary Equity Disclosure [Abstract]
Summary of Authorized, Issued and Outstanding Preferred Shares	The following table summarizes authorized, issued and outstanding preferred shares as of May 7, 2014, immediately prior to the automatic conversion to shares of common stock: Authorized Issued and Outstanding Series A Preferred 31,410 31,407 Series B Preferred 711,987 467,814 Series C Preferred 2,967,678 2,770,633 Series C-1 Preferred 3,076,923 — Series C-2 Preferred 2,347,826 2,347,826 Series D-1 Preferred 10,000,000 6,054,255 Series D-2 Preferred 10,000,000 6,131,338 Total 29,135,824 17,803,273
Summary of Preferred Stock Activity	The following table summarizes convertible preferred stock activity for the years ended December 31, 2014 and 2013 : Shares of Series A Convertible Preferred Stock Series B Convertible Preferred Stock Series C Convertible Preferred Stock Series C-1 Convertible Preferred Stock Series C-2 Convertible Preferred Stock Series D-1 Convertible Preferred Stock Series D-2 Convertible Preferred Stock Balance, December 31, 2012 31,407 467,814 2,770,633 — 2,347,826 — — Issuance of Series D-2 Preferred — — — — — — 1,785,712 Conversion of notes payable — — — — — 6,054,255 3,956,985 Balance, December 31, 2013 31,407 467,814 2,770,633 — 2,347,826 6,054,255 5,742,697 Issuance of Series D-2 Preferred — — — — — — 388,641 Automatic conversion to common stock (31,407 ) (467,814 ) (2,770,633 ) — (2,347,826 ) (6,054,255 ) (6,131,338 ) Balance, December 31, 2014 — — — — — — —

Common Stock (Tables)

Common Stock (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Equity [Abstract]
Summary of Common Stock Shares Activity	The following table summarizes common stock share activity for the three months ended March 31, 2015 : Shares of Common Stock Balance, December 31, 2014 8,512,103 Common stock issued through employee stock purchase plan 15,107 Balance, March 31, 2015 8,527,210	The following table summarizes common stock share activity for the years ended December 31, 2014 and 2013 : Shares of Common Stock Balance, December 31, 2012 335,782 Exercise of stock options 220 Repurchase of common stock (1,934 ) Balance, December 31, 2013 334,068 Exercise of stock options 416 Conversion of preferred stock 1,691,884 Exercise of common stock warrants 275,687 Common stock issued through IPO 6,200,000 Common stock issued through employee stock purchase plan 10,048 Balance, December 31, 2014 8,512,103
Schedule of Reserved Shares of Common Stock for Future Issuance	The Company had reserved shares of common stock for future issuance as follows: March 31, December 31, Outstanding stock options 575,416 615,322 Outstanding Series C-1 Preferred warrants 14,033 14,033 For possible future issuance under 2014 Equity Incentive Plan (Note 8) 561,000 180,610 For possible future issuance under Employee Stock Purchase Plan (Note 8) 52,050 37,746 For possible future issuance under 2015 Inducement Plan (Note 8) 450,000 — Total common shares reserved for future issuance 1,652,499 847,711	The Company had reserved shares of common stock for future issuance as follows: As of As of December 31, December 31, For conversion of Series A Preferred, Series B Preferred, Series C Preferred, Series C-2 Preferred, Series D-1 Preferred, and Series D-2 Preferred and exercise of warrants to purchase Series C-1 Preferred and subsequent conversion of the shares purchased — 1,675,812 Outstanding stock options 615,322 137,610 Outstanding common stock warrants — 257,242 Outstanding Series C-1 convertible preferred stock warrants 14,033 13,879 For possible future issuance under stock option plan 180,610 49,734 For possible future issuance under employee stock purchase plan 37,746 — Total common shares reserved for future issuance 847,711 2,134,277

Stock-based Compensation (Table

Stock-based Compensation (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Fair Value Measurement Techniques		The assumptions used to estimate fair value and the resulting grant date fair values are as follows: Employees Nonemployees Years Ended December 31, Years Ended December 31, 2014 2013 2014 2013 Expected dividend yield — — — — Weighted average expected volatility 68.57% 65.49% 64.10% 65.49% Weighted average risk-free interest rate 2.05% 2.41% 1.75% 2.37% Weighted average expected term (in years) 6.04 6.49 5.30 5.00 Forfeiture rate 5.00% 5.00% 5.00% 5.00%
Schedule of Share-based Compensation, Stock Options, Activity		The activity of the plan for the years ended December 31, 2014 and 2013 is summarized as follows: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding — January 1, 2013 154,277 $ 23.05 5.02 $ 213 Granted 11,525 50.39 Exercised (220 ) 21.01 Canceled (27,972 ) 20.81 Outstanding — December 31, 2013 137,610 $ 25.86 5.23 $ 3,097 Exercisable — December 31, 2013 115,475 $ 23.26 4.50 $ 2,898 Vested or expected to vest — December 31, 2013 136,002 $ 25.70 5.18 $ 3,084 Outstanding — January 1, 2014 137,610 $ 25.86 5.23 $ 3,097 Granted 520,887 $ 9.53 (1) Exercised (416 ) $ 20.40 Canceled (42,759 ) $ 9.57 Outstanding — December 31, 2014 615,322 $ 9.55 9.48 $ 265 Exercisable — December 31, 2014 192,916 $ 9.44 9.48 $ 88 Vested or expected to vest —December 31, 2014 572,926 $ 9.55 9.48 $ 247 (1) The weighted average exercise price table takes into consideration the effect of the option award modifications approved by the Company's board of directors on June 18, 2014, and approved by the Company's shareholders on September 11, 2014. These option award modifications are described in further detail below.
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range		Information as of December 31, 2014, concerning currently outstanding and vested options is as follows: Outstanding Exercisable Exercise Price Number of Shares Weighted- Average Remaining Contractual Life (in years) Number of Shares Weighted- Average Remaining Contractual Life (in years) $6.77 8,000 9.47 — 0.00 7.70 5,944 9.76 5,944 9.76 8.03 5,700 9.50 5,700 9.50 8.73 35,114 9.45 3,494 9.45 9.64 543,374 9.47 176,248 9.47 10.81 17,190 9.93 1,530 9.93 Total 615,322 Total 192,916
Schedule of Share-based Compensation, Unvested Shares Outstanding, by Exercise Price Range [Table Text Block]		Unvested shares as of December 31, 2014 and 2013 are as follows: As of December 31, 2014 As of December 31, 2013 Exercise Price Number of Unvested Shares Exercise Price Number of Unvested Shares $6.77 8,000 $20.40 563 7.70 — 24.48 7,318 8.03 — 25.50 — 8.73 31,620 25.91 — 9.64 367,127 30.60 4,307 10.81 15,660 55.08 9,947 Total 422,407 Total 22,135
Stock-Based Compensation Expense Related to Stock Options	Stock-based compensation expense related to stock options is included in the following line items in the accompanying statements of operations: Three Months Ended March 31, 2015 2014 Research and development $ 52 $ 62 Selling, general and administrative 211 35 Discontinued operations (within cost of revenue, see Note 13) 33 13 Total $ 296 $ 110	Stock-based compensation expense related to stock options is included in the following line items in the accompanying statements of operations: Years Ended December 31, 2014 2013 Research and development $ 394 28 Selling, general and administrative 648 107 Discontinued operations 159 45 Total stock-based compensation expense $ 1,201 $ 180

Income Taxes Income Taxes (Tabl

Income Taxes Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Unrecognized Tax Benefits Roll Forward	The following is a tabular reconciliation of the total amounts of unrecognized tax benefits: December 31, 2014 2013 Unrecognized tax benefit—January 1 $ 623 $ — Additions for tax positions of current period — 333 Additions for tax positions of prior periods — 290 Other — — Unrecognized tax benefit—December 31 $ 623 $ 623
Schedule of Effective Income Tax Rate Reconciliation	Reconciliations of the differences between the benefit for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows: Years Ended December 31, 2014 2013 Amount Percent of Pretax Income Amount Percent of Pretax Income Income taxes from continuing operations at statutory rate $ (2,301 ) 34.0 % $ (10,848 ) 34.0 % State income taxes (471 ) 7.0 % (116 ) 0.5 % Beneficial conversion feature on convertible notes — — % 3,673 (11.5 )% Stock warrant derivative liability (3,427 ) 50.6 % 2,686 (8.4 )% Debt discount amortization — — % 392 (1.2 )% Deemed contribution interest — — % 1,516 (4.8 )% Provision to return adjustments — — % (190 ) 0.6 % Stock-based compensation 268 (4.0 )% 41 (0.1 )% Expiration of capital losses carryforward. — — % 1,511 (4.7 )% Change in statutory state income tax rate — — % 936 (2.9 )% Change in reserve for uncertain tax positions — — % 623 (2.0 )% R&D tax credits (320 ) 4.7 % — — % Other (190 ) 2.8 % (5 ) — % Increase (decrease) in valuation allowance 5,275 (77.9 )% (794 ) 2.5 % Total $ (1,166 ) 17.2 % $ (575 ) 1.8 %
Schedule of Deferred Tax Assets and Liabilities	The components of deferred tax assets and liabilities are as follows: December 31, 2014 2013 Current deferred tax assets: Accrued expenses $ 1,052 $ 612 Stock-based compensation 336 241 Assets of discontinued operations, net of liabilities 1,882 1,938 Other 15 25 3,285 2,816 Noncurrent deferred tax assets (liabilities) Net operating loss carryforwards 29,981 26,286 Research and development credits 2,684 2,373 Deferred financing costs — (800 ) 32,665 27,859 Total deferred tax assets 35,950 30,675 Valuation allowance (35,950 ) (30,675 ) Net deferred tax assets $ — $ —

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Earnings Per Share [Abstract]
Summary of Computation of Basic and Diluted Net Income (Loss) Per Share	The following table summarizes the computation of basic and diluted net loss per share attributable to the Company’s common stockholders: Three Months Ended March 31, 2015 2014 Income (loss) attributable to common stock - basic: Loss from continuing operations $ (5,931 ) $ 45 Deemed dividend for beneficial conversion feature on Series D-2 Preferred — (909 ) Deemed dividend for antidilution adjustments to convertible preferred stock — (214 ) Accretion of convertible preferred stock — (510 ) Loss from continuing operations attributable to common stock - basic (5,931 ) (1,588 ) Income (loss) from discontinued operations, net of income tax expense, attributable to common stock - basic (453 ) 367 Net loss attributable to common stock - basic $ (6,384 ) $ (1,221 ) Income (loss) attributable to common stock - diluted: Loss from continuing operations attributable to common stock - basic $ (5,931 ) $ (1,588 ) Derivative fair value adjustment — (2,783 ) Loss from continuing operations attributable to common stock - diluted (5,931 ) (4,371 ) Income (loss) from discontinued operations, net of income tax expense, attributable to common stock - diluted (453 ) 367 Net loss attributable to common stock - diluted $ (6,384 ) $ (4,004 ) Weighted-average common shares outstanding: Weighted-average common shares outstanding - basic 8,516,467 334,086 Allocation of common stock warrants as participating securities — 274,988 Weighted-average common shares outstanding - diluted 8,516,467 609,074 Income (loss) per share - basic: Continuing operations $ (0.70 ) $ (4.75 ) Discontinued operations (0.05 ) 1.10 Net loss per share - basic $ (0.75 ) $ (3.65 ) Income (loss) per share - diluted: Continuing operations $ (0.70 ) $ (7.17 ) Discontinued operations (0.05 ) 0.60 Net loss per share - diluted $ (0.75 ) $ (6.57 )	The following table summarizes the computation of basic and diluted net loss per share attributable to the Company’s common stockholders: Years Ended 2014 2013 Income (loss) attributable to common stock - basic: Loss from continuing operations $ (5,603 ) $ (31,331 ) Deemed dividend for beneficial conversion feature on Series D-2 Preferred (909 ) (4,232 ) Deemed dividend for antidilution adjustments to convertible preferred stock (214 ) (6,402 ) Accretion of convertible preferred stock (510 ) (5,714 ) Loss from continuing operations attributable to common stock - basic (7,236 ) (47,679 ) Income from discontinued operations, net of income tax expense, attributable to common stock - basic 1,369 870 Net loss attributable to common stock - basic $ (5,867 ) $ (46,809 ) Income (loss) attributable to common stock - diluted: Loss from continuing operations attributable to common stock - basic $ (7,236 ) $ (47,679 ) Derivative fair value adjustment (10,080 ) — Loss from continuing operations attributable to common stock - diluted (17,316 ) (47,679 ) Income from discontinued operations, net of income tax expense, attributable to common stock - diluted 1,369 870 Net loss attributable to common stock - diluted $ (15,947 ) $ (46,809 ) Weighted-average common shares outstanding: Weighted-average common shares outstanding - basic 5,663,311 335,612 Allocation of common stock warrants as participating securities 273,776 — Weighted-average common shares outstanding - diluted 5,937,087 335,612 Income (loss) per share - basic: Continuing operations $ (1.28 ) $ (142.06 ) Discontinued operations 0.24 2.59 Net loss per share - basic $ (1.04 ) $ (139.47 ) Income (loss) per share - diluted: Continuing operations $ (2.92 ) $ (142.06 ) Discontinued operations 0.23 2.59 Net loss per share - diluted $ (2.69 ) $ (139.47 )
Summary of Antidilutive Securities Excluded from Computation of Weighted Average Common Stock Outstanding	The following securities, presented on a common stock equivalent basis, have been excluded from the calculation of weighted average common shares outstanding because their effect is anti-dilutive. Three Months Ended March 31, 2015 2014 Convertible preferred stock: Series A Preferred — 6,149 Series B Preferred — 131,685 Series C Preferred — 783,515 Series C-2 Preferred — 173,213 Series D-1 Preferred — 296,773 Series D-2 Preferred — 300,549 Series C-1 Preferred warrants 14,033 14,033 Stock options 575,416 184,240 ESPP 40,334 —	The following securities, presented on a common stock equivalent basis, have been excluded from the calculation of weighted average common shares outstanding because their effect is anti-dilutive. As discussed in Note 9, in May 2014, upon completion of the IPO, all outstanding shares of the convertible preferred stock were converted into shares of common stock at their conversion prices. Therefore, as of December 31, 2014 , the convertible preferred stock securities were no longer outstanding and will have no impact on net income or net loss per share. Years Ended 2014 2013 Convertible preferred stock: Series A Preferred 6,149 6,149 Series B Preferred 131,685 130,529 Series C Preferred 783,515 776,016 Series C-2 Preferred 173,213 170,967 Series D-1 Preferred 296,773 296,773 Series D-2 Preferred 300,549 281,500 Warrants to purchase Series C-1 Preferred 14,033 13,878 Warrants to purchase common stock — 257,242 Stock options 615,322 137,610 ESPP 65,401 — Convertible notes — —

Related-Party Transactions (Tab

Related-Party Transactions (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Related Party Transactions [Abstract]
Summary of Transactions with Related Parties	The Company had transactions with related parties as follows: Three Months Ended March 31, 2015 2014 Revenue $ 987 $ 1,822	The Company had transactions with related parties as follows: Years Ended December 31, 2014 2013 Revenue $ 7,288 $ 7,288 Selling, general and administrative expense $ 500 $ —

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Summary of Financial Assets and Liabilities Subject to Fair Value Measurements on Recurring Basis		The following table summarizes the conclusions reached as of December 31, 2013 : Balance as of December 31, 2013 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Derivative liability — Series C-1 warrants $ 37 $ — $ — $ 37 Derivative liability — common stock warrants 12,200 — — 12,200 Total derivative liability $ 12,237 $ — $ — $ 12,237
Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis	A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows: Three Months Ended March 31, 2014 Balance at beginning of period $ 12,237 Issuance of warrants 544 Excess of fair value of warrants over proceeds 362 Adjustment to fair value (3,145 ) Balance at end of period $ 9,998	A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows: Years Ended December 31, 2014 2013 Balance at beginning of period $ 12,237 $ 683 Issuance of warrants 544 5,382 Excess of fair value of warrants over proceeds 362 (1,714 ) Adjustment to fair value (10,442 ) 7,886 Reclassification to additional paid-in capital upon exercise of warrants (2,701 ) — Balance at end of period $ — $ 12,237

Discontinued Operations (Tables

Discontinued Operations (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Discontinued Operations and Disposal Groups [Abstract]
Disposal Groups, Including Discontinued Operations	The following table presents a reconciliation of the carrying amounts of assets and liabilities of the Services Business to the amounts presented net in the accompanying balance sheets: March 31, 2015 December 31, 2014 Carrying amounts of assets included as part of discontinued operations: Accounts and unbilled receivables, net $ 1,053 $ 1,501 Prepaid expenses and other current assets 258 289 Property and equipment, net 4,674 4,835 Other assets 64 76 Assets of discontinued operations, net $ 6,049 $ 6,701 Carrying amounts of liabilities included as part of discontinued operations: Accounts payable and accrued expenses $ 689 $ 681 Deferred revenue 445 445 Deferred rent 1,237 1,294 Liabilities related to assets of discontinued operations $ 2,371 $ 2,420 The following table presents revenue, (expenses), gains, and (losses) attributable to discontinued operations: Three Months Ended March 31, 2015 2014 Major line items constituting income (loss) of discontinued operations: Total revenue $ 3,232 $ 4,640 Cost of revenue (3,231 ) (3,960 ) Research and development (431 ) — Selling, general and administrative (23 ) — Income tax expense — (313 ) Income (loss) from discontinued operations, net $ (453 ) $ 367 The following table presents depreciation, capital expenditures, and significant operating and investing non-cash items related to the discontinued operations: Three Months Ended March 31, 2015 2014 Depreciation expense $ 282 $ 282 Purchases of property and equipment $ (171 ) $ (74 ) Stock-based compensation $ 33 $ 13 Changes in deferred rent $ (57 ) $ (15 ) Equipment purchases in accounts payable and accrued expenses $ 25 $ 204	The following table presents revenue, (expenses), gains, and (losses) attributable to discontinued operations: Years Ended December 31, 2014 2013 Major line items constituting income of discontinued operations: Total revenue $ 17,768 $ 16,762 Cost of revenue (15,446 ) (16,305 ) Selling, general and administrative 48 — Gain on insurance recovery 165 — Gain on sale of asset — 988 Income tax expense (1,166 ) (575 ) Income from discontinued operations $ 1,369 $ 870 The following table presents a reconciliation of the carrying amounts of assets and liabilities of the Services Business to assets of discontinued operations, net in the accompanying balance sheets: December 31, 2014 2013 Carrying amounts of assets included as part of discontinued operations: Accounts and unbilled receivables, net $ 1,501 $ 1,062 Prepaid expenses and other current assets 289 246 Property and equipment, net 4,835 5,401 Other assets 76 89 Assets of discontinued operations, net $ 6,701 $ 6,798 Carrying amounts of liabilities included as part of discontinued operations: Accounts payable and accrued expenses $ 681 $ 737 Deferred revenue 445 225 Deferred rent 1,294 1,481 Liabilities related to assets of discontinued operations $ 2,420 $ 2,443 The following table presents depreciation, capital expenditures, and significant operating and investing non-cash items related to the discontinued operations: Years Ended December 31, 2014 2013 Depreciation expense $ 1,132 $ 1,215 Purchases of property and equipment (704 ) (431 ) Proceeds from insurance recovery 216 — Gain on insurance recovery (165 ) — Gain on sale of asset, net of transaction expenses — (988 ) Proceeds from sale of asset, net of transaction expenses — 988 Stock-based compensation 159 45 Changes in deferred rent (187 ) (53 ) Equipment purchases in accounts payable and accrued expenses 34 15 Impairment of fixed asset 51 —

Description of Business and B44

Description of Business and Basis of Preparation - Additional Information (Detail) $ / shares in Units, $ in Thousands	Apr. 28, 2015USD ($)shares	May. 31, 2014shares	May. 07, 2014USD ($)$ / sharesshares	Apr. 25, 2014	Mar. 17, 2014	May. 31, 2014shares	Mar. 31, 2015	Dec. 31, 2014USD ($)shares	Dec. 31, 2013USD ($)
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from initial public offering								$ 62,000
Reverse stock split ratio, description					1-for-4 reverse stock split		1-for-4 reverse stock split
Reverse stock split ratio				0.196	0.25
Number of shares of common stock sold | shares			6,200,000					6,200,000
Public offering price per share | $ / shares			$ 10
Net proceeds from initial public offering (IPO)			$ 54,583
Underwriting discounts and commissions			3,290
Offering expenses			$ 4,127
Number of outstanding shares of convertible preferred stock converted into common stock | shares			1,691,884
Outstanding warrants exercised | shares		275,687	275,687			275,687		275,687
Subsequent Event [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Number of shares of common stock sold | shares	5,376,622
Net proceeds from initial public offering (IPO)	$ 38,012
Subsequent Event [Member] | Estimated [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from initial public offering	$ 37,754
Additional Reverse Stock Split [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Reverse stock split ratio, description				1-for-5.1 reverse stock split			1-for-5.1 reverse stock split
Reverse stock split ratio				0.196
2013 Credit Agreement [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Repayment of debt			$ 15,000

Summary of Significant Accoun45

Summary of Significant Accounting Policies - Concentration Risk (Details) - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Waterstone Pharmaceuticals [Member] | Sales [Member]
Concentration Risk [Line Items]
Percentage of related-party revenue	80.00%	0.00%
R-Pharm, CJSC [Member] | Sales [Member]
Concentration Risk [Line Items]
Percentage of related-party revenue	20.00%	100.00%
Customer Concentration Risk A [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Percentage of related-party revenue	31.00%
Customer Concentration Risk B [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Percentage of related-party revenue	15.00%
Customer Concentration Risk C [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Percentage of related-party revenue		16.00%
Customer Concentration Risk D [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Percentage of related-party revenue		16.00%
Customer Concentration Risk E [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Percentage of related-party revenue		14.00%
Customer Concentration Risk F [Member] | Sales [Member]
Concentration Risk [Line Items]
Percentage of related-party revenue	17.00%
Investor [Member] | Sales [Member]
Concentration Risk [Line Items]
Percentage of related-party revenue	41.00%	43.00%

Summary of Significant Accoun46

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended			3 Months Ended		12 Months Ended
	Jan. 31, 2014	Aug. 31, 2013	Aug. 31, 2012	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Accounting Policies [Abstract]
Deferred offering costs				$ 257		$ 0	$ 1,775
Royalty payments received				0		0
Upfront payment received	$ 500	$ 1,500	$ 313
Deferred revenue recognition period	48 months	70 months	6 months
Revenue recognized from upfront payments				$ 96	$ 93	$ 256	$ 95

Summary of Significant Accoun47

Summary of Significant Accounting Policies - Research and Development Expenses and Reimbursements (Details) - USD ($) $ in Thousands	1 Months Ended			3 Months Ended		12 Months Ended
	Jan. 31, 2014	Aug. 31, 2013	Aug. 31, 2012	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Accounting Policies [Abstract]
Upfront payment received	$ 500	$ 1,500	$ 313
Disposal Group, Including Discontinued Operation, Revenue						$ 122	$ 62
Research and development expense, gross				$ 3,981	$ 1,320	8,513	4,363
Less: Reimbursement of research and development expense				194	0	226	0
Research and development, net				3,787	1,320	8,287	4,363
Deferred revenue recognition period	48 months	70 months	6 months
Revenue recognized from upfront payments				$ 96	$ 93	$ 256	$ 95

Summary of Significant Accoun48

Summary of Significant Accounting Policies - Summary of Revenue, by Segment (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting Information [Line Items]
Revenues	$ 65	$ 65	$ 1,256	$ 95
Sales Revenue, Net [Member]
Segment Reporting Information [Line Items]
Revenues			$ 19,024	$ 16,857
Concentration Risk, Percentage			100.00%	100.00%
Sales Revenue, Net [Member] | UNITED STATES
Segment Reporting Information [Line Items]
Revenues			$ 16,422	$ 15,126
Concentration Risk, Percentage			86.00%	90.00%
Sales Revenue, Net [Member] | Europe [Member]
Segment Reporting Information [Line Items]
Revenues			$ 1,235	$ 1,626
Concentration Risk, Percentage			7.00%	10.00%
Sales Revenue, Net [Member] | Other Non-US [Member]
Segment Reporting Information [Line Items]
Revenues			$ 1,367	$ 105
Concentration Risk, Percentage			7.00%	0.00%

Allowance for Bad Debts (Detail

Allowance for Bad Debts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Allowance for Doubtful Accounts Receivable [Roll Forward]
Balance at Beginning of Period	$ 163	$ 251
Additions Charged to Expense	0	0
Deductions	(163)	(88)
Balance at End of Period	$ 0	$ 163

Prepaid Expenses and Other Cu50

Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid SCY-078 development services		$ 109	$ 0
Prepaid insurance		295	97
Other prepaid expenses		70	141
Other receivable due from R-Pharm	$ 420	226	0
Other current assets		3	5
Prepaid expenses and other current assets	$ 899	$ 703	$ 243

Property and Equipment - Summar

Property and Equipment - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 22,282	$ 22,120	$ 23,070
Less accumulated depreciation	17,608	17,285	17,669
Property, Plant and Equipment, Including Assets Held for Sale, Net	4,674	4,835	5,401
Property and equipment, net	4,674	4,835	5,401
Property and equipment, net of assets of discontinued operations	0	0	0
Equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	8,698	8,552	9,577
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	375	375	378
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 13,209	$ 13,193	$ 13,115

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 323	$ 308	$ 1,238	$ 1,329
Proceeds from insurance recovery			165	0
Discontinued Operations [Member]
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 282	$ 282	$ 1,132	$ 1,215

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Payables and Accruals [Abstract]
Accrued research and development expenses		$ 293	$ 92
Accrued employee bonus compensation		1,464	0
Interest payable		0	23
Employee withholdings		156	61
Other accrued expenses		332	556
Accrued expenses	$ 3,060	$ 2,245	$ 732

Accrued Expenses - Additional

Accrued Expenses - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2014
Payables and Accruals [Abstract]
Severance costs	$ 379
Severance Disbursements		$ 362
Remaining Unpaid Accrued Severance Balance		$ 17

Debt Obligations (Detail)

Debt Obligations (Detail) - USD ($) $ / shares in Units, $ in Thousands	May. 07, 2014	Dec. 11, 2013	Apr. 30, 2010	Dec. 31, 2013	Jun. 30, 2013	Mar. 31, 2015	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	May. 31, 2014	Jan. 31, 2014	Dec. 31, 2011
Debt Instrument [Line Items]
Deemed contribution of a loan guarantee									$ 0	$ 3,930
Gains (Losses) on Extinguishment of Debt									(1,389)	0
Debt Outstanding				$ 15,000					0	15,000
Interest expense						$ (1)		$ 44	$ 48	$ 192
Number of warrants issued to purchase common stock				13,879		14,033			14,033	13,879
Exercise price of warrants												$ 0.20
Issuance of warrants allocated to debt discount									$ 906	$ 1,168
Amortization of deferred financing costs						$ 0		536	755	3,485
Interest expense on beneficial conversion feature									$ 0	10,802
Series D-1 Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Debt conversion, shares issued		6,054,255
Series D-2 Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Number of warrants issued to purchase common stock		87,532							19,048				19,048
Exercise price of warrants		$ 0.20											$ 0.20
Debt conversion, shares issued		3,956,985
Two Thousand Eleven Twelve Notes [Member]
Debt Instrument [Line Items]
Public offering price														$ 0.20
Convertible notes aggregate amount						0			$ 0
Interest Payable						0			0
2010 Credit Agreement [Member]
Debt Instrument [Line Items]
Credit facility agreement amount			$ 15,000
Interest at a rate of London InterBank plus			0.95%
Deemed contribution of a loan guarantee			$ 6,338
2013 Credit Agreement [Member]
Debt Instrument [Line Items]
Deemed contribution of a loan guarantee								3,930		$ 3,930
Repayment of debt	$ 15,000
Gains (Losses) on Extinguishment of Debt							$ 1,389
Debt Outstanding						0			$ 0
Weighted-average interest rate									1.19%	1.20%
Interest expense									$ 48	$ 192
Amortization of deferred financing costs						0		$ 536	755	2,317
December 2011 Note and Warrant Agreement [Member]
Debt Instrument [Line Items]
Debt agreement, maximum borrowing capacity														$ 15,000
Issuance of warrants allocated to debt discount											$ 328
2011-2012 Notes [Member]
Debt Instrument [Line Items]
Convertible notes aggregate amount		$ 11,444		$ 0					0	0
Interest Payable				0					0	0
Debt Instrument, Increase, Accrued Interest		$ 1,640
Debt Instrument, Convertible, Conversion Price		$ 1.40
2011-2012 Notes [Member] | Series D-1 Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Debt conversion, shares issued		6,054,255
2011-2012 Notes [Member] | Series D-2 Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Debt conversion, shares issued		3,291,443
June 2013 Note and Warrant Agreement [Member]
Debt Instrument [Line Items]
Debt agreement, maximum borrowing capacity					$ 1,500
Convertible notes aggregate amount		$ 899		0	899	0			0	0
Fair value of issued warrants					1,168
Fair value of warrants expensed at issuance					269
Issuance of warrants allocated to debt discount					$ 899
Interest Payable				0		$ 0			$ 0	0
Debt Instrument, Increase, Accrued Interest				$ 33
Debt Instrument, Convertible, Conversion Price		$ 1.40
June 2013 Note and Warrant Agreement [Member] | Series D-2 Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Debt conversion, shares issued				665,542
2011 Note and Warrant Agreement and 2013 Note and Warrant Agreement [Member]
Debt Instrument [Line Items]
Required percentage of written consent by holders of outstanding aggregated principle amount of convertible notes									70.00%
2011-2012 Notes and June 2013 Notes [Member]
Debt Instrument [Line Items]
Notes stated interest rate									8.00%
Amortization of deferred financing costs									$ 0	1,168
Debt Instrument, Convertible, Conversion Price		$ 1.40			$ 4.3125
Interest expense on beneficial conversion feature										10,802
Term Loan [Member] | 2010 Credit Agreement [Member]
Debt Instrument [Line Items]
Credit facility agreement amount			5,000
Term Loan [Member] | 2013 Credit Agreement [Member]
Debt Instrument [Line Items]
Credit facility agreement amount				$ 5,000						5,000
Revolving Credit Facility [Member] | 2010 Credit Agreement [Member]
Debt Instrument [Line Items]
Credit facility agreement amount			$ 10,000
Revolving Credit Facility [Member] | 2013 Credit Agreement [Member]
Debt Instrument [Line Items]
Credit facility agreement amount				$ 10,000						$ 10,000
Convertible Notes Payable [Member] | December 2011 Note and Warrant Agreement [Member]
Debt Instrument [Line Items]
Debt agreement, maximum borrowing capacity														15,000
Investor [Member] | Two Thousand Eleven Twelve Notes [Member]
Debt Instrument [Line Items]
Convertible notes aggregate amount														$ 11,444
Number of warrants issued to purchase common stock														26,000
Investor [Member] | Convertible Notes Payable [Member] | 2011-2012 Notes [Member]
Debt Instrument [Line Items]
Convertible notes aggregate amount											$ 11,444			$ 11,444
Number of warrants issued to purchase common stock														26,000
Exercise price of warrants														$ 0.20

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended	12 Months Ended
	Jun. 30, 2014	Mar. 31, 2015USD ($)Agreement	Mar. 31, 2014USD ($)	Jun. 30, 2014	Dec. 31, 2014USD ($)Agreement	Dec. 31, 2013USD ($)
Unrecorded Unconditional Purchase Obligation [Line Items]
Future minimum lease payments		$ 4,540			$ 4,749
Lease expiration		2,019			2,019
Lease expiration extension		Mar. 31, 2024			Mar. 31, 2024
Rent expense		$ 218	$ 231		$ 952	$ 906
Milestone payments from the Company		$ 19,000			$ 19,000
Number of additional license agreements | Agreement		2			2
License agreements fee		$ 2,300			$ 2,300
Research and Development Arrangement, Contract to Perform for Others, Period After Notice Required Before Contract Termination	30 days			30 days
Research and Development Arrangement [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Projected fees and expenses under agreement		$ 500			$ 500
Percent of transaction consideration		4.00%			4.00%
Discontinued Operations [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Rent expense		$ 178	$ 200		$ 827	$ 781
Services Business [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Future minimum lease payments					$ 4,718

Commitments and Contingencies57

Commitments and Contingencies - Future Minimum Lease Payments (Detail) - USD ($) $ in Thousands	Mar. 31, 2015	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Operating Leases, Future Minimum Payments, Remainder of Fiscal Year	$ 826
2,015		$ 1,075
2,016	1,122	1,104
2,017	1,140	1,123
2,018	1,161	1,156
2,019	291	291
Thereafter	0	0
Total	$ 4,540	$ 4,749

Stock-based Compensation - 2015

Stock-based Compensation - 2015 Inducement Plan (Details) - shares	Mar. 31, 2015	Mar. 26, 2015	Dec. 31, 2014
2015 Inducement Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Possible future issuance under equity compensation plan	450,000	450,000	0

Convertible Preferred Stock - A

Convertible Preferred Stock - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	May. 31, 2014	Mar. 13, 2014	Jan. 31, 2014	Dec. 11, 2013	Mar. 31, 2008	Jul. 31, 2006	Aug. 31, 2004	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2002	Dec. 31, 2000	May. 07, 2014	Dec. 10, 2013	Dec. 31, 2001	Dec. 30, 2000
Temporary Equity [Line Items]
Temporary equity, shares issued														17,803,273
Proceeds from sale of preferred stock								$ 0	$ 544	$ 544	$ 2,500
Payments of stock issuance costs										$ 0	$ 95
Outstanding Series C-1 convertible preferred stock warrants								14,033		14,033	13,879
Automatic conversion trigger		$ 20,000
Conversion of preferred stock	1,691,884									1,691,884
Exercise price of warrants	$ 0.20
Other (expense) income related to fair value adjustment of long term derivative liability									(3,145)	$ (10,442)	$ 7,886
Excess of fair value of warrants over proceeds									362	$ 362	$ (1,714)
Series A Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Temporary equity, shares issued										0	31,407		31,407	31,407
Temporary equity issue price per share													$ 7.96
Temporary equity, par or stated value per share										$ 0.001	$ 0.001
Conversion of preferred stock											0
Series B Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Temporary equity, shares issued										0	467,814		110,988	467,814			600,999
Temporary equity issue price per share													$ 9.01				$ 9.01
Value of equipment, intellectual property, and conversion of debt																	$ 2,200
Proceeds from sale of preferred stock													$ 3,215
Payments of stock issuance costs													$ 43
Shares of preferred stock converted to common stock													244,173
Temporary equity, par or stated value per share										$ 0.001	$ 0.001
Conversion price of preferred shares to common stock, per share			$ 32.0076	$ 32.2912											$ 45.95
Conversion of preferred stock											0
Series C Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Temporary equity, shares issued										0	2,770,633	2,867,154		2,770,633
Proceeds from sale of preferred stock												$ 24,000
Payments of stock issuance costs												$ 86
Shares of preferred stock converted to common stock												197,045
Outstanding Series C-1 convertible preferred stock warrants																100,524
Debt converted into preferred shares												$ 4,513
Notes stated interest rate												4.50%
Preferred stock issued during period upon exercise of warrants												23,911
Temporary equity, par or stated value per share										$ 0.001	$ 0.001					$ 0.01
Conversion price of preferred shares to common stock, per share			35.8917	36.2386											51.77
Conversion of preferred stock											0
Series C-1 Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Temporary equity, shares issued							984,615							0
Proceeds from sale of preferred stock							$ 3,200
Outstanding Series C-1 convertible preferred stock warrants						196,923
Conversion price of preferred shares to common stock, per share			45.6062	46.1101											66.30
Conversion of preferred stock											0
Exercise price of warrants						$ 3.25
Warrant expiration date								Jul. 14, 2016			Jul. 14, 2016
Fair value of warrant on issuance date						$ 459
Other (expense) income related to fair value adjustment of long term derivative liability								$ 0	$ 37	$ 37	$ 121
Series C-2 Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Temporary equity, shares issued					2,347,826					0	2,347,826			2,347,826
Proceeds from sale of preferred stock					$ 13,500
Temporary equity, par or stated value per share										$ 0.001	$ 0.001
Conversion price of preferred shares to common stock, per share			$ 77.9382	$ 78.9623											$ 117.30
Conversion of preferred stock											0
Series D-2 Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Temporary equity, shares issued			388,641	1,785,712						0	5,742,697			6,131,338
Temporary equity issue price per share			$ 1.40	$ 1.40
Proceeds from sale of preferred stock			$ 544	$ 2,500
Payments of stock issuance costs				$ 95
Outstanding Series C-1 convertible preferred stock warrants			19,048	87,532						19,048
Temporary equity, par or stated value per share										$ 0.001	$ 0.001
Debt conversion, shares issued				3,956,985
Conversion price of preferred shares to common stock, per share			$ 28.56	$ 28.56
Common Stock, Shares, Fair Value			47.74	$ 48.35
Intrinsic value of beneficial conversion feature				$ 4,232						$ 909
Effective conversion price				$ 0						$ 0
Conversion of preferred stock											3,956,985
Exercise price of warrants			$ 0.20	$ 0.20
Fair value of warrant on issuance date			$ 906	$ 4,214
Excess of fair value of warrants over proceeds			$ 362	$ 1,714
Temporary Equity Shares Issue Price			$ 1.40	$ 1.40
Series D-1 Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Temporary equity, shares issued										0	6,054,255			6,054,255
Temporary equity issue price per share				$ 1.40
Temporary equity, par or stated value per share										$ 0.001	$ 0.001
Debt conversion, shares issued				6,054,255
Conversion of preferred stock											6,054,255
Common Stock [Member]
Temporary Equity [Line Items]
Outstanding Series C-1 convertible preferred stock warrants						14,033				14,033
Exercise price of warrants						$ 45.61				$ 45.61

Convertible Preferred Stock - S

Convertible Preferred Stock - Summary of Authorized, Issued and Outstanding Preferred Shares (Detail) - shares	Dec. 31, 2014	May. 07, 2014	Jan. 31, 2014	Dec. 31, 2013	Dec. 11, 2013	Dec. 31, 2012	Mar. 31, 2008	Aug. 31, 2004	Dec. 31, 2002	Dec. 31, 2000	Dec. 30, 2000
Temporary Equity [Line Items]
Temporary Equity, Shares Authorized		29,135,824
Temporary equity, shares issued		17,803,273
Temporary Equity, Shares Outstanding		17,803,273
Series A Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Temporary Equity, Shares Authorized	0	31,410		31,410
Temporary equity, shares issued	0	31,407		31,407						31,407
Temporary Equity, Shares Outstanding	0	31,407		31,407		31,407
Series B Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Temporary Equity, Shares Authorized	0	711,987		711,987
Temporary equity, shares issued	0	467,814		467,814						110,988	600,999
Temporary Equity, Shares Outstanding	0	467,814		467,814		467,814
Series C Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Temporary Equity, Shares Authorized	0	2,967,678		2,967,678
Temporary equity, shares issued	0	2,770,633		2,770,633					2,867,154
Temporary Equity, Shares Outstanding	0	2,770,633		2,770,633		2,770,633
Series C-1 Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Temporary Equity, Shares Authorized		3,076,923
Temporary equity, shares issued		0						984,615
Temporary Equity, Shares Outstanding	0	0		0		0
Series C-2 Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Temporary Equity, Shares Authorized	0	2,347,826		2,347,826
Temporary equity, shares issued	0	2,347,826		2,347,826			2,347,826
Temporary Equity, Shares Outstanding	0	2,347,826		2,347,826		2,347,826
Series D-1 Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Temporary Equity, Shares Authorized	0	10,000,000		10,000,000
Temporary equity, shares issued	0	6,054,255		6,054,255
Temporary Equity, Shares Outstanding	0	6,054,255		6,054,255		0
Series D-2 Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Temporary Equity, Shares Authorized	0	10,000,000		10,000,000
Temporary equity, shares issued	0	6,131,338	388,641	5,742,697	1,785,712
Temporary Equity, Shares Outstanding	0	6,131,338		5,742,697		0

Convertible Preferred Stock -61

Convertible Preferred Stock - Summary of Preferred Stock Activity (Detail) - shares	May. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Temporary Equity [Line Items]
Conversion of preferred stock	1,691,884	1,691,884
Series A Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Beginning balance		31,407	31,407
Issuance of temporary equity		0	0
Automatic conversion to common stock		(31,407)
Ending balance		0	31,407
Conversion of preferred stock			0
Series B Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Beginning balance		467,814	467,814
Issuance of temporary equity		0	0
Automatic conversion to common stock		(467,814)
Ending balance		0	467,814
Conversion of preferred stock			0
Series C Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Beginning balance		2,770,633	2,770,633
Issuance of temporary equity		0	0
Automatic conversion to common stock		(2,770,633)
Ending balance		0	2,770,633
Conversion of preferred stock			0
Series C-1 Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Beginning balance		0	0
Issuance of temporary equity		0	0
Automatic conversion to common stock		0
Ending balance		0	0
Conversion of preferred stock			0
Series C-2 Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Beginning balance		2,347,826	2,347,826
Issuance of temporary equity		0	0
Automatic conversion to common stock		(2,347,826)
Ending balance		0	2,347,826
Conversion of preferred stock			0
Series D-1 Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Beginning balance		6,054,255	0
Issuance of temporary equity		0	0
Automatic conversion to common stock		(6,054,255)
Ending balance		0	6,054,255
Conversion of preferred stock			6,054,255
Series D-2 Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Beginning balance		5,742,697	0
Issuance of temporary equity		388,641	1,785,712
Automatic conversion to common stock		(6,131,338)
Ending balance		0	5,742,697
Conversion of preferred stock			3,956,985

Convertible Preferred Stock - V

Convertible Preferred Stock - Voting Rights, Divendend Rights, Liquidation Rights, and Conversion Rights (Details) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2015USD ($)	Mar. 31, 2014USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	May. 31, 2014	May. 02, 2014$ / shares	Jan. 31, 2014$ / shares	Dec. 11, 2013$ / shares	Dec. 10, 2013$ / shares	Dec. 31, 2000$ / shares	Dec. 30, 2000$ / shares
Class of Stock [Line Items]
Beneficial conversion feature for antidilution adjustment | $	$ 0	$ 214	$ 214	$ 6,402
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Liquidation Preference, Value						$ 7.96
Convertible Preferred Stock, Conversion Rate of Preferred Shares					0.20
Temporary equity issue price per share										$ 7.96
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Voting Percentage Needed for Approval			65.00%
Preferred Stock, Liquidation Preference, Value						9.01
Convertible Preferred Stock, Conversion Rate of Preferred Shares					0.28
Temporary equity issue price per share										$ 9.01	$ 9.01
Conversion price of preferred shares to common stock, per share							$ 32.0076	$ 32.2912	$ 45.95
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Voting Percentage Needed for Approval			65.00%
Minimum Percentage of Approval Needed from Series C, Needed to Liquidate the Company.			65.00%
Preferred Stock, Liquidation Preference, Value						10.15
Conversion price of preferred shares to common stock, per share							35.8917	36.2386	51.77
Series C-1 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Liquidation Preference, Value						3.25
Convertible Preferred Stock, Conversion Rate of Preferred Shares					0.07
Conversion price of preferred shares to common stock, per share							45.6062	46.1101	66.30
Series C-2 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Voting Percentage Needed for Approval			65.00%
Preferred Stock, Liquidation Preference, Value						$ 5.75
Convertible Preferred Stock, Conversion Rate of Preferred Shares					0.07
Conversion price of preferred shares to common stock, per share							77.9382	78.9623	$ 117.30
Series D Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Dividend Rate, Percentage			8.00%
Series D-1 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Voting percentage required, series D preferred stock			70.00%
Liquidation Preference, Percentage of Original Issue Price						200.00%
Convertible Preferred Stock, Conversion Rate of Preferred Shares					0.05
Temporary equity issue price per share								1.40
Series D-2 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Voting percentage required, series D preferred stock			70.00%
Liquidation Preference, Percentage of Original Issue Price						300.00%
Convertible Preferred Stock, Conversion Rate of Preferred Shares					0.05
Temporary equity issue price per share							1.40	1.40
Conversion price of preferred shares to common stock, per share							$ 28.56	$ 28.56

Common Stock - Additional Infor

Common Stock - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	May. 31, 2014	May. 07, 2014	Jan. 31, 2014	Dec. 11, 2013	May. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	May. 02, 2014	Dec. 31, 2012	Dec. 31, 2011
Schedule of Capitalization, Equity [Line Items]
Common stock, par value						$ 0.001		$ 0.001	$ 0.001
Common stock, shares authorized						125,000,000		125,000,000	70,000,000
Common stock, shares issued						8,527,210		8,512,103	334,068
Common stock, shares outstanding						8,527,210		8,512,103	334,068		335,782
Number of warrants issued to purchase common stock						14,033		14,033	13,879
Exercise price of warrants	$ 0.20				$ 0.20
Exercise of common stock warrants	275,687	275,687			275,687			275,687
Fair value of common stock warrant derivative liabilities							$ 9,998	$ 0	$ 12,237	$ 2,701
Adjustment to fair value							(3,145)	(10,442)	7,886
Excess of fair value of warrants over proceeds							362	362	(1,714)
Change in fair value of derivative liability						$ 0	2,783	$ 10,080	(7,886)
Series D-2 Purchase Agreement [Member]
Schedule of Capitalization, Equity [Line Items]
Number of warrants issued to purchase common stock				87,532
Exercise price of warrants				$ 0.20
Warrants exercisable date				Dec. 11, 2018
Increase in the shares of common stock underlying the warrants issued				54,120
Revised number of common shares underlying the warrants issued				80,120
Series D-2 Convertible Preferred Stock [Member]
Schedule of Capitalization, Equity [Line Items]
Number of warrants issued to purchase common stock			19,048	87,532				19,048
Exercise price of warrants			$ 0.20	$ 0.20
Excess of fair value of warrants over proceeds			$ 362	$ 1,714
Common Stock Warrant [Member]
Schedule of Capitalization, Equity [Line Items]
Adjustment to fair value						$ 0	$ 3,108	$ (10,442)	$ 8,007
2011-2012 Notes [Member]
Schedule of Capitalization, Equity [Line Items]
Number of warrants issued to purchase common stock												26,000
Exercise price of warrants												$ 0.20
June 2013 Note and Warrant Agreement [Member]
Schedule of Capitalization, Equity [Line Items]
Number of warrants issued to purchase common stock				88,987
Exercise price of warrants				$ 0.20
Warrants exercisable date				Jun. 28, 2018
Two Thousand Eleven Twelve Notes [Member]
Schedule of Capitalization, Equity [Line Items]
Number of warrants issued to purchase common stock											26,000
Exercise price of warrants											$ 0.20

Common Stock - Summary of Commo

Common Stock - Summary of Common Stock Shares Activity (Detail) - shares	May. 31, 2014	May. 07, 2014	May. 31, 2014	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Equity [Abstract]
Beginning Balance				8,512,103	334,068	335,782
Exercise of stock options					416	220
Repurchase of common stock						(1,934)
Conversion of preferred stock	1,691,884				1,691,884
Exercise of common stock warrants	275,687	275,687	275,687		275,687
Common stock issued through IPO		6,200,000			6,200,000
Common stock issued through employee stock purchase plan				15,107	10,048
Ending Balance				8,527,210	8,512,103	334,068

Common Stock - Schedule of Rese

Common Stock - Schedule of Reserved Shares of Common Stock for Future Issuance (Detail) - shares	Mar. 31, 2015	Mar. 26, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Class of Stock [Line Items]
For conversion of Series A Preferred, Series B Preferred, Series C Preferred, Series C-2 Preferred, Series D-1 Preferred, and Series D-2 Preferred and exercise of warrants to purchase Series C-1 Preferred and subsequent conversion of the shares purchased			0	1,675,812
Outstanding stock options			615,322	137,610	154,277
Outstanding common stock warrants			0	257,242
Outstanding Series C-1 convertible preferred stock warrants	14,033		14,033	13,879
Total common shares reserved for future issuance	1,652,499		847,711	2,134,277
2014 Equity Incentive Plan [Member]
Class of Stock [Line Items]
For possible future issuance under stock option plan	561,000		180,610	49,734
2014 Employee Stock Purchase Plan [Member]
Class of Stock [Line Items]
For possible future issuance under stock option plan	52,050		37,746	0
2015 Inducement Plan [Member]
Class of Stock [Line Items]
For possible future issuance under stock option plan	450,000	450,000	0

Stock-based Compensation - 2009

Stock-based Compensation - 2009 Stock Option Plan (Details) - 2009 Stock Option Plan [Member]	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period of options	10 years	10 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of exercise price	100.00%	100.00%
Vesting period of options	3 years	3 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of exercise price	110.00%	110.00%
Vesting period of options	4 years	4 years

Stock-based Compensation - 2014

Stock-based Compensation - 2014 Equity Incentive Plan (Details) - shares	Feb. 25, 2015	Jan. 01, 2015	Jun. 18, 2014	Mar. 31, 2015	Dec. 31, 2014	May. 02, 2014	Dec. 31, 2013
2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Effective date of equity incentive plan				May 2, 2014	May 2, 2014
Common stock outstanding percentage				4.00%	4.00%
Number of shares of common stock for future issuance, board of directors prerogative, increase in period				0	0
Aggregate number of shares of the Company's common stock that may be issued	510,726	340,484	351,653
For possible future issuance under stock option plan				561,000	180,610		49,734
2014 Equity Incentive Plan [Member] | Chief Medical Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares returned to common stock available		57,452
2009 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional awards expected to be granted						0
Maximum [Member] | 2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Base number of new shares available for future issuance under equity incentive plan				257,352	257,352
Common stock issuable period				10 years	10 years

Stock-based Compensation - Opti

Stock-based Compensation - Option Valuation Method (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Weighted average value of options granted in period	$ 6.24	$ 25.09
Aggregate fair value of options	$ 3,249	$ 290
Expected dividend yield	0.00%	0.00%
Expected dividend yield, nonemployees	0.00%	0.00%
Weighted average expected volatility	68.57%	65.49%
Weighted average expected volatility, nonemployees	64.10%	65.49%
Weighted average risk-free interest rate	2.05%	2.41%
Weighted average risk-free interest rate, nonemployees	1.75%	2.37%
Weighted average expected term (in years)	6 years 15 days	6 years 5 months 27 days
Weighted average expected term (in years), nonemployees	5 years 3 months 17 days	5 years
Forfeiture rate	5.00%	5.00%
Forfeiture rate, nonemployees	5.00%	5.00%

Stock-based Compensation - Sto

Stock-based Compensation - Stock-based Compensation Plan Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding stock options	615,322	137,610	154,277
Number of shares granted	520,887	11,525
Exercise of stock options	(416)	(220)
Options Canceled in Period	(42,759)	(27,972)
Number of shares exercisable, beginning balance	115,475
Number of Options Vested and Expected to Vest, Ending Balance	572,926	136,002
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Exercise price	$ 9.55	$ 25.86	$ 23.05
Weighted Average Exercise Price of Options Granted in Period, Per Share	9.53	50.39
Weighted Average Exercise Price of Options Exercised, Per Share	20.40	21.01
Weighted Average Exercise Price of Options Canceled, Per Share	9.57	20.81
Weighted average exercise price of options exercisable, per share	9.44	23.26
Weighted Average Exercise Price of Options Vested and Expected to Vest, Per Share	$ 9.55	$ 25.70
Weighted- Average Remaining Contractual Life (in years)	9 years 5 months 23 days	5 years 2 months 23 days	5 years 7 days
Weighted- Average Remaining Contractual Life (in years)	9 years 5 months 23 days	4 years 6 months
Weighted- Average Remaining Contractual Life (in years)	9 years 5 months 23 days	5 years 2 months 5 days
Aggregate Intrinsic Value	$ 265	$ 3,097	$ 213
Aggregate Intrinsic Value of Options Exercisable	88	2,898
Aggregate Intrinsic Value of Options Vested and Expected to Vest	$ 247	$ 3,084

Stock-based Compensation - Ves

Stock-based Compensation - Vested Share-based Compensation, by Exercise Price (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding stock options	615,322		575,416
Weighted- Average Remaining Contractual Life (in years)	9 years 5 months 23 days	5 years 2 months 5 days
Number of Shares	192,916
Weighted- Average Remaining Contractual Life (in years)	9 years 5 months 23 days	4 years 6 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$ 458	$ 801
Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price, Per Share	$ 6.77
Outstanding stock options	8,000
Weighted- Average Remaining Contractual Life (in years)	9 years 5 months 19 days
Number of Shares	0
Weighted- Average Remaining Contractual Life (in years)	0 years
Exercise Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price, Per Share	$ 7.70
Outstanding stock options	5,944
Weighted- Average Remaining Contractual Life (in years)	9 years 9 months 4 days
Number of Shares	5,944
Weighted- Average Remaining Contractual Life (in years)	9 years 9 months 4 days
Exercise Price Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price, Per Share	$ 8.03
Outstanding stock options	5,700
Weighted- Average Remaining Contractual Life (in years)	9 years 6 months
Number of Shares	5,700
Weighted- Average Remaining Contractual Life (in years)	9 years 6 months
Exercise Price Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price, Per Share	$ 8.73
Outstanding stock options	35,114
Weighted- Average Remaining Contractual Life (in years)	9 years 5 months 12 days
Number of Shares	3,494
Weighted- Average Remaining Contractual Life (in years)	9 years 5 months 12 days
Exercise Price Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price, Per Share	$ 9.64
Outstanding stock options	543,374
Weighted- Average Remaining Contractual Life (in years)	9 years 5 months 19 days
Number of Shares	176,248
Weighted- Average Remaining Contractual Life (in years)	9 years 5 months 19 days
Exercise Price Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price, Per Share	$ 10.81
Outstanding stock options	17,190
Weighted- Average Remaining Contractual Life (in years)	9 years 11 months 5 days
Number of Shares	1,530
Weighted- Average Remaining Contractual Life (in years)	9 years 11 months 5 days

Stock-based Compensation - Unv

Stock-based Compensation - Unvested Share-based Compensation, by Exercise Price (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Unvested Shares	422,407	22,135
Stock option compensation not yet recognized	$ 2,683	$ 404
Share based compesation cost recognition period	3 years 2 months 12 days	1 year 9 months 18 days
Intrinsic value of options exercised	$ 11	$ 6
Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price, Per Share	$ 6.77
Number of Unvested Shares	8,000
Exercise Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price, Per Share	$ 7.70
Number of Unvested Shares	0
Exercise Price Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price, Per Share	$ 8.03
Number of Unvested Shares	0
Exercise Price Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price, Per Share	$ 8.73
Number of Unvested Shares	31,620
Exercise Price Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price, Per Share	$ 9.64
Number of Unvested Shares	367,127
Exercise Price Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price, Per Share	$ 10.81
Number of Unvested Shares	15,660
Exercise Price Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price, Per Share		$ 20.40
Number of Unvested Shares		563
Exercise Price Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price, Per Share		$ 24.48
Number of Unvested Shares		7,318
Exercise Price Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price, Per Share		$ 25.50
Number of Unvested Shares		0
Exercise Price Ten [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price, Per Share		$ 25.91
Number of Unvested Shares		0
Exercise Price Eleven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price, Per Share		$ 30.60
Number of Unvested Shares		4,307
Exercise Price Twelve [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price, Per Share		$ 55.08
Number of Unvested Shares		9,947

Stock-based Compensation - Opt

Stock-based Compensation - Option Grants (Details) - USD ($) $ / shares in Units, $ in Thousands	Sep. 11, 2014	Mar. 31, 2015	Dec. 31, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price			$ 9.55			$ 9.55	$ 25.86	$ 23.05
Stock-based compensation		$ 296			$ 110	$ 1,201	$ 180
Weighted average value of options granted in period						$ 6.24	$ 25.09
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant of options to purchase shares of common stock, subject to stockholder approval	396,573
Exercise price	$ 9.64
Stock-based compensation				$ 0
Weighted average value of options granted in period			$ 3.76
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Fair Value	$ 1,490
Vesting period of options	45 months

Stock-based Compensation - O73

Stock-based Compensation - Option Amendments (Details) - USD ($) $ / shares in Units, $ in Thousands	Jun. 18, 2014	Apr. 29, 2014	Sep. 30, 2014	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Sep. 11, 2014	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price					$ 9.55	$ 25.86		$ 23.05
Weighted average value of options granted in period					$ 6.24	$ 25.09
2009 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options to purchase shares of common stock, for which the exercise price was lowered to the IPO price	110,346	53,404
Modified exercise price	$ 9.64	$ 10
Exercise price of options, lower range	20.40	20.40
Exercise price of options, upper range	61.20	61.20
Exercise price	41.87	$ 54.87
Weighted Average Fair Value of Outstanding Option Awards, Immediately Prior to Modification	3.08
Weighted Average Fair Value of Outstanding Option Awards, Immediately After to Modification	$ 5.87
Additional compensation cost				$ 293
1999 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options to purchase shares of common stock, for which the exercise price was lowered to the IPO price	73,087
Exercise price of options, lower range	$ 20.40
Exercise price of options, upper range	25.50
Exercise price	$ 21.50
Weighted Average Fair Value of Outstanding Option Awards, Immediately Prior to Modification							$ 0.78
Weighted Average Fair Value of Outstanding Option Awards, Immediately After to Modification							$ 3.78
Additional compensation cost			$ 225	0
Scenario, Previously Reported [Member] | 2009 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional compensation cost				$ 130

Stock-based Compensation - 201

Stock-based Compensation - 2014 Employee Stock Purchase Plan (Details) - shares	Feb. 25, 2015	Jan. 01, 2015	Jun. 18, 2014	Feb. 28, 2014	Sep. 30, 2014	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issued through employee stock purchase plan						15,107	10,048
2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of shares of the Company's common stock that may be issued	510,726	340,484	351,653
Common stock outstanding percentage						4.00%	4.00%
Number of shares of common stock for future issuance, board of directors prerogative, increase in period						0	0
For possible future issuance under stock option plan						561,000	180,610	49,734
2014 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of shares of the Company's common stock that may be issued						29,411
Effective date of employee stock purchase plan						May 2, 2014	May 2, 2014
Common stock issuable period				10 years		10 years
Common stock outstanding percentage				0.80%		0.80%
Employee stock purchase plan, number of shares, which might be added to common stock outstanding				29,411		29,411
Number of shares of common stock for future issuance, board of directors prerogative, increase in period				0		0
Common stock issued through employee stock purchase plan					10,048
For possible future issuance under stock option plan						52,050	37,746	0
2014 Employee Stock Purchase Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
For possible future issuance under employee stock purchase plan				47,794		47,794

Stock-based Compensation - Com

Stock-based Compensation - Compensation Cost (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based compensation	$ 296,000	$ 110,000	$ 1,201,000	$ 180,000
Cash received from option exercised	0	5,000	9,000	5,000
Tax benefit from compensation expense	$ 0	$ 0	$ 0	$ 0

Stock-based Compensation - Stoc

Stock-based Compensation - Stock-based Compensation Expense Related to Stock Options (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense related to stock options	$ 296	$ 110	$ 1,201	$ 180
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense related to stock options	52	62	394	28
Selling, General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense related to stock options	211	35	648	107
Discontinued Operations [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense related to stock options	$ 33	$ 13	$ 159	$ 45

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Operating Loss Carryforwards [Line Items]
Income tax benefit	$ 0	$ (313)	$ (1,166)	$ (575)
Income (Loss) from continuing operations before taxes	$ (5,931)	$ (268)	(6,769)	(31,906)
Domestic Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforward			81,687	71,757
Tax credit carryforward			2,371
NORTH CAROLINA | State and Local Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforward			85,790	75,990
Tax credit carryforward			150
PENNSYLVANIA | State and Local Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforward			$ 0	$ 80

Income Taxes Income Tax Reconci

Income Taxes Income Tax Reconciliation (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Income taxes at statutory rate			$ (2,301)	$ (10,848)
State income taxes			(471)	(116)
Beneficial conversion feature on convertible notes			0	3,673
Stock warrant derivative liability			(3,427)	2,686
Debt discount amortization			0	392
Deemed contribution interest			0	1,516
Provision to return adjustments			0	(190)
Stock compensation			268	41
Expiration of capital loss carryforward			0	1,511
Change in statutory state income tax rate			0	936
Change in reserve for uncertain tax positions			0	623
R&D tax credits			(320)	0
Other			(190)	(5)
Increase in valuation allowance			5,275	(794)
Income Tax Expense	$ 0	$ (313)	$ (1,166)	$ (575)
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Income taxes at statutory rate, percent of pretax income			34.00%	34.00%
State income taxes, percent of pretax income			7.00%	0.50%
Beneficial conversion feature on convertible notes, percent of pretax income			0.00%	(11.50%)
Stock warrant derivative liability, percent of pretax income			50.60%	(8.40%)
Debt discount amortization, percent of pretax income			0.00%	(1.20%)
Deemed contribution interest, percent of pretax income			0.00%	(4.80%)
Provision to return adjustments, percent of pretax income			0.00%	0.60%
Stock compensation, percent of pretax income			(4.00%)	(0.10%)
Expiration of capital loss carryforward, percent of pretax income			0.00%	(4.70%)
Change in statutory state income tax rate, percent of pretax income			0.00%	(2.90%)
Change in reserve for uncertain tax positions, percent of pretax income			0.00%	(2.00%)
R&D tax credits, percent			4.70%	(0.00%)
Other, percent of pretax income			2.80%	0.00%
Increase in valuation allowance, percent of pretax income			(77.90%)	2.50%
Effective Income Tax Rate, percent of pretax income			17.20%	1.80%

Income Taxes Deferred Tax Asset

Income Taxes Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Accrued expenses	$ 1,052	$ 612
Stock-based compensation	336	241
Assets of discontinued operations, net of liabilities	1,882	1,938
Other	15	25
Gross deferred tax assets, current	3,285	2,816
Net operating loss carryforwards	29,981	26,286
Research and development credits	2,684	2,373
Deferred financing costs	0	(800)
Gross deferred tax assets, noncurrent	32,665	27,859
Total deferred tax assets	35,950	30,675
Valuation allowance	(35,950)	(30,675)
Net deferred tax assets	$ 0	$ 0

Income Taxes Unrecognized Tax B

Income Taxes Unrecognized Tax Benefits (Details) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized tax benefits	$ 623,000	$ 0
Additions for tax positions of current period	0	333,000
Additions for tax positions of prior periods	0	290,000
Other	0	0
Unrecognized tax benefits	623,000	$ 623,000
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	0
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit	0
Income Tax Examination, Penalties and Interest Accrued	$ 0

Discontinued Operations - Addit

Discontinued Operations - Additional Information (Details) - Services Business [Member] $ in Thousands	Jul. 21, 2015$ / h	Mar. 31, 2015USD ($)
Discontinued Operations, Held-for-sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase Obligation | $		$ 3,300
Subsequent Event [Member] | Discontinued Operations, Disposed of by Sale [Member] | Minimum [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Employee hourly rate	100
Subsequent Event [Member] | Discontinued Operations, Disposed of by Sale [Member] | Maximum [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Employee hourly rate	200

Net Loss - Summary of Computati

Net Loss - Summary of Computation of Basic and Diluted Net Income (Loss) Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Earnings Per Share [Abstract]
Income (Loss) from continuing operations	$ (5,931)	$ 45	$ (5,603)	$ (31,331)
Deemed dividend for beneficial conversion feature on Series D-2 Preferred	0	(909)	(909)	(4,232)
Deemed dividend for antidilution adjustments to convertible preferred stock	0	(214)	(214)	(6,402)
Accretion of convertible preferred stock	0	(510)	(510)	(5,714)
Income from discontinued operations, net of income tax expense, attributable to common stock - basic	(453)	367	1,369	870
Loss from continuing operations attributable to common stock - basic	(5,931)	(1,588)	(7,236)	(47,679)
Net loss attributable to common stockholders - basic	(6,384)	(1,221)	(5,867)	(46,809)
Derivative fair value adjustment	0	2,783	10,080	0
Loss from continuing operations attributable to common stock - diluted	(5,931)	(4,371)	(17,316)	(47,679)
Income from discontinued operations, net of income tax expense, attributable to common stock - diluted	(453)	367	1,369	870
Net loss attributable to common stockholders - diluted	$ (6,384)	$ (4,004)	$ (15,947)	$ (46,809)
Weighted-average common shares outstanding - basic	8,516,467	334,086	5,663,311	335,612
Incremental shares from assumed exercise of common stock warrants	0	274,988	273,776	0
Weighted-average of outstanding common stock - diluted	8,516,467	609,074	5,937,087	335,612
Income (loss) per share, continuing operations, per basic share	$ (0.70)	$ (4.75)	$ (1.28)	$ (142.06)
Income (loss) per share, discontinued operations, per basic share	(0.05)	1.10	0.24	2.59
Basic (USD per share)	(0.75)	(3.65)	(1.04)	(139.47)
Income (loss) per share, continuing operations, per diluted share	(0.70)	(7.17)	(2.92)	(142.06)
Income (loss) per share, discontinued operations, per diluted share	(0.05)	0.60	0.23	2.59
Diluted (USD per share)	$ (0.75)	$ (6.57)	$ (2.69)	$ (139.47)

Net Loss Per Share - Summary of

Net Loss Per Share - Summary of Antidilutive Securities Excluded from Computation of Weighted Average Common Stock Outstanding (Detail) - shares	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-Dilutive Securities	0	131,685
Series A Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-Dilutive Securities	0	6,149
Convertible Preferred Stock [Member] | Series A Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-Dilutive Securities			6,149	6,149
Convertible Preferred Stock [Member] | Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-Dilutive Securities			131,685	130,529
Convertible Preferred Stock [Member] | Series C Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-Dilutive Securities			783,515	776,016
Convertible Preferred Stock [Member] | Series C-2 Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-Dilutive Securities			173,213	170,967
Convertible Preferred Stock [Member] | Series D-1 Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-Dilutive Securities			296,773	296,773
Convertible Preferred Stock [Member] | Series D-2 Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-Dilutive Securities			300,549	281,500
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-Dilutive Securities			0	257,242
Warrant [Member] | Series C One Preferred [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-Dilutive Securities	14,033	14,033	14,033	13,878
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-Dilutive Securities	575,416	184,240	615,322	137,610
Equity Unit Purchase Agreements [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-Dilutive Securities	40,334	0	65,401	0
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-Dilutive Securities			0	0
Series C Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-Dilutive Securities	0	783,515
Series C Two Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-Dilutive Securities	0	173,213
Series D Two Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-Dilutive Securities	0	300,549
Series D One Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-Dilutive Securities	0	296,773

Related-Party Transaction - Sum

Related-Party Transaction - Summary of Transactions with Related Parties (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Related Party Transactions [Abstract]
Revenue	$ 987	$ 1,822	$ 7,288	$ 7,288
Selling, general and administrative expense			$ 500	$ 0

Related-Party Transactions - Ad

Related-Party Transactions - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		12 Months Ended
	May. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Related Party Transaction [Line Items]
General and administrative expense				$ 500	$ 0
Investor [Member] | Customer Concentration Risk [Member] | Sales [Member]
Related Party Transaction [Line Items]
Percentage of related-party revenue				41.00%	43.00%
Affiliated Entity [Member]
Related Party Transaction [Line Items]
General and administrative expense	$ 500
Sanofi [Member] | Investor [Member]
Related Party Transaction [Line Items]
Ownership percentage of a related party in a customer of the company				100.00%
Sanofi [Member]
Related Party Transaction [Line Items]
Ownership percentage of a related party in a customer of the company		100.00%
Sanofi [Member] | Sales [Member]
Related Party Transaction [Line Items]
Percentage of related-party revenue		31.00%	39.00%

Employee Benefit Plan (Details)

Employee Benefit Plan (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2014USD ($)h	Dec. 31, 2013USD ($)
Defined Contribution Plan Disclosure [Line Items]
Work hours per week | h	20
Employer matching percent	50.00%
Maximum percentage of contributions per employee	6.00%
Vesting period	4 years
Contribution amount	$ 239	$ 239
Discontinued Operations [Member]
Defined Contribution Plan Disclosure [Line Items]
Contribution amount	$ 176	$ 173

Gain on Sale of Asset (Details)

Gain on Sale of Asset (Details) - USD ($) $ in Thousands	May. 17, 2013	May. 17, 2012	Dec. 31, 2014	Dec. 31, 2013
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on sale of asset			$ 0	$ 988
HEOS Software [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sale proceeds		$ 4,500
Proceeds received	$ 1,000	3,500
Gain on sale of asset	$ 988	3,412
Balance held in escrow		$ 1,000

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Assets and Liabilities Subject to Fair Value Measurements on Recurring Basis (Detail) - USD ($) $ in Thousands	Dec. 31, 2014	May. 02, 2014	Mar. 31, 2014	Dec. 31, 2013
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Derivative liability	$ 0	$ 2,701	$ 9,998	$ 12,237
Fair Value, Measurements, Recurring [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Derivative liability				12,237
Fair Value, Measurements, Recurring [Member] | Series C-1 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Derivative liability				37
Fair Value, Measurements, Recurring [Member] | Common Stock Warrant [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Derivative liability				12,200
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Derivative liability				0
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member] | Series C-1 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Derivative liability				0
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member] | Common Stock Warrant [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Derivative liability				0
Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Derivative liability				0
Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member] | Series C-1 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Derivative liability				0
Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member] | Common Stock Warrant [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Derivative liability				0
Fair value inputs, level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Derivative liability				12,237
Fair value inputs, level 3 [Member] | Fair Value, Measurements, Recurring [Member] | Series C-1 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Derivative liability				37
Fair value inputs, level 3 [Member] | Fair Value, Measurements, Recurring [Member] | Common Stock Warrant [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Derivative liability				$ 12,200

Fair Value Measurements - Sum89

Fair Value Measurements - Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	May. 02, 2014	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Fair Value Disclosures [Abstract]
Beginning balance		$ 12,237	$ 12,237	$ 683
Issuance of warrants		544	544	5,382
Excess of fair value of warrants over proceeds		362	362	(1,714)
Adjustment to fair value		(3,145)	(10,442)	7,886
Reclassification to additional paid-in capital upon exercise of warrants	$ (2,701)		(2,701)	0
Ending balance		$ 9,998	$ 0	$ 12,237

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) $ in Thousands	Dec. 31, 2013USD ($)
Estimate of Fair Value Measurement [Member] | 2013 Credit Agreement [Member] | Fair value inputs, level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Instrument, Fair Value Disclosure	$ 13,023

Significant Agreements (Details

Significant Agreements (Details) - USD ($) $ in Thousands	Oct. 29, 2014	Jan. 31, 2014	Dec. 31, 2014	Oct. 31, 2014	Jan. 31, 2014	Dec. 31, 2013	Aug. 31, 2013	Aug. 31, 2012	Dec. 31, 2014	Mar. 31, 2015
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Deferred revenue recognition period					48 months		70 months	6 months
Other receivable due from R-Pharm			$ 226			$ 0			$ 226	$ 420
Collaborative Arrangement | R-Pharm Collaboration Arrangement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Proceeds from Collaborators							$ 1,500
Milestone payment for first product registration							3,000
Sales based payments							$ 15,000
Deferred revenue recognition period							70 months
Other receivable due from R-Pharm			$ 226						226
Licensing Agreement | Elanco Licensing Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Proceeds from Collaborators						500
Sales based payments						15,000
Deferred revenue recognition period		4 years
Annual service fee, first term						$ 2,750
Annual service fee, period of first term						2 years
Annual service fee, second term						$ 3,000
Annual service fee, period of second term						2 years
Development milestone payment for each compound developed						$ 1,500
Development milestone payment for first regulatory approved product						2,000
Licensing Agreement | Waterstone Licensing Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone payment for first product registration				$ 4,000
Option exercise period	18 months
Upfront payment				1,000
Additional upfront payment				$ 500
Licenses Revenue									1,000
Licensing Agreement | UNITED STATES | Elanco Licensing Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Sales based payments						4,000
Licensing Agreement | European Union | Elanco Licensing Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Sales based payments						$ 1,500
Merial [Member] | Investor [Member] | Merial Research Services Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Term of contract to perform research for others			2 years
Compensation receivable from research for others			$ 7,900						$ 7,900
Term of contract to perform research for others, option to extend			1 year

Discontinued Operations - Carry

Discontinued Operations - Carrying Amounts of Assets and Liabilities of the Services Business (Details) (Details) - USD ($) $ in Thousands	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Property and equipment, net	$ 4,674	$ 4,835	$ 5,401
Services Business [Member] | Discontinued Operations, Held-for-sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accounts and unbilled receivables, net	1,053	1,501	1,062
Prepaid expenses and other current assets	258	289	246
Property and equipment, net	4,674	4,835	5,401
Other assets	64	76	89
Assets of discontinued operations, net	6,049	6,701	6,798
Accounts payable and accrued expenses	689	681	737
Deferred revenue	445	445	225
Deferred rent	1,237	1,294	1,481
Liabilities related to assets of discontinued operations	$ 2,371	$ 2,420	$ 2,443

Discontinued Operations - Reven

Discontinued Operations - Revenue, Expense, Gain, and Losses Attributable to Discontinued Operations (Details) (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on sale of asset			$ 0	$ 988
Income tax expense	$ 0	$ (313)	(1,166)	(575)
Income from discontinued operations	(453)	367	1,369	870
Services Business [Member] | Discontinued Operations, Held-for-sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total revenue	3,232	4,640	17,768	16,762
Cost of revenue	(3,231)	(3,960)	(15,446)	(16,305)
Selling, general and administrative	(431)	0	48	0
Gain on insurance recovery	(23)	0	165	0
Gain on sale of asset			0	988
Income tax expense	0	(313)	(1,166)	(575)
Income from discontinued operations	$ (453)	$ 367	$ 1,369	$ 870

Discontinued Operations - Depre

Discontinued Operations - Depreciation, Capital Expenditures, and Significant Operating and Investing Non-Cash Items Related to Discontinued Operations (Details) (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation	$ 323	$ 308	$ 1,238	$ 1,329
Proceeds from insurance recovery			216	0
Gain on insurance recovery			(165)	0
Gain on sale of asset, net of transaction expenses			0	(988)
Proceeds from sale of asset, net of transaction expenses			0	988
Stock-based compensation	296	110	1,201	180
Changes in deferred rent	(57)	(15)	(187)	(53)
Impairment of fixed asset			51	0
Services Business [Member] | Discontinued Operations, Held-for-sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation	282	282
Purchases of property and equipment	(171)	(74)	(704)	(431)
Proceeds from insurance recovery			216	0
Gain on insurance recovery			(165)	0
Gain on sale of asset, net of transaction expenses			0	(988)
Proceeds from sale of asset, net of transaction expenses			0	988
Stock-based compensation	33	13	159	45
Changes in deferred rent	(57)	(15)	(187)	(53)
Equipment purchases in accounts payable and accrued expenses	$ 25	$ 204	34	15
Impairment of fixed asset			$ 51	$ 0

Subsequent Events - Equity Inc

Subsequent Events - Equity Incentive Plan (Details) $ / shares in Units, $ in Thousands

Apr. 01, 2016shares

Oct. 01, 2015shares

Jun. 04, 2015director$ / sharesshares

Jun. 03, 2015

May. 01, 2015$ / sharesshares

Apr. 28, 2015USD ($)

Apr. 01, 2015shares

Feb. 25, 2015shares

Feb. 20, 2015shares

Jan. 01, 2015shares

Sep. 11, 2014$ / shares

Jun. 18, 2014shares

May. 07, 2014USD ($)

Jun. 30, 2015USD ($)$ / sharesshares

Dec. 31, 2014$ / sharesshares

Dec. 31, 2013$ / sharesshares

May. 12, 2015$ / sharesshares

Mar. 31, 2015shares

Mar. 26, 2015shares

Dec. 31, 2012$ / sharesshares

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Net proceeds from initial public offering (IPO) | $

$ 54,583

Number of shares granted

520,887

11,525

Outstanding stock options

615,322

137,610

154,277

Exercise price | $ / shares

$ 9.55

$ 25.86

$ 23.05

Number of unvested shares

422,407

22,135

2014 Equity Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Addition to aggregate number of shares of the Company's common stock that may be issued

510,726

340,484

351,653

For possible future issuance under stock option plan

180,610

49,734

561,000

Subsequent Event [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Net proceeds from initial public offering (IPO) | $

$ 38,012

Number of shares granted

425,967

Subsequent Event [Member] | 2014 Equity Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Addition to aggregate number of shares of the Company's common stock that may be issued

510,726

510,726

340,484

Weighted-average incremental fair value | $ / shares

$ 3.54

Expected incremental compensation cost | $

$ 819

Additional compensation cost | $

$ 466

Subsequent Event [Member] | Compensatory Plan with Service Business Employees [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Expiration period of options

48 months

Outstanding stock options

55,964

Number of unvested shares

33,274

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price | $ / shares

$ 9.62

Subsequent Event [Member] | Compensatory Arrangement with Executive Officer [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of unvested shares

50,814

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price | $ / shares

$ 9.53

Subsequent Event [Member] | Chief Medical Officer [Member] | 2014 Equity Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares returned to common stock available

57,452

Subsequent Event [Member] | Chief Executive Officer [Member] | 2014 Equity Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares granted

80,000

330,000

Maximum [Member] | Subsequent Event [Member] | 2015 Inducement Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

For possible future issuance under stock option plan

450,000

Chief Executive Officer [Member] | Subsequent Event [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares granted

330,000

Chief Medical Officer [Member] | Subsequent Event [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares granted

125,000

Vice President [Member] | Subsequent Event [Member] | 2015 Inducement Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares granted

60,000

Director [Member] | Subsequent Event [Member] | 2014 Equity Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of directors who resigned | director

3

Outstanding stock options

48,283

Exercise price | $ / shares

$ 9.01

Director [Member] | Maximum [Member] | Subsequent Event [Member] | 2014 Equity Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Post employment options exercise period

48 months

Director [Member] | Minimum [Member] | Subsequent Event [Member] | 2014 Equity Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Post employment options exercise period

36 months

90 days

Chief Financial Officer [Member] | Subsequent Event [Member] | 2014 Equity Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Post employment options exercise period

36 months

Outstanding stock options

74,490

Exercise price | $ / shares

$ 9.53

Number of unvested shares

50,814

Weighted average exercise price | $ / shares

$ 9.49

Executive Officer [Member] | Subsequent Event [Member] | Compensatory Arrangement with Executive Officer [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number of Options Held by Former Employee in End of Quarter

74,490

Employee Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise price | $ / shares

$ 9.64

Vesting period of options

45 months

Employee Stock Option [Member] | Subsequent Event [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Expiration period of options

10 years

Employee Stock Option [Member] | Chief Executive Officer [Member] | Subsequent Event [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Expiration period of options

10 years

Employee Stock Option [Member] | Chief Medical Officer [Member] | Subsequent Event [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Expiration period of options

10 years

Services Business [Member] | Subsequent Event [Member] | 2014 Equity Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Post employment options exercise period

48 months

Outstanding stock options

37,517

Exercise price | $ / shares

$ 9.62

Number of unvested shares

23,052

Weighted average exercise price | $ / shares

$ 9.61

Services Business [Member] | June 2015 Terminated Employees [Member] | Subsequent Event [Member] | 2014 Equity Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Post employment options exercise period

48 months

Outstanding stock options

17,715

Exercise price | $ / shares

$ 9.64

Number of unvested shares

8,331

Weighted average exercise price | $ / shares

$ 9.64

Retention Plan [Member] | Non-executive Employee [Member] | Subsequent Event [Member] | 2014 Equity Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Post employment options exercise period

48 months

Outstanding stock options

121,550

Exercise price | $ / shares

$ 9.13

Number of unvested shares

85,990

Weighted average exercise price | $ / shares

$ 8.95

Share-based Compensation Award, Tranche One [Member] | Subsequent Event [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage

25.00%

Vesting period of options

1 year

Share-based Compensation Award, Tranche Two [Member] | Subsequent Event [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period, Number of Monthly Installments

36 years

Subsequent Events - Compensato

Subsequent Events - Compensatory Agreements (Details) - USD ($) $ / shares in Units, $ in Thousands	Jul. 21, 2015	May. 12, 2015	May. 04, 2015	Jun. 30, 2014	Jul. 23, 2015	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Subsequent Event [Line Items]
Severance costs				$ 379
Number of shares exercisable							192,916	115,475
Number of unvested shares							422,407	22,135
Weighted average exercise price of options exercisable, per share							$ 9.44	$ 23.26
Compensatory Arrangement with Executive Officer [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Number of unvested shares		50,814
Nonvested options weighted average grant date fair value		$ 9.49
Compensatory Arrangement with Executive Officer [Member] | Chief Financial Officer [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Cash award granted		$ 138
Severance costs		$ 179
Compensatory Arrangement with Executive Officer [Member] | President [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Cash award granted	$ 100
Retention compensation payable, maximum	$ 900
Severance costs, payment period	12 months
Number of shares exercisable					84,613
Number of unvested shares					183,268
Weighted average exercise price of options exercisable, per share					$ 9.61
Nonvested options weighted average grant date fair value					$ 9.41
Services Business [Member] | Discontinued Operations, Held-for-sale [Member] | Employee Severance [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Restructuring reserve						$ 999
Services Business [Member] | Discontinued Operations, Disposed of by Sale [Member] | Employee Severance [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Payments for restructuring	$ 215
Retention compensation payable, maximum	$ 814
Retention Plan [Member] | Employee Severance [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Expected restructuring cost						$ 1,161
Maximum [Member] | Compensatory Arrangement with Executive Officer [Member] | President [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Post employment options exercise period	48 months
Fair Value, Measurements, Nonrecurring [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Service Business assets, fair value			$ 572
Estimate selling costs			778
Fair Value, Measurements, Nonrecurring [Member] | Services Business [Member] | Discontinued Operations, Held-for-sale [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Impairment charges recorded			$ (1,350)

Subsequent Events - Sale of th

Subsequent Events - Sale of the Services Business (Details) $ / shares in Units, $ in Thousands	Jul. 21, 2015USD ($)$ / h	May. 04, 2015USD ($)	Jun. 30, 2015USD ($)	Dec. 31, 2014$ / sharesshares	Dec. 31, 2013$ / sharesshares	Dec. 31, 2012$ / sharesshares
Subsequent Event [Line Items]
Outstanding stock options | shares				615,322	137,610	154,277
Exercise price | $ / shares				$ 9.55	$ 25.86	$ 23.05
Number of unvested shares | shares				422,407	22,135
Discontinued Operations, Disposed of by Sale [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Potential success fee payable			$ 500
Percent of transaction consideration			4.00%
Payment of success fee	$ 450
Unrecorded Unconditional Purchase Obligation, Initial Retainer Paid	50
Discontinued Operations, Disposed of by Sale [Member] | Services Business [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Sale proceeds	3,875
Working capital adjustment	824
Consideration held in escrow	$ 500
Consideration held in escrow, period held in escrow	12 months
Consideration received after adjustments	$ 2,549
Fair Value, Measurements, Nonrecurring [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Service Business assets, fair value		$ 572
Estimate selling costs		778
Fair Value, Measurements, Nonrecurring [Member] | Discontinued Operations, Held-for-sale [Member] | Services Business [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Impairment charges recorded		$ (1,350)
Minimum [Member] | Discontinued Operations, Disposed of by Sale [Member] | Services Business [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Employee hourly rate | $ / h	100
Maximum [Member] | Discontinued Operations, Disposed of by Sale [Member] | Services Business [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Employee hourly rate | $ / h	200
Employee Severance [Member] | Discontinued Operations, Disposed of by Sale [Member] | Services Business [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Payments for restructuring	$ 215
Retention compensation payable, maximum	$ 814

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) $ / shares in Units, $ in Thousands	Jul. 22, 2015USD ($)ft²	Jul. 17, 2015USD ($)	May. 12, 2015USD ($)$ / shares	May. 01, 2015USD ($)$ / shares	Apr. 28, 2015USD ($)$ / sharesshares	May. 07, 2014shares	Jun. 30, 2014USD ($)	Dec. 31, 2014USD ($)shares	Dec. 31, 2013USD ($)	Mar. 31, 2015USD ($)
Subsequent Event [Line Items]
Common stock issued through IPO | shares						6,200,000		6,200,000
Payments of stock issuance costs								$ 0	$ 95
Severance costs							$ 379
Proceeds from initial public offering								62,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Common stock issued through IPO | shares					5,376,622
Public offering price | $ / shares					$ 7.70
Payments of stock issuance costs					$ 3,388
Subsequent Event [Member] | Estimated [Member]
Subsequent Event [Line Items]
Payments of stock issuance costs					3,646
Proceeds from initial public offering					$ 37,754
Research and Development Arrangement [Member]
Subsequent Event [Line Items]
Projected fees and expenses under agreement								$ 500		$ 500
Research and Development Arrangement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Contract initial term		18 months
Projected fees and expenses under agreement		$ 3,300
Jersey City, New Jersey [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Sublet premises area | ft²	10,141
Monthly base rent	$ 25
Percent increase in base rent annually	3.00%
Payment of security deposit	$ 74
Compensatory Arrangement with Executive Officer [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Nonvested options weighted average grant date fair value | $ / shares			$ 9.49
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price | $ / shares			$ 9.53
Compensatory Plan with Service Business Employees [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Nonvested options weighted average grant date fair value | $ / shares				$ 9.62
Maximum Incentive Compensation Payable				$ 1,300
Expiration period of options				48 months
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price | $ / shares				$ 9.62
Executive Officer [Member] | Compensatory Arrangement with Executive Officer [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Cash award granted			$ 138
Severance costs			$ 179